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WHO malaria elimination targets require sustained and robust surveillance systems to identify 
difficult-to-diagnose, low-density malaria infections which threaten control efforts. The WHO 
‘T3: Test, Treat and Track’ initiative further reinforces the importance of these principles (Cox 
2010). Early detection and treatment of malaria is especially important during pregnancy given 
its adverse outcomes. Prior to administration of antimalarials, the WHO recommends 
confirmation of diagnosis of malaria. The current gold standard for this is still microscopy, with 
rapid diagnostic tests (RDTs) commonly employed where microscopy services are limited. 
However, both methods are insufficiently sensitive to detect low-density or “sub-microscopic” 
infections. Individuals harbouring these infections act as an infectious transmission reservoir 
contributing to ongoing transmission in low-transmission/near-elimination settings. 
Unfortunately, only molecular methods such as qPCR- which are largely restricted to use in 
well-supported laboratories- are currently suited to diagnosing these individuals. 
Aims 
There is an urgent need for sensitive diagnostic tools for malaria that are better suited to low-
resource settings. The overall objective of the thesis is to investigate new diagnostic tests, 
molecular techniques, and adaptations to enhance the detection of low-density malaria 
infections in limited-resource settings. This thesis aims to explore new diagnostics suitable for 
1) molecular surveillance and 2) improved point-of-care (POC) diagnosis. The specific objectives 
are to: 
1) Assess the suitability of high-throughput molecular assays for differentiating Plasmodium species 
(Chapter 2) 
2) Develop a new molecular test for malaria control applications on a portable, field-friendly platform 
(Chapter 3) 
3) Characterise the diagnostic performance of a new RDT for detecting low density malaria 
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during pregnancy in low and high transmission settings (Chapter 4-6) 
Methods and key findings 
The differentiation of the main species of Plasmodium is important not only for the treatment 
of liver stages unique to P. vivax, but also for accurate surveillance of malaria epidemiology. 
Chapter 2 explores molecular techniques; namely, High Resolution Melt Curve Analysis 
(HRMCA) and real-time qPCR, to develop a multiplex qPCR suitable for the detection of the 
species of malaria most prevalent in the study areas of interest: Indonesia and Kenya. As a 
result, a new 4-plex qPCR assay was optimised and utilised in a large clinical trial to confirm 
infection amongst asymptomatic women in Indonesia. The feasibility of using whole blood 
directly in the 4-plex was also demonstrated, as was the transfer of the qPCR to the more 
portable Magnetic Induction Cycler (MIC™) device (chapter 3). 
Using the multiplex qPCR as a reference standard, the diagnostic performance of a new ultra-
sensitive P. falciparum RDT (uRDT) was retrospectively assessed in a Stop Malaria in Pregnancy 
clinical trial in Indonesia (chapter 4). The uRDT’s performance was compared to that of the 
widely used Pf/Pan CareStart RDT (csRDT). The overall similar performance of the two RDTs 
(uRDT 20% sensitivity, 98% specificity and csRDT 23%, 96%) led to an investigation into 
antigenic mutations that may account for RDT insensitivity (chapter 5). The results from this 
study suggest a high proportion of infections that were qPCR positive and RDT negative are 
attributable to HRP2 deletions. 
The uRDT performance in comparison to csRDT was further investigated amongst pregnant 
women in Kenya, to investigate the effects of transmission intensity. The sensitivity of the uRDT 
(79.9%) was significantly higher than that of the csRDT (74%), although the specificity was 
significantly lower (uRDT; 90.4% and csRDT; 93.0%). Overall, the performance of the two tests 
(as indicated by the Diagnostics Odds Ratios, Kappa values and AUROC values) were non-
significantly different to each other. 
Finally, a novel assay for mosquito insecticide resistance was developed on the portable point-
of-care Genedrive® platform, demonstrating its potential for use as a field-friendly diagnostic 
tool for malaria control. 
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Conclusions 
The uRDT evaluations performed here contribute to critical understanding of how these tests 
perform in pregnant women in different transmission settings. The results suggest that in low 
transmission settings this test may not offer an improvement on currently used RDTs, 
particularly for screening asymptomatic infections during pregnancy. In contrast, the uRDT may 
be better suited for this role in higher transmission settings, such as in Kenya. Although the 
uRDT demonstrated lower specificity in the latter scenario, the negative outcomes associated 
with malaria during pregnancy together with the safety of current antimalarial therapies 
mitigate the risks of unnecessary treatment. 
The poor sensitivity of both HRP2-targetting RDTs do not support their use for screening for 
malaria during pregnancy, with the caveat that the off-label use of stored samples may have 
affected their sensitivity. The evidence of HRP2 deletions is the first report of these mutations 
in Indonesia. Although further confirmatory studies are needed to strengthen these findings, 
they flag a potential barrier to the current test and treat policies for screening pregnant women 
in Indonesia. The work highlights the urgent need for wider and more in-depth HRP2 studies in 
this region to better inform these programs. 
Overall, this thesis tackles several pertinent challenges around improving malaria diagnostics. It 
highlights issues that need to be considered during the product design, development and 
assessment phases. It also incorporates useful evaluation studies of novel tests with the 
potential to make malaria diagnostics more accessible. Its translational approach is suited to 
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1.1. Malaria life cycle and pathogenesis 
 
Malaria is a parasitic disease caused by unicellular eukaryote Plasmodium. In humans, 
Plasmodium falciparum, P. vivax, P. malariae, P. knowlesi and P. ovale (sub-species ovale curtisi 
and ovale wallikeri) are the main infective species. 
Most Plasmodium species have an anthroponotic life cycle, with the exception of 
P. knowlesi which can also infect some macaques (Cox 2010), but also require a mosquito 
vector for transmission (Nilsson, Childs et al. 2015). Humans first acquire infection through the 
bite of an infected Anopheline mosquito. Only female mosquitoes can transmit the parasite, as 
they require blood meals to support egg development. Infective sporozoites residing in the 
mosquito’s salivary gland are injected into the skin, where they traverse the dermis, entering 
the blood. Once in circulation, they sequester to the liver, traversing Kupffer cells before 
infecting liver cells (~5-6 days post-infection). Here, asexual reproduction ‘schizogony’ is 
initiated, or in the case of P. vivax and P. ovale infections, hypnozoites may form lying dormant 
for long periods of time (months to year) (Nilsson, Childs et al. 2015). (Figure 1.1) 
During asexual reproduction, a ring stage parasite first develops maturing into 
trophozoites and then into schizonts. Mature schizonts can develop into multiple infective 
merozoites or early stage gametocytes. Formation of asexual merozoites causes the cell to 
rupture, once again releasing these stages back into circulation, where they can re-infect other 
circulating red blood cells and re-initiate asexual reproduction (24- 72 hour cycle depending on 
the species). (Figure 1.1) 
Sexual reproduction, however, comprises seven developmental stages of the 
gametocytes (8 days). Male and female gametocytes are ingested upon feeding of another 
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mosquito. Within seconds they fuse in the mid-gut of the mosquito, forming a zygote that 
continues to develop into an ookinete (~2 weeks). This stage invades the mid-gut lining and 
matures into an oocyst filled with maturing sporozoites. These are released into the mosquito 
haemolymph where they are able to sequester to the salivary glands. Upon the mosquito’s next 
blood meal, they are injected alongside the mosquito saliva into the skin of the human host 
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Figure 1.1. Schematic of the malaria life cycle.  
Development of the Plasmodium parasite within the human and mosquito hosts. Image source: 
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1.1.1. Malaria epidemiology 
 
Malaria is prevalent in 87 countries across South-East Asia, the Eastern Mediterranean, 
Western Pacific, the Americas and Africa. Despite efforts to control the disease, there are 219 
million cases and 405,000 deaths due to malaria every year (WHO 2017).  The majority of cases 
and deaths occur in sub-Saharan Africa, with Nigeria alone accounting for 25% of the global 
burden of malaria (WHO 2019). Plasmodium falciparum remains the most prevalent malaria 
parasite in the WHO African Region, thus accounting for the majority of global malaria cases (fig 
1.2A) (WHO 2019). Although the incidence rate of malaria has declined globally from 71 (2010) 
to 57 (2018) cases per 1000 population at risk, between 2010 and 2018, concerning the rate of 
change decelerated drastically, stagnating progress over the past 4 years. Likewise, reduction in 
malaria deaths has stemmed since 2016 globally. Only the WHO African region and the South-
East Asian region showed a reduction in mortality in 2018 compared to 2010 (Ryan, Stoute et 
al. 2006).  
Indonesia is co-endemic for both P. falciparum (63%) and P. vivax (37%), with scarce P. ovale 
and P. malariae infections (Mideo, Reece et al. 2013). In chapters 2-5, samples from Timika, 
West Papua in Indonesia were investigated. This region in has the highest prevalence of both 
malaria species with over 100 cases/ 1000 population (fig 1.2B) (Bartoloni and Zammarchi 
2012). In contrast, chapter 6 investigates samples in an African context in Western Kenya, 
where the P. falciparum dominates with only infrequent P. vivax infections occurring in some 
Duffy-negative populations (WHO 2019). The prevalence of P. falciparum is highest in this 
littoral region on the shores of Lake Victoria (fig 1.2C). 
 




Pathogenesis is caused by the parasites’ usurpation of red blood cells, sequestration to vital 
organs and synchronised release of antigenic material, eliciting strong immune responses and 
resulting in a range of symptoms. (WHO 2019) The most common of these are characterised as 
‘uncomplicated malaria’ and include fever, headache, vomiting, diarrhoea and general malaise. 
However, the disease can rapidly progress (< 24hrs) to severe malaria, resulting in anaemia, 
splenomegaly, thrombocytopenia and renal dysfunction, which can eventually lead to coma and 
death (WHO 2019).  
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A. Global incidence of P. falciparum malaria shown as cases/ 1000 population at risk, and prevalence of B.i) P. falciparum and B.ii) P. vivax 
malaria in Indonesia, and C) P. falciparum in Kenya. Source: WHO malaria world report (Desai, ter Kuile et al. 2007)   
A. 
Figure 1.2. Map of malaria of case incidence rate 
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B.i) Plasmodium falciparum prevalence in Indonesia (relevant to chapters 2-5).     
 
B.ii) Plasmodium vivax prevalence in Indonesia (relevant to chapters 2-5). 
Timika, West Papua 
Timika, West Papua 
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C. Plasmodium falciparum prevalence in Kenya (relevant to chapter 6). 
 
 
Disease severity is influenced by many factors including age, immune factors, parasite 
species/density, host factors such as haemoglobinopathies or co-infection with other diseases. 
Malaria is most lethal in children under 5 years of age, accounting for 67% (272,000) of malaria 
death globally (Desai, Hill et al. 2018). Although complicated by different immune factors, this is 
largely due to lack of immunity which is acquired with age. 
Pregnant women also represent a particularly vulnerable demographic at risk of malaria, 
with around 11 million pregnant women exposed to malaria infections (Duffy, G. et al. 2006). In 
addition to the clinical symptoms described above, Malaria in Pregnancy (MiP) is additionally 
associated with maternal anaemia, preeclampsia, post-partum haemorrhage, and poor birth 
outcomes including low birth weight, spontaneous abortion, still birth and prematurity, as well 
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as infant mortality (Bartoloni and Zammarchi 2012, Bhatt, Weiss et al. 2015). 
Plasmodium falciparum species can also sequester to the placenta, through interaction 
between placental chondroitin sulphate and the pfVAR2CSA antigen on the surface of 
merozoite stages (Sinka, Bangs et al.). Immunity against pfVAR2CSA-harbouring parasites is 
however acquired with parity. Women acquire immunity against these particular strains with 
increasing exposure during each pregnancy, thus primigravid mother lacking immunity are 
more susceptible to infection and adverse outcomes (Sinka, Bangs et al. 2012). 
 
1.1.2. Disease control  
Malaria control is mainly targeted at its two hosts; 1) vector control to reduce interactions 
between mosquitoes and humans and 2) early detection, prophylactic and curative therapies 
for the human host.  
The global success in reducing malaria over the last 15 years can be largely attributed to 
vector control interventions (Singh and Daneshvar 2013). As Africa accounts for over 92% of 
global malaria cases and 93% of malaria deaths, the main vectors of malaria are the Anopheline 
species most prevalent in this region: An. gambiae, An. stephensi and An. funestus (Carrasco, 
Lefèvre et al. 2019). In other regions of the world where P. vivax, P. ovale and P. malariae are 
more prevalent, the dominant vector species include An. darlingi (S America), An. sundaicus s.l 
(SE Asia), An. koliensis (Asia-Pacific) and An. culicifacies (W Asia) (Ranson and Lissenden 2016). 
Currently, the main vectors of P. knowlesi belong to the Anopheles leucosphyrus group, which 
inhabit forested areas in Southeast Asia where the long-tailed and pig-tailed macaque hosts 
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reside (Mulamba, Riveron et al. 2014). 
  
The use of insecticides in control programs has been central to the decline in malaria, e.g. 
distribution of long-lasting insecticide-treated nets (LLITNs), Indoor Residual Spraying (IRS) and 
larval breeding site management. However, with the spread of insecticide resistance 
threatening this progress, it is important to closely monitor the efficacy of insecticides used in 
these programs. Insecticide resistance can be broadly categorised into behavioural and 
physiological resistance. Behavioural resistance includes changes in feeding patterns e.g. 
feeding times and host preference (Donnelly, Isaacs et al. 2016). Physiological changes including 
cuticular thickening and genetic mutations affecting insecticide metabolism, impair the efficacy 
of the insecticide (Donnelly, Isaacs et al. 2016). Knockdown resistance (kdr) caused by point 
mutations in the target active-site results in insensitivity to pyrethroids and cross-resistance to 
DDT (later detailed in chapter 3). Where two kdr mutations were once geographically defined 
within sub-Saharan Africa the prevalence of both alleles is now widespread, and in some areas 
in combination to a multiplying mutation which escalates insecticide insensitivity (Neafsey, 
Juraska et al. 2015). 
Providing insecticide use remains the mainstay of vector control, fastidious monitoring 
and rapid response to the changing landscape of insecticide resistance becomes increasingly 
important (White, Verity et al. 2015). The tools used to track resistance should ideally suit the 
settings they are intended to be used in areas where malaria is prevalent. In this way, the 
characteristics required of these tools overlap with those required for diagnosing malaria 
infection (Hoffman, Vekemans et al. 2015). 
Page 25 of 266 
 
1.1.2.2. Vaccines 
The pre-erythocytic stage vaccine Mosquirix (RTS,S/A S01) is the only licensed malaria vaccine 
to date, having gained approval for use in 2015 (Hodgson, Ewer et al. 2015, Ademolue and 
Awandare 2018, Su, Lane et al. 2019). In 2019, pilot vaccination programmes were rolled out in 
Ghana, Kenya and Malawi, for us in young children and infants in whom the vaccine has 
previously demonstrated the greatest protective effects. The vaccine is based epitopes in the 
Circumsporozoite Protein (CSP) of P. falciparum and the Hepatitis B virus envelope protein. 
Other vaccines in Phase I-II stages of the pipeline include those that target different life-stages 
of the parasite e.g. blood stages, transmission blocking vaccine that target the sexual stages, 
and combination vaccines that target multiple stages (Sedegah, Hollingdale et al. 2015, Kamau, 
Alemayehu et al. 2013, Hoffman, Vekemans et al. 2015, Mueller, Shakri et al. 2015, Richie, 
Billingsley et al. 2015, Ademolue and Awandare 2018). Diagnostics also play an important role 
in measuring the efficacy of vaccine candidates (WHO 2015, Su, Lane et al. 2019, WHO 2019). In 
the early phases of development, the sensitivity of the diagnostic is most critical not only to 
ensure treatment is rapidly administered, but also to most accurately estimate the efficacy of 
the vaccine. For this nucleic acid detection methods are most accurate, but not appropriate for 
use in low-resource settings. 
  
1.1.3. Diagnosis and treatment 
According to WHO recommendations, patients with suspected malaria should only be provided 
with treatment following prompt diagnosis of infection (WHO 2019). Given the potential 
severity of malaria, it is important that the infection is diagnosed as early as possible. Current 
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methods for diagnosing malaria, as well as new diagnostics in the pipeline are described in 
depth later in this Chapter (section 1.3). 
Artemesinin-based combination therapies (ACTs) are recommended as the first-line treatment 
of uncomplicated malaria. With no alternative therapies to artemesinin soon to enter the 
market, the use of artemesinin-based mono-therapies is actively discouraged and efforts are 
being made towards withdrawing these from the market (WHO 2015).  
There are currently 5 ACTs, all manufactured at a fixed dose:  Artemether-Lumafantrine, 
Dihydroartemesinin Piperiquine, Artesunate-Mefloquine, Artesunate- Sulfadoxine- 
Pyrimethamine, Artesunate- Amodiaquine and Artesunate-Pyronaridine. Alternatively, Quinine 
in combination with Doxycycline may be used for management of severe malaria (Frampton 
2018). For chemoprevention, Chloroquine (for P. vivax), Doxycycline, Mefloquine, Proguanil (in 
combination with Chloroquine) or Artesunate with or without Sulfadoxine- Pyrimethamine, are 
recommended by the WHO (WHO 2015). The main consideration in treatment choice is 
determined by the species and drug-resistant strains in circulation. In areas with multiple 
Plasmodium species, it is important to identify P. vivax and P. ovale species so that anti-
hypnozoite therapy can be administered alongside the anti-schizont/gametocyte therapy (WHO 
2015). All 5 have gametocidal activity except against stage V gametocytes, which instead 
require Primaquine or Tafenoquine (Peters and Van Noorden 2009, WHO 2017). These two 
drugs prevent transmission of the parasite to the mosquito, in addition to clearing P. vivax and 
P. ovale hynozoites, and thus prevent relapses. However in patients with G6PD (glucose-6-
phosphate dehydrogenase) deficiencies Primaquine can cause haemolysis of red blood cells, 
and should therefore be tested for this disorder prior to administration of the drug (Cheruiyot, 
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Auschwitz et al. 2016).  Impairment of the G6PD enzyme results in in a build of oxidative stress 
triggered by oxidative drugs such as Primaquine. This results in destruction and elimination of 
red blood cells in the spleen (Battle, Lucas et al. 2019).  
This complicates malaria Mass Drug Administration (MDA) programs, whereby 
populations are treated without prior testing. Due to immense efforts required for MDA 
programmes, these are currently only recommended for low-transmission settings nearing 
elimination, or for complex settings where drug-resistance is concerning (e.g. in the Greater 
Mekong region) or in emergencies where the health system becomes compromised (e.g. during 
Ebola virus outbreaks) (Rajahram, Cooper et al. 2019). In addition to use of monotherapies, 
drug-resistance in malaria is largely driven by sub-therapeutic dosing whether through 
unregulated manufacture or counterfeit drugs, and improper administration/ non-adherence. 
The World Wide Antimalarial Resistance Network (WWARN) provides open access resources 
relevant to antimalarial resistance. They work towards monitoring the emergence and spread 
of resistance, as well as international advocacy in these areas (D'Abramo, Gebremeskel Tekle et 
al. 2018). 
Monitoring species composition also becomes important in areas nearing P. falciparum 
elimination, as there is evidence that the prevalence of P. vivax can supersede P. falciparum 
where there is a decline in P. falciparum transmission (Rahimi, Thakkinstian et al. 2014). There 
is also mounting evidence that non-falciparum and emerging P. knowlesi infections may be 
more severe than originally thought (WHO 2015, WHO 2016, WHO 2017). Together these 
factors are shifting global attention to include non-falciparum species and highlighting the need 
for diagnostics for multiple species. 
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The WHO define malaria elimination as a “reduction to zero of the incidence of infection caused 
by a specified malaria parasite in a defined geographical area as a result of deliberate 
efforts” (WHO 2018). In 2016 the WHO identified 21 countries for malaria elimination by 2020, 
as part of the ambitious E-2020 initiative within the wider Global Technical Strategy (GTS) for 
malaria (WHO 2014, WHO 2017). These countries were chosen based on recent malaria case 
trends, declared malaria goals and guidance from experts in the field. Data from 2017 showed 
that 10 out of 21 were on track to reach elimination by 2020, however, nearing the end of 
2019, only Algeria and Paraguay are now WHO-certified as having eliminated malaria (WHO 
2014). Certification is a voluntary process that requires proof that there is no indigenous 
malaria transmission within that country for 3 consecutive years. They must also demonstrate 
that robust surveillance systems are in place to prevent a rebound in transmission (Tietje, 
Hawkins et al. 2014).  
 
As countries near elimination, the feasibility of maintaining elimination is affected by a number 
of factors, well summarised in figure one (O'Brien, Delage et al. 2015). Monitoring the shifting 
dynamics of malaria epidemiology is paramount to rapidly respond to cases and outbreaks 
(WHO 2015). For this, more active case detection (ACD) becomes essential- screening outside of 
health care settings regardless of symptoms- while passive case detection (PCD) approaches 
must be sustained, i.e. capturing data from those who present to health care providers 
(O'Brien, Delage et al. 2015). (Figure 1.3)  
 
Screening within healthcare settings is also essential with regards to Transfusion-Transmitted 
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Malaria (TTM), where parasites are unintentionally transmitted to patients of tainted blood 
transfusions. This can cause severe disease in the recipient, which is particularly problematic in 
non-endemic countries where individuals lack immunity to malaria (Owusu-Ofori, Gadzo et al. 
2016). The WHO provides guidelines for hemovigilance (Tietje, Hawkins et al. 2014), however 
the choice of diagnostic used to screen blood donors for malaria differs nationally. Currently, in 
sub-Saharan Africa microscopy is still the most widely used for screening donor banks, whereas 
antibody testing followed by an RDT or nucleic acid testing to confirm infection- is more 
common in higher-resource settings such as in non-endemic countries (WHO 2014). Evaluation 
of more sensitive RDTs could also offer a practical and affordable diagnostic test for endemic 
settings where most people would have anti-malarial antibodies (Doolan, Dobaño et al. 2009). 
 
To maximise resources, ACD is targeted to populations that meet different criteria 
depending on the setting e.g. recent travellers to an endemic country. Reactive Case Detection 
(RCD) is a form of targeted surveillance, where individuals in contact (temporally, spatially, 
categorically) with a confirmed case (passively or actively identified) are selectively screened. In 
this fashion, interventions can be better tailored to the local epidemiology (Carneiro, Roca-
Feltrer et al. 2010). The tools used to identify infections for active surveillance are critical for 
accurate and timely reporting. It is also important that the correct health system infrastructure 
is in place to support the use of these. 
 
 
Page 30 of 266 
 
Figure 1.3. Factors influencing elimination and the likelihood of sustaining elimination. 





Modelling has shown that areas with a higher malaria baseline or the ‘intrinsic malaria 
transmission level ‘require a higher coverage of more significant intervention efforts to achieve 
similar outcomes to an area with low malaria baselines. It is therefore important to implement 
control strategies proportionate to baseline malaria rates (Carneiro, Roca-Feltrer et al. 2010). 
For the estimation of baseline malaria rates, potential contributors to transmission or sources 
of infection, i.e. the ‘infectious reservoir’, need to be defined. This will guide interventions to 
halt transmission. 
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1.1.4. Parasite density 
Acquired immunity is central to preventing malaria (van Gool, van Wolfswinkel et al. 2011). 
However, the relationship is not well defined, due to the complexity between repeated 
exposure, age and acquired immunity in different epidemiological settings (Doolan, Dobaño et 
al. 2009). It was thought that a lack of exposure results in a lack of immunity, explaining the 
high levels of morbidity and mortality in under 5-year olds. It therefore follows that adults in 
high-endemic countries can withstand high density infections (>1000 parasites/ µl) without 
clinical signs. It is also well established that when a source of exposure is removed, e.g. in 
migrants moving from endemic to non-endemic countries, protective immunity rapidly 
declines, resulting in clinical malaria at much lower parasite densities in subsequent infections 
(Whittaker, Slater et al. 2019). This effect is also seen in naïve individuals travelling to endemic 
countries, who can develop disease at much lower parasite densities. Due to the lack of 
immunity in the individuals, parasitaemia rapidly increases (Whittaker, Slater et al. 2019). 
 It is thought that immunity- although not sterile- can mediate symptoms and severity 
through repression of parasite reproductivity (i.e. parasite density). Individuals who are not 
frequently exposed to parasites, such as those in low-transmission settings, would lack the 
acquired immunity necessary to control parasite reproduction (Ouedraogo, Eckhoff et al. 2018). 
However, it has been consistently shown that low density infections are most prevalent in areas 
of low transmission where acquired immunity is also low (fig 1.4) (Pett, Goncalves et al. 2016, 
Whittaker, Slater et al. 2019).  
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Figure 1.4. Impact of sub-microscopic infections in different transmission settings.  
Image taken from Whittaker et al., (Whittaker, Slater et al. 2019)  
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1.1.5. The silent reservoir 
Falling below the detection limit of microscopy (50 parasites/ µl blood), low-density or 
‘submicroscopic’ malaria infections have been described as a silent reservoir of infection (see 
Table 1.3 for diagnostic limits of detections). Such low densities rarely elicit symptoms and so 
asymptomatic individuals do not seek healthcare, therefore are not treated yet continue to 
harbour parasites. Despite the low densities of parasites, individuals are gametocytaemic and 
infectious to mosquitoes (Slater, Ross et al. 2019), therefore a source of continued 
transmission. The presence and density of gametocytes in the human host underpins 
estimation of transmission potential. Microscopy, as well as rt-PCR for stage-specific RNA are 
most commonly used to assess gametocytaemia (Okell, Bousema et al. 2012).  
A recent review showed the ubiquity of gametocytaemic, submicroscopic infections 
across a range of transmission settings, but that the proportion of these increased in low-
transmission settings (Okell, Bousema et al. 2012, Mosha, Sturrock et al. 2013, Bousema, Okell 
et al. 2014, Nash, Prevots et al. 2017, Slater, Ross et al. 2019). To prevent a rebound in 
transmission, it is important to actively identify these individuals, especially in near-elimination 
settings. Although disease severity is exacerbated with parasite load, it is not clear exactly how 
this is controlled and what role immunity plays. Longitudinal serology studies show a truly 
complex relationship between immunity, parasite density and clinical presentation (Ademolue 
and Awandare 2018, Bjorkman 2018).  
In a high transmission setting in Tanzania, children who did not develop infection had 
fewer anti-parasite antibodies (specifically AMA; apical membrane antigen and MSP1; 
merozoite surface protein 1) during infancy, but showed a higher IL-1B cytokine (anti-disease) 
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profile in their cord blood (Hofmann, Karl et al. 2017). Anti-disease immunity is acquired quickly 
and early during childhood, whereas anti-parasite immunity develops with exposure to the 
parasite and therefore age. Together with innate immune responses, specific antibody 
responses to liver- and blood-stages might explain the variation in disease outcomes. (Searle, 
Katowa et al. 2017) 
Another hypothesis is that strains circulating in these settings are less virulent. Bjorkman 
et al. (2018) suggests the more virulent strains could be being selected against through 
generation of symptoms that cause health-seeking behaviour (Bjorkman 2018). Thus, these 
strains will be cleared when the patient is diagnosed and treated. This would also result in a 
better primed immune system for subsequent infections. (Drakeley 2018) Another factor is 
infection comprising multiple strains or ‘super-infections’ that cause symptoms through a 
sudden increase in parasitaemia. This is supported by studies in Papua New Guinea (WHO 2014) 
and Zambia (Childs and Buckee 2015), where newly imported strains caused symptomatic 
malaria. (Mueller, Schoepflin et al. 2012) This supports modelling that highlights the 
importance of importation rate with regards to eliminations strategies (Slater, Ross et al. 2019). 
 
1.1.6. Infection chronicity 
The timing of sampling is also an important factor of reported parasite density. Cross sectional 
studies only provide a snapshot of the epidemiology of asymptomatic malaria. It is likely that 
recent parasite exposure influences the parasite density in subsequent infections. 
The handful of longitudinal studies, across a range of transmission settings, tell us that 
the dynamics are dependent on the locality. Chronic low-density infections (6-9 months) are 
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known to follow high-density clinical infection, potentially enabling transmission across 
transmission seasons. This is reflected in the variation in symptoms observed during different 
seasons, but more work is needed on gametocytaemia persistence to see how infectivity is 
affected. (Gruenberg, Lerch et al. 2019, Roh, Tessema et al. 2019.)  
Slater et al. (2019) found that due to the dynamic nature of parasite density during an infection, 
asymptomatic episodes were predictive of patent infection, although they could not distinguish 
between reinfection and recrudescence (Slater, Ross et al. 2019). Historically, markers such as 
Merozoite Surface Protein 1 and 2, and glutamate-rich protein (GLURP) have been used to 
genotype strains of Plasmodium for surveillance and monitoring of drug/ vaccine trials. 
However, studies have shown preferential amplification of shorter alleles over longer alleles 
obscuring results in multiclonal infections (Zhong, Koepfli et al. 2018). A recent study shows 
that in-depth sequencing of markers containing many single nucleotide polymorphisms flanked 
by intergenic tandem repeats improves identification of different genotypes in multiclonal 
infections. 
  
Currently, there is conflicting evidence around the genetic diversity of infections in low-
transmission settings and so it is suggested that Multiplicity of Infection (MOI) may be more 
important in determining symptoms (Bjorkman 2018, Drakeley 2018). 
 
1.1.7. Impact on transmission 
Drakeley et al. (2018) discuss four different archetypes of the overall infectious reservoir and 
their relative contribution in greater depth (Bechtsi and Waters 2017). In summary, the most 
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important factors seem to be: the length of time that individuals are gametocytaemic, 
gametocyte density- although less so- and whether the individual develops symptoms and 
obtains treatment (Slater, Ross et al. 2019). More genotyping studies would be advantageous 
to shed light on these theories, however low amounts of parasite DNA make these 
investigations difficult. (Mugambi, Peter et al. 2018)  
Parasite conversion to sexual development is epigenetically controlled (Tietje, Hawkins 
et al. 2014), and demonstrably higher in lower endemicity settings (Peeling, Holmes et al. 
2006). This impacts on the choice of drugs for elimination programs. Overall, these factors 
highlight the importance of active identification and treatment of asymptomatic individuals, 
especially within an elimination context. This needs to include active identification of infections 
to prevent future disease in the individual, and identification of hotpops and hotspots at a 
population level to prevent resurgence. 
 
1.2. The diagnostic pipeline 
 
The diagnostic pipeline is long and costly one. The development of an in-vitro diagnostic (IVD) 
begins by understanding the problem it is intended to solve and the specific market needs. 
Product development low-middle-income countries (LMIC) requires additional considerations 
to those in other countries. Electricity, cold-chain and skilled human resources are often limited 
in these settings, as is the appropriate infrastructure to support the distribution and use of 
diagnostic tests.  
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Understanding the purpose of the IVD as well as the market will help define the ‘use-scenario’ 
(who is going to use it and in what health care setting) and other characteristics which come 
together to form a target product profile (TPP). A TPP describes the minimal and optimal 
requirements for the final product, including the size, cost, throughput, run-time and storage, 
as well as details of analytical performance (Land, Boeras et al. 2019).  
 
1.2.1. Use-scenarios 
There is no one-size-fits-all test for malaria. Point-of-care tests (POCT) have different 
requirements to those used for surveillance- they need to meet criteria that enable their use 
near a patient. In Table 1, Tietje et al., (2014) outline the different requirements of tests in 
different use-scenarios, specifically in an elimination context where preventing transmission is 
most critical (Tietje, Hawkins et al. 2014). 
In 2006, Peeling et al. defined criteria for POCTs for sexually transmitted infections, for 
consideration in LMICS. The WHO has since adopted the ASSURED criteria for general 
development of POCTs: Affordable, Sensitive, Specific, User-friendly, Robust/Rapid, Equipment-
Free, Deliverable (Tietje, Hawkins et al. 2014).  
The first consideration is affordability, which is largely dependent on the amount of 
information gained from that test. For example, a test that accurately identifies malaria, HIV 
and syphilis simultaneously (the 3 biggest causes of mortality in pregnant women in 
sub- Saharan Africa) is less burdensome on resources. Even if this test is priced higher than the 
three separate tests combined, it could still be more cost-effective overall.  
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Secondly, the POCT must be user friendly i.e. as simple to operate as possible, 
minimizing training and resources. A maximum of 3-6 operator steps is suggested for LRS 
(project 2014). The desired sensitivity and specificity are determined by the potential impact of 
the results following testing. Sensitivity is mostly influenced by disease severity and the impact 
of missing a positive case e.g. if it is highly lethal and/or infectious. The specificity, on the other 
hand, is affected by the risks associated with unnecessary treatment e.g. highly toxic drugs 
/severe side effects, as well as impact of misdiagnosis and treatment costs. Differential 
diagnoses of malaria include a multitude of lethal diseases- most commonly diarrhoeal 
diseases, sepsis and viral haemorrhagic fevers- and so misdiagnosis could be as dangerous as 
missing malaria itself. Thus, malaria diagnostics need to be both highly sensitive and highly 
specific. POCTs must also be robust, due to the non-ideal storage conditions (lack of cold-chain 
and extreme temperatures) common in LMICs. Their patient-facing usage also requires them be 
rapid (<30 min).  
Finally, a POCT is ideally equipment-free and deliverable. These criteria go hand in hand, 
reducing upfront and maintenance costs of often bulky equipment, as well as minimising the 
complexity and therefore training requirements. It follows that an equipment-free test is also 
logistically more deliverable. Although the ASSURED criteria were first designed for POCTs, they 
provide a good basis for more complex, high-throughput tests. 
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Table 1.1. Target Product Profile (TPP) framework for malaria diagnostics in an elimination 
context.  
Table is taken from Tietje et al. (FIND 2019) 
TPP  POC Case Detection Point of contact ID High-throughput ID 
Requirements Low cost  Portable Higher cost  
 Easy to use Rapid results Standardised 
 Rapid results High sensitivity (low LOD) High throughput 
 High specificity  High sens/spec (low LOD) 
        
Use-scenarios Passive case detection Mass/ Focal testing e.g. Surveillance 
 Case follow-up Networks/ community/ borders Laboratory confirmation 
    Surveys Parasite quantification 
 
For active screening, test and treat strategies have been explored as a cost-saving strategy, 
especially for these settings. These programs have the additional benefit of being more publicly 
acceptable as they avoid treatment of uninfected individuals and reduce the potential to drive 
drug resistance. 
For Mass Test and Treat (MTAT) and surveillance programmes, many samples need to 
be screened at once, often necessitating batching and storage of samples. This inevitably 
creates physical and temporal distance between the test operator and the patient. Although 
Focused Test and Treat strategies (FTAT) can be lower throughput than MTAT, they still require 
highly sensitive tests with a rapid turnaround. Both strategies are used to screen geographically 
defined areas dubbed “Hotspots”, which are often related to behavioural patterns, e.g. 
occupations of the people in an area. Hot populations (hotpops) on the other hand are 
demographically defined, often silent infectious reservoirs in hard to reach locales. Pregnant 
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women in low-transmission settings could be an example of this, as asymptomatic placental 
malaria is difficult to diagnose (histological methods). It is important to identify and monitor 
hotspots and hotpops to prevent rebounding transmission. In Table 1.1, Tietje et al. (2014) 
categorise different use-scenarios for low-transmission settings describing proposed screening 
strategies for each (FIND 2019).  
Intermittent Screening and Treatment during pregnancy (ISTp) strategies for example 
could be considered an FTAT strategy, whereby only pregnant women are tested for malaria 
during crucial antenatal visits, regardless of symptoms and administered treatment if 
necessary. This controls malaria during pregnancy, but data could also inform epidemiological 
surveys for monitoring. It is also possible and preferable that new diagnostics could be used in 
several use-scenarios if they meet the required TPP requirements e.g. a highly sensitive 
molecular test, may be used at point of care if cheap and rapid enough.  
 
1.2.2. TPPs 
In collaboration with the WHO, the Foundation for Innovative New Diagnostics (FIND) develops 
publicly available TPPs for diagnostics needed for poverty-driven diseases such as malaria. 
Through engagement and consensus with key stakeholders, these TPPs act as a starting point 
for product developers. Their most recently published TPPs for malaria include 1) the 
simultaneous detection of multiple pyrogenic pathogens and 2) drug-resistance assays. 
Monitoring drug resistance and insecticide resistance, although important, are not discussed 
extensively in this thesis. However, the phenomenon of ‘diagnostic resistance’ (parasite 
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mutations that affect detection) is explored in Chapter 5, whilst insecticide resistance is 
considered in Chapter 3. For the focus of this thesis, TPPs specific to the detection of the 
malaria parasites within an elimination context are discussed. 
In 2014, a detailed TPP for a POCT for the rapid detection of low-density malaria 
detection was developed by FIND (FIND 2019). Most notably, they recommend that the POCT 
should be “performed under zero infrastructure conditions” suitable for “both ACD for control 
interventions and PCD for case management, as well as for use in surveillance”. The other 
requirements are commonly used for POCT TPPs: sensitivity 97-99%, specificity 90-99%, storage 
10-40 °C for >36month etc. They identify Histidine Rich-Protein 2 as a primary target suggesting 
the inclusion of a second Pf-specific analyte and/or a Pan-Plasmodium or P. vivax analyte. 
However, since the publication of this TPP they have further defined specific POCT TPPs for 1) 
acute P. vivax infections ‘PvA’, 2) P. vivax sub-patent infections ‘PvB1’ and 3) a P. vivax 
surveillance tool ‘PvB2’. (Okell, Bousema et al. 2012) 
Unlike for POCTs, it is generally accepted that the molecular surveillance of malaria requires 
skilled professional operators, as increased capabilities bring increased complexity. This 
generally translates to a need for infrastructure of at least a Level 1 healthcare facility setting.  
This year, Médecins Sans Frontiers (MSF) developed a TPP for the multiple analyte diagnostics 
platforms (MAPDx), in partnership with FIND and the WHO (Slater, Ross et al. 2015). Led by the 
Febrile Illness Diagnostic group, many of their priorities overlap with the FIND TPP for the 
detection of multiple pyrogenic pathogens. The breakdown of diagnostic silos through multiple 
detection technologies is a running theme in the diagnostics landscape. Although the MAPDx 
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TPP stipulates a platform with dual-detection capabilities for both genetic and immunological 
targets, its other criteria can guide development of either category. Although they identify 
several promising platforms that are commercially available/ in late development, they 
conclude that none of them currently satisfy their TPP (Drakeley 2018). 
Although there are no published TPPs for a molecular surveillance tool for identifying 
malaria in elimination settings, a TPP developed for drug-resistance surveillance shares many of 
the desirable characteristics and several publications discuss these with particular reference to 
elimination settings (WHO 2014, FIND 2019). The WHO additionally provide guidance on 
selecting diagnostics malaria specifically in low transmission settings (Tietje, Hawkins et al. 
2014). In their 2014 policy brief, they recommend the use of a sensitive NAAT in 4 out of 5 use-
scenarios: “Malaria epidemiological surveys, Focus investigations; reactive infection detection 
after identification of an index case, Mass screening and treatment” and “Screening of special 
populations (e.g. at border crossings)” (Wongsrichanalai, Barcus et al. 2007). The main 
difference between these is the degree of urgency for results. Considering these resources 
Table 1.1 briefly outlines a TPP for a rapid malaria NAAT for broad screening purposes in low-
transmission settings. Although current POCTs are not suitable for these use-scenarios, but with 
advances in technology new tests may fill this gap. The following section describes the currently 
used tests for malaria and those in the pipeline with potential to fulfil the proposed TPP 
(Table 1.2). Other characteristics e.g. stability/shelf/instrument design life are identical to those 
described by FIND (Unitaid 2018, WHO 2019). 
 
Page 43 of 266 
 
Table 1.2. General TPP for a malaria surveillance tool suitable for use in an elimination context. 









User Trained lab personnel  
Target Detection of key malaria species, ideally in additional to parasite 
specific-resistance markers 
Setting Level 2 healthcare settings (L1 unlikely to be carrying out 
epidemiological surveys) 









Analytes Nucleic acids 
Throughput 8-40 samples/8 hr day 
Test kit Self-contained kit that provides all reagents with minimal 
additional consumables (e.g. pipette tips) 
Specimen Minimally: whole blood, preferably other non-invasive sample 
e.g. saliva and urine 
Sample volume  <5ml whole blood, ideally finger prick (5-50 µl) 
Sample preparation Ideally integrated in the cartridge, otherwise 3 max steps 













Sensitivity/Specificity As in text for POCT 
LoD 1 parasite per microliter will detect 95% of infectious reservoir, 
therefore 97% sensitivity in the settings require LoD of 0.1 p/µl 
Test result Quantitative with qualitative threshold to inform clinical 
decisions 
Time to result <90 min 
Controls Integrated internal control, no need to for positive/negative 
control every run 
Cost < USD $5, but this may increase with additional targets 
Safety No biosafety cabinet required, minimal handling of biohazardous 
material; easily decontaminated platform   
Disposal Simple waste disposal route: recyclable or combustible cartridges 
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1.3. Malaria diagnostic landscape 
 
1.3.1. The gold standard 
The WHO recommends diagnosis of clinical malaria by microscopy or RDT. Despite the 
obvious pitfalls of microscopy - the need for extensively-trained professionals, subjectivity and 
a supportive infrastructure to maintain quality control/assurance- it allows species 
differentiation and quantification (fig 1.5) at a very low cost (WHO 2016). This has kept 
microscopy as the universal gold standard since the Giemsa staining techniques was developed 
over 100 years ago.  
 
Figure 1.5. Microscopy slide of Giemsa stained P. falciparum in a thin blood smear. 
Image source www.cdc.gov/parasites 
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Malaria rapid diagnostic tests (RDTs) were developed as simple tools, still cheap (< US$ 1) and 
useful where microscopy was not feasible. The demand for RDTs is rising with sales almost 
doubled between 2017 and 2018 (412 million RDTs globally), of which 16 countries account for 
80% of the demand (Beisel, Umlauf et al. 2016, Unitaid 2018). Of this market, 63% is for 
P. falciparum RDTs specifically (WHO 2016, WHO 2018). 
 
These immunochromatographic lateral flow tests comprise a nitrocellulose paper strip with at 
least 2 lines (control plus test lines) of immobilised antibodies or antigens to capture target 
antigens or antibodies respectively. Blood (generally venous, but capillary when patient was 
declined) is added (a drop, ~ 5- 10 µl) to the first well, followed by a buffer which allows the 
sample to flow across the strip. The sample flows across a conjugate pad containing detection 
antibodies (conjugated to a coloured substrate e.g. colloidal gold) which elicits a colour change 
within 15-20 minutes in the presence of the target. (Figure 1.6) 
 
Although a massive global market, in the field diagnostic performance of malaria RDTs can vary 
due to non-adherence to the manufacturer’s guidelines (timing/ blood volume), poor storage 
conditions and inherent differences in sensitivity/ specificity (Maltha, Gillet et al. 2013).  To 
control for analytical performance and consequently make recommendations, the WHO 
performs rigorous prequalification testing of malaria RDTs. The WHO- Foundation for 
Innovative New Diagnostics (FIND) Malaria RDT Evaluation Programme was launched in 2006 to 
bring transparency to quality assurance of commercial RDTs, the program has helped to 
accelerate the development and implementation of new malaria RDTs (Wu, van den Hoogen et 
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al. 2015). However, currently prequalification only includes sensitivity testing above  of 200 p/ 
µl (the widely accepted RDT  limit of detection; LOD), which is not suitable for the sub-
microscopic infections described earlier (Slater, Ross et al. 2015). 
 
Figure 1.6. Schematic diagram of an antigen-capturing lateral flow device (LFD).  
Parasite-specific antibodies (green) capture parasite antigen, which also bind detection antibodies 
(purple) conjugated to a coloured substrate (red circle). The control line is produced through binding of 
the control antibody (black) directly to the detection antibody. Image adapted from Maltha et al. 2013 
(Slater, Ross et al. 2019). 
 
 
1.3.2. Approaching detection limits 
It is generally accepted that microscopy’s LOD ranges between 50 parasites/ µl for expert 
microscopists and 100-200 p/ µl under non-ideal field conditions, whilst the LOD of RDTs are in 
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the range of 100-200 p/ µl (Ahmed, Levy et al. 2015). Modelling shows in a medium-high 
transmission setting, a diagnostic with an LOD of 100 p/ µl will identify >95% of disease, it will 
only detect ~50% of infections identified by more sensitive molecular methods such as 
Polymerase Chain Reaction (PCR [LOD < 1 p/ µl]). This is drastically reduced to just 14% where 
PCR prevalence is less than 10% (low-transmission settings) (Piper, J. et al. 1999, Das, Peck et al. 
2018). 
Despite advances in technology, for POCT only RDTs have been implemented in the field 
worldwide. However, it is apparent that more sensitive RDTs are needed. It is first important to 
understand the factors that contribute to the performance of RDTs in order to improve them.  
The choice of target analyte or combination of target analytes in an RDT is critical to its 
performance. Most P. falciparum RDTs are based on the detection of Histidine Rich Protein 
(HRP2), while fewer detect pan-Plasmodium aldolase and lactate dehydrogenase (genus 
specific). RDTs that detect a combination of these antigens show greater sensitivity than a 
single-antigen RDT (Gamboa, Ho et al. 2010). This enables a level of redundancy that 
compensates for variable antigen concentrations (Jain, Chakma et al. 2014) or mutations which 
affect protein shape and thus the efficacy of capture antibodies (Gascoyne, Satayavivad et al. 
2004, Katis 2015). Novel biomarkers, including those for specific to gametocyte stages, for new 
RDTs are in the early stages of discovery and are yet to be commercialised (Soti, Kinoti et al. 
2015). The dynamic fluctuation of parasite analytes over the course of an infection, coupled 
with the complexity of immunological responses (described above) has hindered biomarker 
discovery. 
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Variation during manufacture is a factor in RDT performance, as is the binding affinity 
and spacing of monoclonal antibodies on LFDs. A change in the source of any components 
affecting these can have profound effects. The quality of the nitrocellulose membrane is also 
crucial for the migration of liquids to the line where capture antibodies are embedded. Thus, 
methods that focus the path of liquid migration across the paper membranes are also being 
explored (Shekalaghe, Cancino et al. 2013). Precision direction of the flow of sample and 
subsequent buffers utilises the principles of microfluidics, as in lab-on-a-chip devices (reviewed 
in Gascoyne et al., 2004) (Oyet, Roh et al. 2017). 
 
Finally, operational factors such as adherence to the manufacturing guidelines, storage 
conditions, accurate data entry and record keeping are also important. These issues highlight 
the need for better training and call for the use of an automated data entry device, preferably 
connected to a centralised database.  
 
1.3.3. Reading aids 
Automated readers which interpret RDT results are being explored to 1) eliminate the 
subjectivity of interpreting faint lines, 2) facilitate accurate data-keeping through barcoding and 
automated uploading to a cloud database. They generally operate in one of two ways: either 
through an integrated image capture and analysis system, or through analysis of images 
captured by smartphones or Tablet devices.  
Currently the Deki Reader™ (Fio Corporation, Canada) is the only reader to be evaluated 
for use with malaria RDTs in several countries (Davis, Gibson et al. 2014, Herrera, Vallejo et al. 
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2014, Scherr, Gupta et al. 2016, Scherr, Gupta et al. 2016, Kalinga, Mwanziva et al. 2018), with 
subsequent roll out in Kenya. The utility of automated readers has also enabled movement 
towards quantifying tests that are designed to be qualitative. Scherr et al. (2015) report 
quantification of parasitaemia down to 20 p/ µl on Paracheck-Pf® RDTs (Orchid Biomedical 
Systems, India) using their iPhone5 mobile app system (Dalrymple, Arambepola et al. 2018). 
Their reader offered a lower LOD than visual readings by inexperienced operators, but not in 
comparison to more experienced ones (Kamaliddin, Joste et al. 2019).  
 
1.3.4. Concentration techniques 
Simple, low-cost sample concentration techniques could also offer a quick remedy for 
improving existing RDTs. Martin et al. (Martin, Rajasekariah et al. 2009) demonstrated that a 
simple pre-processing step using their ‘low-resource extraction cassette’ improved the 
sensitivity of 5 commercially available RDTs, dropping their detection limits down to 3-13 
parasites/ µl. The device is based on magnetic agarose beads and a series of washes, and 
although requiring some skill to perform, this format of concentrating blood in a pre-RDT step 
might be more rapidly rolled out whilst newly developed higher sensitivity RDTs progress in the 
pipeline of validations and evaluation. 
Although the specificity of malaria RDTs is generally good (>97%), it is important to 
consider factors that compromise specificity of LFDs. Aside from the poorer sensitivity of RDTs 
compared to NAATs, antigen persistence is a critical factor of discrepancy between these test 
types (Kamaliddin, Joste et al. 2019). Following clearance of an infection nucleic acids are 
degraded relatively quickly, making NAATs better suited for identifying active infection or 
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monitoring treatment efficacy (Lee, Jang et al. 2014, Gatton, Ciketic et al. 2018)  In comparison, 
proteins however degrade slower, antigen-tests therefore remain positive for longer and are 
thus more indicative of recent rather than active infection (WHO 2015). False RDT positives as a 
result of cross-reactivity with human anti-mouse antibody and rheumatoid factors has also 
been demonstrated (Saiki, Gelfand et al. 1988, Singh, Bobogare et al. 1999). 
 
1.4. Molecular testing 
 
The high cost of molecular testing, in addition to cold-chain requirements, restricts their use to 
well-resourced settings. With increasing effort toward 1) improving detection of low-density 
infections and 2) enhancing accessibility, molecular testing is becoming more feasible in LRS 
where malaria is most prevalent. However, the reproducibility and therefore robustness of 
molecular testing has come under question after studies showed significant variation between 
technical replicates. Together with uncertainties around the impact of treating asymptomatic 
infections, the WHO currently only recommends molecular testing for research purposes only 
i.e. genotyping, epidemiological and resistance mapping. For this, they offer an External Quality 
Assurance (EQA) scheme (Singh, Sung et al. 2004) to guide the use of NAATs, in the hope that 
resultant data will be more reliable and comparable.  
1.4.1. NAATs 
PCR is a well-established NAAT, used since the 1980s (Rougemont, Van Saanen et al. 2004). 
Nested PCR is a technique used to enhance the sensitivity of conventional PCR, by first 
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amplifying a larger fragment DNA and then further amplifying species-specific fragments within 
the amplicon, followed by electrophoresis for visualisation. The “Snounou” nested PCR (nPCR) 
developed in 1993 was until recently the most commonly used reference standard (Shokoples, 
Ndao et al. 2009). It targets the 18S rRNA gene in Plasmodia allowing differentiation between 
the 4 main species. In 2005 it was updated to include the P. knowlesi species, which had since 
been recognised as a human pathogen (Kamau, Alemayehu et al. 2013). Although a more 
sensitive assay (10 p/ µl LOD) than the gold standard, the procedure is extremely time-
consuming (~6 hrs), prone to contamination due to the transfer of the first amplicon to the 
second reaction mix and vulnerable to misinterpretation following electrophoresis due to 
subjective reading of bands on gels. 
Fluorescence-based PCR, whether using intercalating dyes that bind double stranded 
DNA or fluorophore-conjugated probes (sequence-specific oligonucleotides), it still requires -
skilled professionals and is more expensive than conventional PCR. On the other hand, these 
methods are less laborious, less subjective and less prone to contamination than nPCR. 
 
1.4.2. Probe based qPCR 
Hydrolysis probes comprise a donor dye and conjugated quencher molecule. The quencher is 
cleaved upon enzymatic activity, enabling the donor to fluoresce. One of the most popular 
hydrolysis probes is the TaqMan probe which is cleaved by Thermophilus Aquaticus (Taq) 
polymerase activity.  
Multiplexing of these probes allows the simultaneous detection of multiple Plasmodium  
species, making this one of the most commonly employed assays for the detection of malaria in 
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blood (Murphy, Prentice et al. 2012, Navarro, Serrano-Heras et al. 2015, Wu, van den Hoogen 
et al. 2015, Meerstein-Kessel, Andolina et al. 2018). However, they are mainly suited to well-
equipped laboratories only e.g. reference hospitals in HICs, epidemiological surveys and 
drug/vaccine development assays e.g. in Controlled Human Malaria Infection models (CHMI) 
(Unwin, Ahmed et al. 2020). These have been especially useful in detecting P. falciparum 
gametocytes for assessing transmission (Schneider, Wolters et al. 2005). Advances in probe 
technology have expanded the molecular toolbox for the development of NAATs (Navarro, 
Serrano-Heras et al. 2015). 
Molecular beacons e.g. HyBeacon probes (later discussed in Chapter 3) are sufficiently 
sensitive fluorescent probes (WHO 2014) (Hodgson, Douglas et al. 2015), but have not yet been 
widely used for malaria, possibly as the cost is similar to existing TaqMan assays. Likewise, 
integrated primer-probe technologies (e.g. Scorpions, Amplifluor®, LUX™, Cyclicons, Angler®) 
and nucleic acid analogues (PNA, LNA®, ZNA™) have potential, but are yet to be applied for 
malaria detection (Imwong, Hanchana et al. 2014). 
One major downside to fluorescence assays is the requirement for typically 
cumbersome and expensive (> £20,000) fluorometers or qPCR machines. With advances in 
technology, these devices are being miniaturised to overcome this (further discussed in Chapter 
3). Miniaturisation not only enhances portability but can reduce the volume of clinical sample 
and expensive reagents required, which also enables more rapid heating and cooling of the 
smaller volume.  
Another issue is that multiple targets normally require multiple fluorophores, incurring 
additional costs. Melt curve analysis (MCA, discussed in Chapter 2-3) can overcome this to 
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some extent but is highly dependent on the DNA sequence of the targets. 
In order to become ASSURED, molecular tests must be simplified. Whether through 
elimination of instrumentation, elimination of DNA extraction steps, minimisation of operator-
involved steps or use of technology that shortens the runtime, these improvements will also 
serve to reduce inherent costs. The difficulty arises in maintaining high sensitivity/specificity in 
a reproducible manner. There are several approaches to enhancing the sensitivity of NAATs for 
low density infections.  
 
1.4.3. Improving detection 
1.4.3.1. Assayed volume 
First, the volume of sample examined can be increased to maximise the chance of it containing 
parasite material. The WHO recommend the use of 5 μl blood minimum for NAATs with a limit 
of detection of 2 p/ µl max, which corresponds to the detection of 10 parasites in one reaction 
and thus a log fold improvement to microscopy (Steenkeste, Incardona et al. 2009). To 
maximise the amount of blood assayed, a prior concentration technique is normally needed.  
The ‘reference standard’ for concentrating/purifying DNA is extraction using commercial 
kits- commonly Qiagen Blood and Tissue DNeasy kits, which are expensive and laborious 
(further discussed in ch6.1.2). These concentrate DNA ~4-fold (<200 µl blood results in >50 µl 
DNA) for whole blood samples, or directly (without concentration) extract DNA for dried blood 
spots (<50 µl blood for 50 µl DNA). Alternatively, a larger volume of venous blood (5 ml) is 
drawn from the patient and processed en masse (Hofmann, Mwingira et al. 2015). However, 
this is not ideal for the patient, it requires skill to draw blood and incurs costs associated with 
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storage (EDTA tubes and cold chain). The extraction kits have the additional effect of removing 
NAAT-inhibitory factors in the whole blood. Although more ASSURED methods exist (explored 
in Chapter 3), the simplest are direct-blood assays. No single technique has been widely 
validated and adopted. Labs instead prefer familiar methods that suit project budgets. It would 
be useful to standardise DNA extraction using an ASSURED method and compare studies 
globally. 
 
1.4.3.2. Higher copy target 
Until very recently, the 18s rRNA gene has been the mainstay of molecular testing for malaria, 
being highly conserved and having multiple copies within the genome (4- 5 depending on the 
species and strain). Sequencing of the P. falciparum genome in 2002 has since enabled the 
design of more complex assays, utilising parasite DNA from cultures. Many continuous culture 
cell lines exist for P. falciparum e.g. 3D7, FVO, NF54 and 7G8, facilitating research around this 
species. Unfortunately, the genome has a low GC content (19%), complicating the design of 
molecular assays which perform better with high GC% targets for stronger primer/probe 
interactions.  
There are therefore limited suitable multi-copy DNA targets that are also suitable for the 
design of diagnostic NAAT for P. falciparum. Unlike P. falciparum, P. vivax has a relatively high 
GC content (45%), but the design of NAATS for P. vivax is limited by our inability to culture the 
species. Its elusive life cycle includes hypnozoite stages, complicating the maintenance of 
P. vivax in the laboratory and so no continuous cell lines are available. Thus, research on the 
unculturable species P. vivax, P. ovale and P. malariae is most often based on short-lived 
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primary cell cultures from clinical isolates. Alternatively, published genomes can be used to 
create synthetic DNA. Reliance on these methods has made fundamental research on these 
species very difficult, hindering the development of new drugs and diagnostics for these 
species. 
Mitochondrial DNA targets such as the Cytochrome B gene- a single copy gene per 
mitochondrion (20-150 mitochondria/ parasite)- offer a higher number of targets (Hofmann, 
Gruenberg et al. 2018), however subtelomeric targets offer higher still (Hofmann, Antunes 
Moniz et al. 2019). The varATS and TARE-2 genes have 59 and ~250 copies/genome and so have 
been targeted for ultra-sensitive detection of P. falciparum (Murphy, Prentice et al. 2012). This 
assay has proven more sensitive than conventional qPCR in clinical trials (Murphy, Prentice et 
al. 2012, Taylor, Howell et al. 2014). 
 
1.4.3.3. RNA targets 
When conserved high-copy number genes are scarce, an alternative strategy is to target RNA 
transcripts rather than DNA. The higher number of copies increases the likelihood of detection 
in smaller sample volumes. Reverse-transcriptase PCR (rt-PCR) assays are currently one of the 
most sensitive assays for malaria detection (Table 1.3), however they traditionally require the 
addition of an RNA preservative to the sample, as well as cold chain supply for storage (-80 for 
long term) and an internal control. The RT-PCR for 18s rRNA developed by Murphy et al., is 
currently the most sensitive, used to monitor vaccine trials (Taylor, Lanke et al. 2017). However, 
the 1000-fold decrease in limit of detection offered by RNA assays could present a new 
problem: over-sensitivity. The potential for cross-contamination between samples even at a 
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low level can produce false positives, and thus compromise specificity. This is a particular issue 
when extracting dried blood spots, as DNA can be transferred from the cutting device (usually a 
hole puncher) if not efficiently cleaned between samples (Cheng, Wang et al. 2015). To 
overcome this, Murphy et al. (2012) developed a custom-built laser cutting device to minimise 
handling of spots, only feasibly implemented in well-resourced settings. Although direct-blood 
lab-on-a-chip methods exist for RNA assays (McNamara, Kasehagen et al. 2006, Pett, Gonçalves 
et al. 2016) for high throughput screening the preservation and storage of RNA again becomes 
an issue. 
 
1.4.3.4. Coupling technologies 
Coupling technologies to mitigate the pitfalls of one test with the benefits of another is a 
common strategy to improve diagnostics. For example, Capture and Ligation probe PCR (CLIP-
PCR) offers a high-throughput method for amplifying RNA using an overnight lysate step instead 
of prior extraction/additional reverse transcription steps. The closed system from sample 
application to qPCR minimises the risk of cross contamination, also only amplifying the signal 
rather than the target (Mens, van Amerongen et al. 2008). 
PCR-Ligase Detection Reaction (PCR-LDR) is another example of coupling technology for 
accessibility. Originally requiring gel electorophoresis, it has since been adapted to a 
fluorescent microsphere assay (LDR-FMA) format using sequence specific microspheres 
(Luminex FlexMap probes). (Roth, de Bes et al. 2018) Again, this still requires gel 
electrophoresis and a fluorescence reader.  
Due to the complex relationship of immunity, asymptomatic and sub-microscopic 
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infection, immunological assays have not been discussed extensively here. However, Enzyme 
Linked Immunosorbent Assays (ELISA) and Indirect Fluorescent Antibody Tests (IFAT) are widely 
used to measure antibodies against- or antigens produced by- specific life stages (sporozoite 
(CSP and SPZ), asexual (HRP2/LDH) and gametocytes (Pfs25) (Abramowitz 1996). Although 
sensitivity of these assays is better than microscopy/RDTs, they fare poorly in comparison to 
NAATs, especially with low-density infections. Their use is mainly restricted to research 
purposes as they are laborious, time-consuming and expensive. Nonetheless, the principles of 
these techniques can be coupled to NAATs as a simpler method for instrumentation-free 
reading.  
Nucleic acid lateral flow immunoassays (NALFIA) which detect DNA-probe complexes 
using lateral flow devices (commercially available immunochromatographic cassettes or 
dipsticks [Abingdon Health, UK]) are a good example of this (Notomi, Okayama et al. 2000). In 
recent field evaluations in a low-transmission setting in Kenya, a direct-blood PCR-NALFIA (db-
PCR-NALFIA) for Pan/ falciparum achieved good sensitivity and specificity (both ~85 %) in 
comparison to qPCR (Mallepaddi, Lai et al. 2018). 
 
1.4.4 Isothermal NAATs  
Loop-mediated isothermal Amplification (LAMP) offers an alternative method for the simple 
visualisation of amplicon. The amplification reaction produces insoluble magnesium 
pyrophosphate, which accumulates to the point where it is visible to the naked eye. The 
isothermal properties of LAMP also eliminate the need for thermocyclers, requiring only an 
inexpensive heat block. These assays bypass the conventional thermal denaturation step in a 
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PCR, instead utilising enzymatic initiation followed by cyclical amplification, known as ‘auto-
cycling displacement’.  
This principle was first used in the Self-Sustained Sequence replication (3SR) method 
(Guatelli et al., 1990), but was quickly applied to other techniques including Nucleic Acid 
Sequence-Based Amplification (NASBA) and Strand Displacement Amplification (SDA). Although 
these achieved rapid amplification of DNA, poor specificity was reported due to linear 
amplification regardless of the presence of template (Polley, Gonzalez et al. 2013).  
 
In 2000, Notomi et al. developed (LAMP) to improve the specificity of these assays 
(Hopkins, Gonzalez et al. 2013). The new technique involved a complex design of 4 primers 
detecting 6 distinct targets within the same region of DNA. Several LAMP assays for malaria 
have since been evaluated in field trials (Schallig, Schoone et al. 2003, Poon, Wong et al. 2006, 
Unitaid 2018, Hsiang, Ntshalintshali et al. 2019), with several commercially available (Schneider, 
Wolters et al. 2005). The first and most thoroughly evaluated LAMP assay, the Eiken LoopAMP 
kit, detects the Plasmodium genus and, separately, P. falciparum species (more detail in 
Chapter 2). Briefly, studies have reported good sensitivity and specificity of this kit across the 4 
main malaria species. This has led to the development of the ‘PURE-DNA’ extraction kit (Eiken, 
Japan) to accompany the LoopAMP. Several other LAMP assays use similar heating protocols 
(Heated blood LAMP) (Pett, Gonçalves et al. 2016) or dilution methods (Illumigene, Meridian) in 
place of expensive DNA extraction kits, which are normally the main bottleneck in molecular 
testing.  
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With increased availability of genomic data and advances in technology, quantitative NASBA 
(QT-NASBA) assays were developed for the detection of DNA from the 4 main species of 
Plasmodia (Mens, Spieker et al. 2007, Pett, Gonçalves et al. 2016) as well as RNA transcripts for 
P. falciparum gametocytes (Kersting, Rausch et al. 2014). These assays will be especially useful 
for monitoring the dynamics of infective and non-infective stages in response to control 
strategies or in elimination settings.  Although highly sensitive and specific, the intra- and inter-
assay variability of QT-NASBA is higher than in qPCR (Li, Kumar et al. 2013, Ghindilis, Chesnokov 
et al. 2019). 
 
Recombinase Polymerase Amplification (RPA) (Kersting, Rausch et al. 2014), Tandem 
Oligonucleotide Repeat Cascade Amplification; TORCA (Reboud, Xu et al. 2019) and 
thermophilic Helicase-dependent amplification (tHDA) (Mallepaddi, Lai et al. 2018) also offer 
highly sensitive iNAATs for malaria detection. Most of these however require a colorimeter, 
fluorometer or LFD coupling for visualisation. Although in the early stages of development/ 
validation coupling of iNAATs to LFDs e.g. Lateral flow-RPA (Reboud, Xu et al. 2019) and LF-
LAMP (Crannell, Rohrman et al. 2014, Kersting, Rausch et al. 2014) has simplified these tests 
further, and with good sensitivity thus far (98% sensitivity for LF-LAMP in Uganda, and LOD 4-20 
parasites/ µl for LF-RPA) (Cordray and Richards-Kortum 2012, Quan, Sauzade et al. 2018). RPA is 
additionally useful as it runs at body temperature (~37 °C) eliminating the requirement for a 
heat block (Imai, Tarumoto et al. 2017). Table 1.3 summarises the characteristics of each of the 
major molecular techniques.  
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Table 1.3. Comparison of diagnostic techniques for malaria. 
Table source: adapted from Cordray et al. (Imai, Tarumoto et al. 2018). 
Index Test 
LOD  




(%) Reference test 
Microscopy 50 20 min/slide 0.2 97 100 Microscopy 
RDT >100 20 min/slide 0.45- 1.4 100 93 Microscopy 
PCR < 5 1 hr 1.5- 4 100 90 PCR 
rt-PCR 0.1- 10 1 hr 4- 5 91 96 Microscopy 
PCR-LDA 0.3- 10 1 hr 0.3* 99 94 Microscopy 
PCR-ELISA < 30 6 hr 0.3* 91 96 PCR 
LAMP 0.2-5 30 min- 2 hr 0.4- 0.7 76- 99 90-100 PCR/Microscopy 
NASBA 
0.01- 
0.1 60 min 5-20 100 86 Microscopy 
NALFIA 0.3- 3 1- 1.5 hr na 98 99 PCR 
RDT: rapid diagnostic test; PCR: polymerase chain reaction; RT: reverse transcription; LDA: lactate dehydrogenase 
assay; ELISA: enzyme-linked immunosorbent assay; LAMP: loop-mediated isothermal amplification; NASBA: nucleic 
acid sequence–based amplification; NALFIA: nucleic acid lateral flow immunoassay, LOD: Limit of detection, na: not 
available. 
 
1.4.5. Novel platforms 
Digital droplet PCR (ddPCR) is a new quantitative PCR technique that eliminates the need for a 
standard curve. It achieves sensitive detection through measuring amplification within single 
droplets (~15,000 droplets total), giving highly accurate and reproducible results. Most 
laboratories use their in-house standard curves for qPCR, either using synchronised cultures or 
synthetic plasmid DNA for non-falciparum species, rather than a universal reference standard 
curve. These ddPCR techniques may help to make data more comparable across the globe. 
Although the instrumentation incurs significant upfront costs (~$100K) compared to qPCR ($20-
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30K), the principle of droplet amplification could possibly be applied to the other more 
ASSURED amplification techniques. (Hayashida, Orba et al. 2019) 
The capacity to detect and sequence amplicon would be useful for confirming the presence and 
species, genotyping drug-resistance markers to influence treatment and tracking lineage for 
monitoring. Currently, sequencing of malaria is largely restricted to HIC due to the costly 
instrumentation and complexity of operation. Imai et al. (2018), have coupled LAMP with the 
portable MinION sequencer (Nanopore, Oxford) in a bid to track the C580Y mutation associated 
with artemisinin resistance in P. falciparum (Al-Shehri, Power et al. 2019, Land, Boeras et al. 
2019). However, the method currently uses expensive and laborious extraction methods and 
interpretation of the MinION data requires some skill. Simplification of sample pre-processing 
in a similar system has been demonstrated for Chikungunya (direct-blood LAMP-MinIon), but 
not for malaria (Ghayour Najafabadi, Oormazdi et al. 2014). With further simplification of the 
back-end analyses of sequence data, this platform could offer a useful, portable tool for 
sequencing in the low-resource settings.  
 
1.4.6. Non-invasive samples  
The ‘holy grail’ of malaria diagnostics would ultimately use non-invasive samples for diagnosis. 
So much so that the ASSURED has been updated to REASSURED to include real-time 
connectivity (e.g. mobile phone readers) and ease of use (non-invasive samples) (Ghayour 
Najafabadi, Oormazdi et al. 2014). This has patient benefits, obviates the need for skilled 
personnel and reduces costs. Historically, the sensitivity of urine (60-70 %) and saliva (70-83 %) 
assays have fared poorly in comparison to tests using blood from symptomatic patients 
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(Ghayour Najafabadi, Oormazdi et al. 2014, Ghayour Najafabadi, Oormazdi et al. 2014). A 
recent study reported similar sensitivity (73%) when using stool sample, providing opportunity 
to screen other parasites e.g. helminths simultaneously (Correa, Coronado et al. 2017, Al-
Shehri, Power et al. 2019). The new approaches to improving NAATs discussed in this Chapter 
could enhance these non-invasive molecular assays. Initial studies have shown that nPCR 
targeting a higher copy gene (e.g. CytB) improves the sensitivity of saliva and urine based tests 
(Berna, McCarthy et al. 2015). Conversely targeting higher copy genes in a new LAMP assay (18s 
rRNA) did not improve sensitivity in comparison to qPCR methods (Kelly, Su et al. 2015). 
Research on fingerprinting of Plasmodium volatiles has been explored primarily with 
regards to odour attractants for mosquito control, however interest in their use for malaria 
diagnostics is growing. (Guest, Pinder et al. 2019, Heraud, Chatchawal et al. 2019, Maia, Kapulu 
et al. 2019). These studies still largely rely on complex mass spectrometry techniques, but 
detection methods are being simplified. This year it was reported that well-trained dogs have 
the capability to identify malarial volatiles. It has been proposed that these dogs could assist in 
rapid screening at border crossings where imported malaria is a significant risk (Mwanga, Minja 
et al. 2019). More portable infra-red devices are being trialled for chemically fingerprinting 
malaria infections (Karl, Gutiérrez et al. 2011, Saha, Karmakar et al. 2012, Karl, Laman et al. 
2015).  
Finally, new techniques exploiting the unique physiology of infected red blood cells 
(iRBC) also offer an alternative strategy for non-invasive malaria diagnosis that have almost 
zero running costs. Generally, tests detecting the electromagnetic properties of hemozoin 
produced by the parasite, have been more successful than detection of deformability of 
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infected RBCs (Newman, Matelon et al. 2010, Fook Kong, Ye et al. 2015, Karl, Mueller et al. 
2015, Kasetsirikul, Buranapong et al. 2016, McBirney, Chen et al. 2018, Heraud, Chatchawal et 
al. 2019, Thamarath, Xiong et al. 2019). It has been demonstrated that the magnetically-
induced spin of parasite-derived hemozoin crystals in whole blood, is measurable using 
inexpensive and portable magnetic resonance devices, although larger clinical evaluation 
studies are needed (WHO 2016). 
Raman spectroscopy of malaria parasites in blood is another emerging field for non-invasive 
malaria diagnostics. A large clinical trial in Thailand using handheld spectrometers for malaria 
diagnosis, proved to be highly sensitive (98%) amongst symptomatic patients in Thailand (Chua, 
Lim et al. 2015). These technologies and their stage in the diagnostic pipeline are summarised 
in figure 1.7 (Cordray and Richards-Kortum 2012).  
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Figure 1.7. The pipeline of emerging malaria diagnostics. 
Image taken from: UnitAid report (Unitaid 2018) 
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1.5. Aims and objectives 
 
As areas of low malaria transmission approach elimination, low density asymptomatic infections 
prevail. To end transmission these infections must be identified and treated. There is an urgent need 
for sensitive diagnostic tools for malaria that are better suited to low-resource settings.  
This thesis aims to 1) explore new diagnostics suitable for molecular surveillance and 2) evaluate new 
POC tests for use-scenarios where molecular testing is simply not feasible.  
The specific objectives are to: 
1) Assess the suitability of high-throughput molecular assays for differentiating Plasmodium 
species (Chapter 2). This objective addresses the need for robust malaria surveillance in areas 
nearing elimination. In this scenario, the most sensitive assays (molecular tests) are needed to 
detect low-density infection as early as possible. 
 
2) Develop a new molecular test for malaria control on a portable, field-friendly platform 
(Chapter 3). Simplification of complex molecular assays will facilitate the implementation of 
these more sensitive tests, for use in lower-resource settings where they are critically needed. 
 
3) Characterise the diagnostic performance of a new RDT for detecting low density malaria 
during pregnancy in low and high transmission settings (Chapter 4-6). Whilst 
accessibility of molecular testing is improving, RDTs are still a necessary tool for low-cost 
and rapid diagnosis of malaria. With recent post-market evaluations reporting varying 
results in uRDT performance- depending on the transmission setting, presence of 
symptoms and population studied- we evaluate the uRDT in both Asian and African 
contexts, amongst a particularly vulnerable and understudied population: pregnant 
women. 
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2.0. Declarations 
Provision of samples 
DNA from clinical samples provided by Dr Jayne Jones (LSTM), previously underwent species 
confirmation by microscopy carried out by her laboratory. Likewise control DNA obtained from 
3D7 cultures was provided by Dr Grazia Carmada (LSTM). DNA controls for malaria species were 
provided by Dr Debbie Nolder (LSHTM/ PHE). 
STOP-MiP blood samples were collected by staff outlined in the STOP-MiP trial protocol. DNA 
was extracted from these samples by staff at the Eijkman Institute of Molecular Biology (EIMB), 
who also carried out the LAMP testing at EIMB, Jakarta. DNA samples were transported to the 
UK for further laboratory testing described below  
Laboratory work 
I carried out 100% of the HRMCA laboratory testing. I performed 50% of the Duplex testing of 
the STOP-MiP DNA samples, the other 50% was performed by Mrs Sylvia Sance Marantina from 
the EIMB whom I trained in the assay during her visit to LSTM.  
Building on Ms Rachel Byrne’s BSc work (LSTM/ University of Liverpool) optimising a mono-plex 
qPCR for P. falciparum, I further optimised and expanded this to develop the 4-plex qPCR 
described in this Chapter. Mr Chris Williams (LSTM) provided technical assistance in the 
determination of the 4-plex LOD and carried out some (33%) of the screening of the STOP-MiP 
samples by 4-plex qPCR. Mr Chris Willliams and Ms Nadia Kontogianni also provided technical 
assistance in screening discordant results by nPCR (33%). I carried out the rest of the 4-plex and 
nPCR screening.  
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Analyses 
I performed 100% of the analyses in this Chapter. 
Idea conception, intelligent and experimental design 
Dr Emily Adams (ERA) significantly contributed to the intelligent and experimental design of the 
work in this Chapter. ERA, Professor Feiko Ter Kuile and Dr Rukhsana Ahmed, were also 
essential in facilitating and coordinating the collaboration between LSTM and the Eijkman 
Institute of Molecular Biology for this work. 
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2.1.1. Chapter summary 
 
In this Chapter different molecular methods were investigated for their potential as reference 
tests for future evaluations of field-ready malaria diagnostics. Following poor performance of 
two established tests (HRMCA and Duplex assay), a new 4-plex qPCR was developed utilising 
different prime/probe sets from published assays. The 4-plex qPCR was implemented in a 
clinical trial, forming a part of the composite reference test for diagnosis of malaria. This 





For case management of malaria, it is important to determine the causative species of a malaria 
infection as it can influence treatment decisions. Diagnostic tests that differentiate species are 
also crucial for malaria surveillance and monitoring dynamics of species composition in 
response to interventions. For this, more sensitive diagnostic tests are needed. This Chapter 
investigates three molecular tests suited for malaria surveillance and for use as reference 
standards in diagnostic evaluations.  
Methods 
Three molecular assays: a high-resolution melt curve analysis assay for five species of malaria 
(P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi), a new 4-plex qPCR (excluding 
P. knowlesi) and a reference rt-PCR assay ‘Duplex’ (P. falciparum and P. vivax/ ovale/ malariae), 
were implemented and the limit of detection (LOD) quantified using P. falciparum cultures. A 
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pilot study used clinical samples diagnosed with malaria (by microscopy) to validate the 
HRMCA. The 4-plex qPCR was validated using samples from a clinical trial in Indonesia. LAMP 
was used as a reference test, with nested PCR as a gold standard. 
Results 
The HRMCA and Duplex assays had an LOD of 2-20 parasites/ µl, and the qPCR had an LOD of 
0.2-2 p/ µl. The qPCR had poor agreement with the LAMP, potentially due to poor specificity of 
LAMP, or trace contamination, nPCR confirmed the presence of many LAMP false positives. 
Conclusion 
This Chapter highlights some of the challenges associated with evaluating new diagnostics that 
rival the sensitivity of the existing gold standard test. Different strategies could be considered 
















There is a need for more sensitive diagnostics for detecting low-density malaria. In this Chapter 
we assess the accuracy of molecular assays that offer cost-savings, a simple work flow and/or 
differentiation of multiple Plasmodium species identification to replace the cumbersome 




First, a high-resolution melt curve analysis (HRMCA) (Shokoples, Ndao et al. 2009) was assessed 
using control samples of DNA confirmed by microscopy and qPCR (Shokoples, Ndao et al. 2009).  
Dissociation analysis or “Melt curve analysis” (MCA) is a cheaper alternative to probe-based 
multiplex qPCR making it attractive to low-resource settings. HRM primers are designed to 
produce amplicons that dissociate from fluorescent probes at distinct temperatures: coined 
melting temperatures (Tm). The rate of this dissociation is calculated as the change in 
fluorescence over time, producing a unique melt curve, which peaks in fluorescence at the 
characteristic Tm. 
The Tm is determined by factors such as the sequence of nucleotides as well the base 
composition and length of the amplicon sequence. A long amplicon with a high ratio of 
pyrimidines (guanine or cytosine) to purines (adenosine or cytosine) a high “GC” content, 
requires more energy to denature, thus have a higher Tm. 
The shorter the sequence, the fewer bonds to break and therefore a lower Tm is 
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observed. Likewise, nucleotide stacking plays a role in Tm, a pyrimidine followed by a purine 
(Y/R) increases the Tm in comparison to a purine/purine R/R. 
MCAs can be designed without specific- probes, instead using non-specific intercalating 
dyes such as SYBR™ Green which bind most dsDNA. This lowers the cost of the assay as 
sequence-specific probes are expensive to manufacture, however it can compromise specificity 
if probes bind to primer dimers and any other dsDNA present in the reaction. 
Multiplex assays for species ID are also feasible using MCA- if the target gene sequence 
is sufficiently different between species, yet conserved within the primer binding sites. This 
enables the use of only one primer set for the identification of multiples species.  
Although High-resolution melt (HRM) curve analysis (HRMCA) assays can be designed to 
work with general intercalating dyes such as SYBR, new assays utilise more specialised HRM 
dyes that bind dsDNA e.g. EvaGreen or SYTO 9. These dyes are less toxic, functional across a 
broader range of concentrations and are less selective in the amplicons they bind to. The 
combination of being able to use a higher concentration and the higher saturation of dsDNA 
with the dye enhances the resolution of the fluorescence peaks produced. This enables targets 
with more similar melting temperatures to be included, potentially allowing more targets to be 
multiplexed within a single assay. 
Most recently Chua et al. (2015) demonstrated the application of this technology for 
identification of the five main species of human malaria: P. falciparum, P. vivax, P. malariae, 
P. ovale and P. knowlesi. They designed a single set of primers targeting a highly conserved 
region of the 18S SSU rRNA gene in all five species, but with a highly variable region between 
primer binding sites to produce amplicons with distinct melting temperatures. With a lower 
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LOD of 1-100 copy numbers and runtime of under 2 hrs, their assay showed 100% concordance 
with PlasmoNex(TM)- a hexaplex PCR system that detects six species.  Their method utilises 
differential MCA (dMCA) to more accurately distinguish between similar melt curves. 
This high throughput method, multiple target design and lack of need for specific 
probes, reduces the cost per sample making it an attractive diagnostic tool for reference 
laboratories. In this Chapter the aim was to validate this assay, using stored, clinical samples 
from travellers returning to the UK. 
2.2.2. Introduction to RT-PCR 
 
Real-time PCR techniques are currently the most sensitive tests for detecting malaria 
(Rougemont, Van Saanen et al. 2004). The 18Ss rRNA gene (DNA) is most commonly targeted 
for molecular detection of malaria. Hydrolysis probes utilise the hydrolysing activity of 
polymerases (e.g. TaqMan- an enzyme derived from Thermoaquaticus spp. that is active at high 
temperature) to release a quencher from the donor dye (fluorophore) on the probe, allowing it 
to fluoresce. Although RNA-based rt-PCRs (Cheruiyot, Auschwitz et al. 2016) offer higher 
sensitivity than DNA-based ones, they are problematic in other ways (instability of RNA and 
potential for cross-contamination (see Ch1.4.3.3). 
 
Multiplexing probes has enabled sensitive detection of multiple species of Plasmodium  (Bass, 
Nikou et al. 2008, Meerstein-Kessel, Andolina et al. 2018), as well as identification of 
gametocytes (Bass, Nikou et al. 2010). However, hydrolysis probes are expensive, and these 
assays require a single probe per species. It is therefore more economical to use as fewer 
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probes as possible. A commonly used assay for xenomonitoring is published by Bass et al. 
(Ahmed, Levy et al. 2015) for the simultaneous detection of P. falciparum and P. ovale/P. vivax/ 
P. malariae (Povm) 18S DNA. This assay uses just two primer/ probe sets to make this 
distinction, reducing the cost of the assay. Given the good reported sensitivity (Chua, Lim et al. 
2015, HTA 2015) we determined the LOD of this assay in our laboratory to assess its suitability 
for low-density malaria surveillance. 
In addition to this a multiplex qPCR with a lower LOD was optimised for detecting 
asymptomatic, low density malaria. The qPCR was used in a Stop Malaria in Pregnancy (STOP-
MiP) trial  as part of a composite molecular test (microscopy, RDT, qPCR, LAMP and nPCR) for 
detection of malaria (Bass, Nikou et al. 2008). In this Chapter I assess the performance of the 










2.3.1.1. Control DNA 
DNA was extracted from P. falciparum sorbitol-synchronised 3D7 trophozoite cultures. To 
estimate the number of 18S rRNA copies present, the DNA was quantified using a Qubit kit 
(ThermoFisher Scientific, UK) and the concentration was converted to number of genomes 
(22MB size). DNA from non-falciparum Plasmodium species were provided by Public Health 
England (courtesy of Dr Debbie Nolder, LSHTM). Parasite load was not quantified by in these 
samples.  
2.3.1.2. Clinical samples 
Stored DNA samples collected from travellers returning to the UK from abroad between 2002-
2011 were used to validate the HRMCA. These samples were DNA extracted (n=12) from whole 
blood samples was provided by LSTM ‘s Clinical Parasitology Diagnostics laboratory (courtesy of 
Dr Jayne Jones). Samples that were positive for any Plasmodium species (by microscopy) and 
conveniently available within the diagnostic archives were selected for investigation.  
2.3.1.3. HRMCA index test 
The RT-PCR-HRM reaction mixture was identical to those described by Chua et al. (Ahmed, Levy 
et al. 2015), except Type-it HRM master mix (Qiagen, Germany) was used in place of 
MeltDoctor® HRM master mix. Briefly, 20 µl reactions contained 2x Type-it HRM master mix 
(Qiagen, cat#206542), 0.1 µM of each primer (forward primer 5′-GRAACTSSSAACGGCTCATT-3′ 
and reverse primer 5′ -ACTCGATTGATACACACTA-3′) (Eurofins) and 1 µl of DNA. Thermal cycling 
conditions were identical to those published, except we lowered the annealing temperature 
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after optimisation on the RotorGene-Q 5plex HRM platform (Qiagen, Germany) as follows: 
initialisation at 95 °C for 10 min, 95 °C for 15 sec and 58°C for 1 minute (40 cycles), followed by 
a final melt program gradually increasing the temperature (0.1 °C/ sec) from 60°C until 95 °C. 
DNA controls were performed duplicate, whilst validation test samples were in singlets. Melting 
curve plots were generated and analysed using the Rotor-Gene Q software. 
2.3.1.4. Analytical sensitivity and specificity 
Ten-fold serial dilutions of control DNA were used to estimate the limit of detection (LOD) for 
P. falciparum only. This could not be quantified for non-falciparum species as they were 
sourced from clinical isolates (see above). 
2.3.1.5. Ethics 
Clinical samples were received by the Clinical Parasitology Diagnostic Laboratory (LSTM) for 
diagnosis of malaria. Following clinical diagnosis, the samples were used to optimise and 
evaluate alternative malaria diagnostics. It was not feasible nor practical to gain consent for 
samples stored in a diagnostic archive, however small volumes of unconsented sample may 
occasionally be used for diagnostic validation for use within the HTA-licensed establishment 
i.e. the CPDL (Ahmed, Levy et al. 2015). 
 
2.3.2 Duplex assay 
 
2.3.2.1. Control DNA 
The LOD for detection of P. falciparum was estimated using serial dilutions of quantified DNA 
obtained from control DNA (as in section 2.3.1). 
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2.3.2.1. Duplex index test 
The primers, probes, and cycling conditions used here were identical to those used by Bass et 
al. (Ahmed, Poespoprodjo et al. 2019): initial hold at 95°C for 10 min, 40 cycles at 95°C for 10 
sec and 60°C for 45 sec. the reaction mix (20 µl total volume) contained: 2x SensiMix (Bioline, 
QT615-05), 1 µl DNA, 800 nM of each primer and 300 nM of P. falciparum probe and 200 nM of 
the probe for P. ovale/ vivax/ malaria. Primers/ probes sequences were as follows: P. 
falciparum probe (5'FAM-TCTGAATACGAATGTC-MGB 3'), P. ovale/ vivax/ malaria probe (5'VIC-
CTGAATACAAATGCC-MGB 3'), forward primer (5'-GCTTAGTTACGATTAATAGGAGTAGCTTG-3') 
and reverse (5'- GAAAATCTAAGAATTTCACCTCTGACA-3'), obtained from (ThermoFisher 
Scientific, UK). Real-time fluorescence was measured using the Mx3000P (Agilent, UK)  and the 
end-point fluorescence was analysed using MxPro QPCR software. 
 
2.3.3. 4-plex qPCR 
 
2.3.3.1. Samples 
The control samples used are outlined as above (section 2.3.1). 
Clinical samples 
Blood samples were collected from pregnant women in Timika and Sumba, Indonesia between 
2013-2016 as part of the STOP-MiP (Stop malaria in pregnancy) trial (ISRCTN: 34010937).  
Briefly, Timika is a coastal region in the Mimika district of West Papua. The area has moderate 
(15% prevalence (Kamau, Alemayehu et al. 2013)) year-round transmission, with all four main 
species of Plasmodium prevalent. The second site Sumba island is co-endemic for P. vivax and 
P. falciparum with year-round low transmission (Alemayehu, Melaku et al. 2015) (further detail 
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in Chapter 3 methods). During the trial, venous bloods (4 ml) were obtained at enrolment, 
antenatal visits and at delivery, where placental and cord bloods were also obtained where 
possible (Kamau, Alemayehu et al. 2013). Dried blood spots were prepared using 50 µl of blood 
and then stored at room temperature with silica in zip lock bags. 
 
2.3.3.2. DNA extraction  
DNA extractions using dried blood spots (DBS) were carried out at the Eijkman Institute of 
Molecular Biology (EIMB), Jakarta, using the Chelex method. Briefly, 6 mm filter paper 
(Whatman 3MM) punches were incubated on 0.5 % saponin overnight, before centrifugation 
and removal of the supernatant. Following rigorous PBS washing, the DBS was heated in 20 % 
Chelex 100-Ion Exchanger for 10 min (Biorad Laboratories, CA) at 100 °C, and the remaining 
supernatant stored at -20 °C. 
 
2.3.3.3. LAMP reference test 
LAMP testing was also performed at the EIMB throughout the trial. LAMP assays were carried 
out using the LoopAMP™ Malaria Pan Detection Kit (Eiken Chemical Company, Japan). Briefly, 
the LAMP reagents were reconstituted in 15 μl water/ tube and left to stand for 2 mins, before 
adding 15 μl of extracted DNA as recommended by FIND (personal communication with Dr 
Xavier Ding). Samples were incubated for 40 min at 65 °C and then 5 min at 80 °C. Results were 
interpreted under a UV light, where a green colour change indicated a positive result.  At the 
end of the trial- and following LAMP testing- DNA was transported to LSTM, UK for subsequent 
qPCR and nPCR testing for quality control. 
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2.3.3.4. qPCR 
For qPCR, primers and probes published by Kamau et al. (2013) for P. falciparum and P. vivax 
identification were used (Shokoples, Ndao et al. 2009). These were chosen having recently been 
identified as most sensitive in a review of molecular methods for malaria (Singh, Bobogare et al. 
1999, Shokoples, Ndao et al. 2009). The threshold of this duplex assay was tested in 
combination with primers and probes for Pan-Plasmodium , P. ovale and P. malariae species 
(previously published by Shokoples et al. (Singh, Bobogare et al. 1999)). This 4-plex qPCR assay 
was developed for the detection of Pf, Po, Pv and Pm. For this, qPCR reactions (10 µl total 
volume) contained: 2 μl DNA, QuantiFast Pathogen PCR Mix (Qiagen) and primers and probes as 
outlined in Chapter 3 (Table 4.1). Thermocycling conditions were as follows: 10 min at 95 °C, 15 
sec for 95 °C and 60 sec for 60 °C. Fluorescence was acquired using the Rotor-Gene Q 5plex 
HRM Platform (Qiagen, Germany) and cycling threshold (Ct) values (with a cut-off of 38 cycles) 
were calculated using the Rotor-Gene Q series software version 1.7 (Qiagen).  
 
2.3.3.5. Nested PCR (nPCR) 
The nPCR was performed on qPCR/LAMP discordant samples, using primers and cycling 
conditions described in Singh et al.(Ahmed, Levy et al. 2015) The nPCR was used as the gold 
standard and each sample tested in triplicate whereby a single positive result determined the 
sample as positive for Plasmodium  spp. The LOD of this assay was ~6 parasites/ μl (Ahmed, 
Poespoprodjo et al. 2019).  
All molecular testing was carried out by operators who were blinded to the clinical information 
of the participants. 
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2.3.3.6. Statistics 
Diagnostic performance indicators (sensitivity, specificity, negative predictive value, positive 
predictive value, diagnostic odds ratio, kappa value) were estimated using SPSS software and 
the Varstats Clinical Calculator (Chua, Lim et al.). Kappa values <0.2 were considered a poor 
agreement, 0.21-0.40 fair, 0.41-0.6 moderate, 0.61-0.8 very good (Bousema, Okell et al. 2014). 
The difference in proportions (detection of positives and negatives) was estimated using 
McNemars fishers exact test in SPSS software v26. The sample size here supports diagnosis of 
participants in the STOP-MiP trial rather than for diagnostic evaluation purposes, consequently 
the study in validation described here, consequently the 95% confidence intervals are used 
here to indicate confidence in data. Post-hoc analyses shows both studies in Timika and Sumba 
are well powered (P= 80% >) to estimate sensitivity and specificity. 
 
2.3.3.7. Ethics 
As above, ethical approval was granted under the STOP-MiP trial (Kamau, Alemayehu et al. 
2013) by the LSTM, UK, the Eijkman Institute for Molecular Biology, and the National Institute 
of Health Research and Development, Ministry of Health, Jakarta, Indonesia. Written informed 
consent was obtained from all participants. 
  




2.4.1. HRMCA Results 
 
2.4.1.1. Analytical performance 
HRMCA showed single peaks at an average melting temperature of 74.1°C for P. malariae, 
74.3°C for P. falciparum and 75.6°C for P. knowlesi control DNA. Two consistent peaks were 
observed for P. ovale at 76.5°C and 77.25 °C. P. vivax also produced two peaks at 76.8 °C with a 
lesser peak at 77.6 °C. One replicate of the P. vivax sample produced one peak at 74.3°C and 
another at 76.8°C. (Fig 2.1.1A) However, the dMCA showed that these P. vivax samples were 
more similar to the other P. vivax samples than to the P. falciparum samples (fig 2.1.1B). The 
differential analysis of the other samples also showed clear grouping within species. (Fig 2.1.1)  
To investigate the effect of DNA concentration, we analysed 10-fold serial dilutions of 
P. falciparum (Table 2.1.1) and non-falciparum species (Table 2.1.2). The LOD of the HRMCA for 
P. falciparum was determined as 10 copies/ µl (Table 2.1.1). Generally, the detection of non-
falciparum species was unreliable below a dilution of 1 in 10, except for P. knowlesi (only run in 
singlet due to low sample volume). (Table 2.1.2) 
 
2.4.1.2. Clinical validation 
We tested DNA extracted from 12 clinical samples confirmed by microscopy: 5x P. ovale, 3x 
P. vivax, 2x P. malariae and 2x P. falciparum. The dMCA correctly identified 50% of these 
samples: all 3 P. falciparum samples and one P. vivax sample. The other samples were too 
significantly different from any of the controls for a call to be made. (Figure 2.1.2) 
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Figure 2.1.1. HRMCA of 5 species of Plasmodium. 
A. MCA and B. dMCA (each line represents one technical replicate) for P. falciparum (red), P. 
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Figure 2.1.2. Differential MCA of clinical samples. 
Samples included P. ovale (pink, n=5), P. vivax (green, n=3), P. malariae (blue, n=2) and P. falciparum 
(red, n=2), with a positive P. falciparum DNA control (black, n=1) for differential analysis (normalised 
fluorescence minus normalised fluorescence of the P. falciparum control. 
 
 
Table 2.1.1. HRMCA copy number limit of detection for P. falciparum. 
Target Copies HRMCA call MeanⱿ Tm °C Confidence (%) 
1000 P. falciparum 74.3 98.5 
100 P. falciparum 74.4 93.8 
10 P. falciparum 74.3 94.6 
1 Unknown 74.4 46.5 
0.1 Unknown 74.4 - 
0.01 Unknown 74.4 - 
Ɀ Technical duplicates and *Confidence as calculated by the Rotor- Gene Q HRM software 
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Table 2.1.2. HRMCA limit of detection for non- falciparum species. 
Species Dilutionꭞ HRMCA call Confidence (%) * 
P. vivax 1:10 P. vivax 82.8 
1:10 P. vivax 82.8 
1:100 Unknown - 
1:100 Unknown - 
1:1000 Unknown - 
1:1000 Unknown - 
P. malariae 1:10 P. malariae 91.07 
1:10 P. malariae 91.07 
1:100 Unknown - 
1:100 Unknown - 
1:1000 Unknown - 
1:1000 Unknown - 
P. ovale 1:10 P. ovale 99.94 
1:10 P. ovale 99.94 
1:100 Unknown - 
1:100 P. ovale - 
1:1000 Unknown - 
1:1000 Unknown - 
P. knowlesi 1:10 P. knowlesi 100 
1:100 P. knowlesi 95.51 
1:1000 Unknown - 
ꭞ All species except P. knowlesi were run in technical duplicates and *Confidence as calculated by the Rotor- Gene 
Q HRM software 
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2.4.2. Duplex results 
 
The LOD for the detection of P. falciparum was estimated using serial dilutions of quantified 
DNA obtained from cultures. The LOD was determined as 100 copies/ µl (equivalent to 
approximately 20 parasites/ µl), as only 1 of 2 replicates was detected (Ct 39.23) at 
10 copies/ µl (2 p/ µl) and no amplification was observed below this. (Figure 2.2.1)  
 
Figure 2.2.1. Duplex standard curve of P. falciparum 3D7 DNA serial dilutions. 








Page 98 of 266 
 
2.4.3. 4-plex qPCR results 
 
The LOD of P. falciparum species in the 4-plex qPCR assay was determined by testing serial 
dilutions of DNA (100- 104 target copies/ µl) extracted from 3D7 cultures. There was a strong 
correlation (R2=0.997) between copy number and Ct value. (Figure 2.3.1) The highest level of 
variation was observed at 100 copies/ µl (95% CI Ct ± 2.5). The LOD of non-falciparum species 
could not be quantified, however a linear trend of increasing Ct with dilution was observed for 































Figure 2.3.1. The 4-plex qPCR limit of detection for P. falciparum species. 
Ten-fold serial dilutions P. falciparum DNA was tested (n= 12 replicates) by 4-plex qPCR. Each 
dot represents a replicate (n=12), bars represent mean± 95% and dashed line depicts the Ct 
cut-off (38). 
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Figure 2.3.2. The 4-plex qPCR limit of detection for species. 
Ten-fold serial dilutions of P. vivax (squares, n= 10), P. ovale (diamonds, n= 6) and P. malariae (circles, n= 
6) DNA were tested. Each dot represents a technical replicate, bars represent 95% CI around the mean 




2.4.3.1. Detection of malaria 
The diagnostic algorithm in figure 2.3.3 shows the number of samples from each site that was 
tested by LAMP, qPCR and nPCR. Samples included all LAMP positive samples from both sites 
and ~5% LAMP negative samples in the STOP-MiP trial. Samples from Timika included 639 
LAMP positive samples and 328 negatives (n=967), while Sumba samples (n=910) included 658 
LAMP positives and 252 negatives (Table 2.3, appendix table 2.7.1). A description of the 
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table 2.7.1. The distribution of qPCR Cts obtained for different species (confirmed by LAMP) are 
detailed in appendix 2.7. Interestingly, all P. falciparum positive samples (by qPCR) in Sumba 
were co-infected with P. vivax (fig 2.3.4 and appendix 2.7). 
 
Figure 2.3.3. Diagnostic algorithm for sample testing by qPCR, LAMP and nPCR. 
 
 
2.4.3.2. Diagnostic performance 
Using LAMP as a reference test, the qPCR sensitivity was higher in Timika (55.9%; 95% CI 51.9- 
59.7%) than in Sumba (29.5%; 26.1- 33.2). Specificity, however, was higher in Sumba (95.6%; 
92.1- 97.7%) than in Timika (82.3%; 77.7- 86.2%). The level of agreement between LAMP and 
qPCR is almost double in Sumba (κ= 9.16; 95% CI 4.89-17.15) than in Timika (κ= 5.89; 4.26-8.15), 
but with overlapping confidence intervals. (Table 2.3) Finally, McNemar’s test confirms that 
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overall the proportion of infections detected by the qPCR is significantly different to that 
detected by LAMP.  (Table 2.3) Figure 2.3.4 shows the breakdown of co-infections determined 
by qPCR. All P. ovale and P. malariae samples detected by qPCR were confirmed by LAMP. 
 
Discordant samples (n= 388; Sumba, 291; Timika) underwent nPCR testing (fig 2.3.3).  
There were 7 samples in Sumba that were positive by qPCR (two repetitions), but negative by 
both LAMP and nPCR, whilst in Timika there were 12. There were also 33 and 51 qPCR-negative 
samples that were positive by both LAMP and nPCR, in Sumba and Timika respectively.  
 
Figure 2.3.4. Positive samples detected by LAMP and qPCR.  
The number of mutually detected positive samples in A) Sumba and B) Timika is shown (bold) within the circle 
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Table 2.3. Diagnostic performance of 4-plex qPCR compared to LAMP reference test in Indonesia 
Site n TP FN TN FP Sensitivity % Specificity % PPV % NPV % DOR  Agreement (k) 
Timika 967 357 282 270 58 55.9 82.3 86 48.9 5.6 0.33* 
(95% CI)      (51.9-59.7) (77.7-86.2) (82.2-89.1) (44.7-53.2) (4.3-8.2) (0.27-0.38) 
            
Sumba 910 194 464 241 11 29.5 95.6 94.6 34.2 9.2 0.16* 
(95% CI)           (26.1-33.2) (92.1-97.7) (90.3-97.2) (30.7-38.8) (4.9-17.2) (0.13-0.20) 
 
Note- n, number of samples; TP, True Positive; FP, False positive; TN, True Negative; FN, False Negative; Sens, sensitivity; Spec, specificity; (Lower 
95% CI- Upper 95% CI); PPV, Positive Predictive Value; NPV, Negative Predictive Value; DOR, Diagnostics odds ratio; k, Kappa value    





The HRMCA shows unreliable identification of non-falciparum clinical infections, particularly for 
P. vivax and P. ovale. Chua et al. (2015) report LODs of 0.025, 0.25, 0.027, 0.27 and 0.15 p/ µl 
for P. vivax, P. knowlesi, P. ovale, P. malariae and P. falciparum, respectively. Here we 
empirically determined the LOD as 2 p/ μl for P. falciparum, albeit with DNA extracted from 
cultures rather than plasmid DNA, which would be more accurate. The average Tm for each 
species reported here are in keeping with those reported by Chua et al. demonstrating its 
transferability to a different rt-PCR platform (Shokoples, Ndao et al. 2009).  
 We did however experience frequent contamination with P. falciparum DNA in our NTCs 
and non-falciparum samples. The data shown here represent the few experiments without 
contamination. This should be repeated with more biological and technical replicates, to 
identify the source of contamination. 
Another issue we encountered was the two shoulders in the melting peaks for P. vivax and 
P. ovale, which led to inaccuracies in the identification of these species. This could be remedied 
by further optimisation by lowering primer concentrations.  
 
In our study, clinical samples of non-falciparum species were not quantifiable and therefore the 
LOD was not determined for these species. Instead we estimated the maximum dilution factor, 
which will vary depending on species and parasite density. Ideally synthetic DNA would be used 
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to quantify LOD for these species. Finally, due to the contamination issues, few replicates were 
included in the analyses and so it was difficult to characterise this assay. 
MCA is generally qualitative and is prone to biased amplification of DNA that is most abundant. 
This could complicate the analysis of co-infections, whereby the assay may only amplify the 
DNA of the species with the highest parasite density. Due to the different replication rates, 
clearance and initial infection load, multiple Plasmodium species can be present at very 
different densities, which could result in amplification bias leading to missed infections and 
impact on treatment. Future validation of this assay should include clinical samples with 
confirmed Plasmodium co-infections, to guide implementation in different epidemiological 
settings. In conclusion, the observed LOD excludes its use for infections below 2 p/ μl such as 
those that are prevalent in low-transmission settings and commonly asymptomatic (Peeling, 
Holmes et al. 2006). 
 
2.5.2. Duplex 
The LOD for the Duplex assay determined here as 10-100 copies/ µl (~2-20 parasites/ µl) 
supports the original reported LOD of this assay. Given asymptomatic infection often falls below 
10 parasites/ µl, this assay would not be suited for screening of asymptomatic malaria. A more 
sensitive assay (4-plex qPCR) was thus pursued for the use in asymptomatic individuals in 
moderate transmission settings (Indonesia). It is important to consider the LOD of this assay as 
it is widely utilised for mosquito-infection studies and could result in the underestimation of 
infection/prevalence amongst vector populations in low-transmission settings. 
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2.5.3. 4-plex malaria qPCR 
The LOD of the 4-plex qPCR (1-10 copies/ µl; 0.2-2 p/ µl) was approximately 10-fold lower than 
that of the HRMCA or Duplex assays explored in this Chapter. This is in keeping with reported 
LODs (Slater, Ross et al. 2015, WHO 2016) for the primer/probe sets that were used to develop 
it.  A strong correlation was also observed between Ct and copy number for all species, 
suggesting the assay could be quantitative. 
The overall agreement of the 4plex with the LAMP PCR was categorised as poor in Sumba and 
fair in Timika. This mostly reflects the very low sensitivity of the qPCR in comparison to LAMP, 
however most of these were negative when assessed by the gold standard nPCR (n=576). This 
could indicate poor specificity of LAMP or cross-contamination during sample processing. Given 
that LAMP gives a binary result positive/ negative, it is impossible to know if trace 
contamination during the complex chelex DNA extraction step, could have caused such a high 
number of LAMP false positives. LAMP false positives may have been introduced at two main 
stages. First, during the hole-punching of the DBS samples where the same hole punch is used 
for multiple samples. Although the hole-punch is decontaminated between samples, this step is 
highly reliant on the rigour of the operator. Following DNA extraction, cross-contamination can 
be introduced during the DNA addition step. This is especially likely as the kit requires 1:1 (15 
µl) ratio of DNA: master mix, meaning large volumes of DNA are being pipetted.  
 
In 2010, an Intermittent Screening and Treating during pregnancy (ISTp) policy was introduced 
in Sumba. Using RDTs, the prevalence of malaria in the area was an estimated 7 % using the 
gold standard nPCR. Within the STOP-MiP study the prevalence by qPCR in Sumba was 5 % 
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(assuming no additional infections are detected in the remaining 95% of LAMP negatives), 
whilst LAMP was 10.3 %. The qPCR prevalence estimated here (2013-2016) is thus more in line 
with nPCR estimates in 2012, in the same area. 
 
Further characterisation of this 4-plex qPCR- including quantified LOD, robustness, inter-
lab/operator variability and analytical performance in field-settings, would support its use in 




This Chapter describes the development and validation of a 4plex qPCR able to identify the four 
main species of Plasmodium. The Chapter highlights the issues surrounding diagnostic 
evaluations when an index test may have superior sensitivity to the gold standard.  
Finally, the 4-plex qPCR developed here was utilised in the STOP-MiP trial in combination with 
LAMP and nPCR data to form a composite molecular reference test. The reference test was 











Table 2.7.1. Distribution of Ct values for infections in Timika (n=967) and Sumba (n=910). 
A. Sumba 
 Pf Pv Po Pm 
N Ct positive 286 193 0 0 
No Ct 624 717 910 910 
Mean 34.9 37.7   
Std. Error of Mean .3 .2   
Median 34.8 37.5   
Mode 27.6a 37.0a   
Std. Deviation 5.1 2.6   
Skewness -.21 .44   
Std. Error of Skewness .14 .18   
Range 22.9 13.4   
Minimum 22.1 31.6   
Maximum 44.9 44.9   
Percentiles 25 31.7 36.2   
50 34.8 37.5   
75 38.6 39.1   











 Pf Pv Po Pm 
N Ct positive 446 286 1 5 
No Ct 521 681 966 962 
Mean 35.7 35.5 36.6 35.8 
Std. Error of Mean .2 .2  1.1 
Median 35.8 35.8 36.6 35.3 
Mode 32.7a 39.4 36.6 33.0a 
Std. Deviation 3.4 3.9  2.4 
Skewness -.20 -.36  .19 
Std. Error of Skewness .12 .14  .91 
Range 21.3 21.1 .00 5.6 
Minimum 23.6 23.7 36.6 33.0 
Maximum 44.9 44.8 36.6 38.6 
Percentiles 25 33.6 33.1 36.6 33.5 
50 35.8 35.8 36.6 35.3 
75 38.0 38.3 36.6 38.2 




Page 109 of 266 
 
2.8. Acknowledgments 
I would like to thank Dr Thomas Edwards (Centre for drugs and diagnostics, LSTM) for his time 
training me in HRM and MCA. I am also grateful to Dr David Weetman for his donation of the 
Duplex reagents, as well as Ms Emily Rippon’s time and patience training me in the Duplex 
assay (Vector Biology department, LSTM). Finally, I would like to thank the huge number of staff 
and participants in the STOP-MiP trial for their efforts towards the study.  
Page 110 of 266 
 
2.9. Publication outputs
Page 111 of 266 
 
Page 112 of 266 
 
Page 113 of 266 
 
Page 114 of 266 
 
Page 115 of 266 
 
Page 116 of 266 
 
Page 117 of 266 
 
Page 118 of 266 
 
Page 119 of 266 
 
Page 120 of 266 
 
Page 121 of 266 
 
Page 122 of 266 
 
Page 123 of 266 
 




Page 125 of 266 
 
2.10. References 
Ahmed, R., et al. (2015). "Performance of four HRP-2/pLDH combination rapid diagnostic tests and field 
microscopy as screening tests for malaria in pregnancy in Indonesia: a cross-sectional study." Malar J 
14(1475-2875 (Electronic)): 420. 
Ahmed, R., et al. (2019). "Efficacy and safety of intermittent preventive treatment and intermittent 
screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for 
the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial." 
Lancet Infect Dis 19(9): 973-987. 
Alemayehu, G., et al. (2015). "Burden of malaria among adult patients attending general medical 
outpatient department and HIV care and treatment clinics in Oromia, Ethiopia: a comparative cross-
sectional study." Malar J 14: 501. 
Bass, C., et al. (2008). "PCR-based detection of Plasmodium in Anopheles mosquitoes: a comparison of a 
new high-throughput assay with existing methods." Malar J 7: 177. 
Bass, C., et al. (2010). "The Vector Population Monitoring Tool (VPMT): High-Throughput DNA-Based 
Diagnostics for the Monitoring of Mosquito Vector Populations." Malar Res Treat 2010: 190434. 
Bousema, T., et al. (2014). "Asymptomatic malaria infections: detectability, transmissibility and public 
health relevance." Nat Rev Microbiol 12(12): 833-840. 
Calculator-1, C. "VassarStats: Website for Statistical Computation." Retrieved 23 Oct 2018, 2018, from 
www.vassarstats.net/clin1.html 
Cheruiyot, A. C., et al. (2016). "Assessment of the Worldwide Antimalarial Resistance Network 
Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field 
Samples with Various Initial Parasitemia Levels." Antimicrob Agents Chemother 60(4): 2417-2424. 
Chua, K. H., et al. (2015). "Development of High Resolution Melting Analysis for the Diagnosis of Human 
Malaria." Sci Rep 5: 15671. 
HTA (29 Jul 2015). "Information for research tissue banks." Guidance for professionals. Retrieved 
18/07/2020, www.hta.gov.uk/policies/information-research-tissue-banks 
Kamau, E., et al. (2013). "Multiplex qPCR for detection and absolute quantification of malaria." PLoS One 
8(8): e71539. 
Meerstein-Kessel, L., et al. (2018). "A multiplex assay for the sensitive detection and quantification of 
male and female Plasmodium falciparum gametocytes." Malar J 17(1): 441. 
Peeling, R. W., et al. (2006). "Rapid tests for sexually transmitted infections (STIs): the way forward." Sex 
Transm Infect 82(suppl 5): v1. 
Rougemont, M., et al. (2004). "Detection of four Plasmodium species in blood from humans by 18S rRNA 
gene subunit-based and species-specific real-time PCR assays." J Clin Microbiol 42(12): 5636-5643. 
Shokoples, S. E., et al. (2009). "Multiplexed real-time PCR assay for discrimination of Plasmodium species 
with improved sensitivity for mixed infections." J Clin Microbiol 47(4): 975-980. 
Singh, B., et al. (1999). "A genus- and species-specific nested polymerase chain reaction malaria 
detection assay for epidemiologic studies." Am J Trop Med Hyg 60(4): 687-692. 
Page 126 of 266 
 
Slater, H. C., et al. (2015). "Assessing the impact of next-generation rapid diagnostic tests on 
Plasmodium falciparum malaria elimination strategies." Nature 528(7580): S94-101. 




Page 127 of 266 
 




3.0. Declaration of contribution .............................................................................................................. 128 
3.1.1. Chapter summary ......................................................................................................................... 128 
3.1.2. Abstract......................................................................................................................................... 129 
3.2. Introduction ..................................................................................................................................... 131 
3.2.1. Portable platforms .................................................................................................................... 131 
Figure 3.1. Portable platforms for molecular detection of malaria. ................................................ 134 
3.1.2. Simplification of DNA extraction ............................................................................................... 136 
3.1.3. Aims .......................................................................................................................................... 137 
3.3. Methods ........................................................................................................................................... 138 
3.3.1. MIC™ ......................................................................................................................................... 138 
3.3.2. Genedrive® assay development ................................................................................................ 138 
3.3.3. Simplified DNA extraction ......................................................................................................... 140 
Figure 3.2. DNA extraction work flow using RapiPREP beads ......................................................... 142 
3.3.4. Statistics .................................................................................................................................... 142 
3.3.5. Ethics ......................................................................................................................................... 142 
3.4. Results.............................................................................................................................................. 143 
3.4.1. MIC™ ......................................................................................................................................... 143 
Table 3.1. Comparison of qPCR results run on the MIC™ and Rotor-Gene Q (RG). ......................... 143 
3.4.2. Genedrive®................................................................................................................................ 143 
3.4.3. Simplified DNA extraction ......................................................................................................... 144 
Figure 3.3. The effect of thinning solution (NaOH) on DNA yields in eluate and flow-through. ...... 145 
Figure 3.4. Comparison of qPCR results following extraction with different DNA preparatory steps.
 ........................................................................................................................................................ 146 
3.5. Discussion ........................................................................................................................................ 147 
3.6. Conclusions ...................................................................................................................................... 151 
3.7. Acknowledgments............................................................................................................................ 151 
3.8. Publication Output ........................................................................................................................... 152 
3.9. References………………………………………………………………………………………………………………………..………….159 
Page 128 of 266 
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contributed to the intelligent and experimental design of the work in this Chapter, as well as 
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3.1.1. Chapter summary 
 
This Chapter explores low-cost, portable diagnostic platforms which aim to improve the 
accuracy and accessibility of molecular malaria diagnostics. First, the feasibility of transferring 
the 4-plex qPCR (developed in Chapter 2) to the portable MIC™ (Magnetic Induction Cycler, 
Biomolecular Systems, UK) was investigated. This was followed by a study of simplified DNA 
extraction techniques using RapiPREP beads to improve its suitability of this assay in low-
resource settings.  Finally, as part of my MRC CASE studentship funding, I completed a six-
month industrial placement with genedrive® plc in Manchester. I spent this time learning about 
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the process of designing and developing a new diagnostic assay, which lead to the optimisation 
of an assay for insecticide resistance on the mobile Genedrive platform which was subsequently 




The miniaturisation of cumbersome and costly instrumentation for molecular analyses offers 
new promise for sensitive diagnostic testing in field-settings. Here, two portable molecular 
platforms: the MIC™ and the Genedrive® are investigated for the detection of malaria and 
insecticide resistance respectively. The use of RapiPREP beads in DNA extraction methods were 
also investigated in a bid to overcome the common bottle of sample pre-processing. 
Methods 
First, a melt curve analysis test was designed for use on the Genedrive® for the detection of 
three genetic mutations responsible for knock-down resistance in mosquitoes. Primer/probe 
sets were optimised and validated using DNA from field-caught mosquitoes. 
Second, the performance of the 4-plex malaria assay (described in Chapter 2) run on the 
RotorGene-Q (non-portable) was compared to its performance when run on the portable MIC™ 
platform. The Ct values for each machine were compared using positive control samples for 
P. falciparum, P. vivax and P. ovale. Finally, the DNA yield obtained using a RapiPREP TB-bead 
protocol was compared to the use of whole blood directly in the 4-plex qPCR. 
Results 
Validation of the Genedrive® assay showed 100% agreement with the current gold standard 
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test for these mutations. The 4-plex qPCR Ct values were comparable when performed on the 
MIC™ and the RotorGene-Q. The concentration of DNA yielded from the RapiPREP protocol was 
akin to using diluted whole-blood directly in the 4-plex qPCR assay.  
Conclusions 
A novel melt curve test was developed for insecticide resistance in mosquitoes. In comparison 
to the gold standard, the Genedrive assay uses just two probes instead of six, has a simple work 
flow and is run on a portable rtPCR platform.  
Demonstration of the feasibility in transferring the 4-plex qPCR to the portable MIC™ platform, 
in addition to results showing the assay could be simplified for use with whole blood directly- 
demonstrates promise for performing this assay in field-settings.  
 
  




There are a multitude of hurdles that new diagnostics face in reaching their intended market. 
From validation through to implementation, many promising diagnostics fail to make the jump 
and succumb to the “diagnostic graveyard”. For malaria diagnostics, developers face difficulties 
in navigating local regulatory and policy requirements, and often lack an understanding of how 
to support diagnostics in the low-resource settings where malaria is most prevalent. Knowledge 
transfer between local healthcare professionals, academics and industry can help developers to 
understand key barriers upfront (FIND 2019). This Chapter includes a collaboration with 
industrial partners genedrive® plc to tackle two major barriers preventing the use of molecular 
diagnostics in the field, 1) the prerequisite for laborious DNA extraction, and 2) the requirement 
for cumbersome and costly instrumentation. 
 
3.2.1. Portable platforms 
For clinical management of malaria, microscopy and malaria RDTs are accurate tools to use to 
detect disease at the point-of-care. However, for surveillance in elimination settings, clinical 
trials monitoring controlled human malaria infection (CHMI) or treatment efficacy, microscopy 
and RDTs are not sensitive enough to pick up low-density infections and thus molecular testing 
is preferable (WHO 2016). Molecular testing is normally restricted to central reference 
laboratories, however, with advances in technology they are now entering the realms of ‘near-
POC’ (nPOC) diagnostics (WHO 2016). The movement toward miniaturisation of traditionally 
cumbersome equipment (Nwakanma, D'Alessandro et al. 2014), and simplification/ integration 
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or indeed complete elimination of prerequisite DNA extraction steps, reduces costs and 
simplifies work flow making molecular testing more accessible. 
These field deployable PCR devices are useful for obtaining rapid results that could influence 
responses at a programmatic level. In low-middle income countries even central reference 
laboratories often lack the healthcare infrastructure necessary to support molecular testing 
(Tsai, Liu et al. 2019). Adapting PCR assays for the field will enable more accurate diagnoses on 
the ground in close to real time. 
Isothermal molecular techniques e.g. LAMP have largely eliminated the requirement for bulky 
and costly equipment, and the reagents are often lyophilised, eliminating the need for cold 
chain (Ng-Nguyen, Stevenson et al. 2017). They do still however require a heat block, 
sometimes a visual analyser (e.g. UV light), are not multiplexed and are still expensive at more 
than USD $5 per test (personal communication) (O'Sullivan, Linnane et al. 2018).  
QPCR has the advantage of being quantitative, and with miniaturisation, lyophilisation of 
reagents and multiplexing, its associated costs could be reduced. Here we investigate the use of 
two portable PCR platforms as nPOC diagnostic tools for low-resource settings: The MIC™ 
(Biomolecular Systems, UK) and the Genedrive® (genedrive® plc, UK). 
 
The Genedrive® is currently marketed as a point-of-care, rt-PCR platform that is relatively cheap 
(~USD $5000 compared to >$20,000 for other qPCR instruments; personal communications) 
although not yet commercially available, portable (battery operated) and operated by a single 
button (fig 3.1A). The device uses a single wavelength optical system (400-470nm LEDs, 535nM 
photodiodes) to read a test cartridge. The device’s unique heating and cooling mechanism 
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generates rapid results (< 1hr) in comparison to most PCR based assays (>2hrs). 
Genedrive plc’s existing assays include detection of: Hepatitis C virus (HCV), IL-28 SNP 
mutations to determine HCV treatment (Auburn, Campino et al. 2011), M. tuberculosis (Walsh, 
Metzger et al. 1991), white-spot shrimp virus and a test for susceptibility to gentamycin-
induced deafness (personal communications).  
 
The MIC™ (Biomolecular Systems, UK) is a portable (2kg) PCR machine that uses patented 
magnetic induction for rapid thermo-cycling (35 cycles in < 25 min for short cDNA amplicons). A 
spinning rotor mechanism and custom tubes allow for uniform heating across samples to 
reduce variability. (Figure 3.1B) The Bluetooth-capable device has up to 4 optical channels and 
can run 48 samples. The provided software is also capable of connecting to and analysing up to 
ten devices in parallel. Studies using the MIC™ have used it to detect a variety of pathogens 
including parasites , viruses and bacteria as well as mutations in various organisms (Shenai, 
Armstrong et al. 2016, Duffy, Mottez et al. 2017).  
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A. The Genedrive® platform (Kifude, Rajasekariah et al. 2008) 
 
B. The MIC™ (source: www.biomolecularsystems.com) 
 
  
Figure 3.1. Portable platforms for molecular detection of malaria. 
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Given its suitability as a POC diagnostic platform, we investigated the feasibility of developing a 
Genedrive® assay for malaria. Although the qPCR assay was developed (Chapter 2), genedrive® 
plc prioritised the use of serum over whole-blood, due to their investment in HCV diagnosis. 
Since the concentration of parasite DNA in serum is lower than in blood (Zainabadi, Nyunt et al. 
2019) ,and especially in low-density infections, and consequently incompatible with genedrive 
priorities, other samples were considered. Hence, we developed an insecticide resistance assay 
to be used on mosquitoes, which was chosen due to simple techniques to extract DNA from 
mosquitoes and its potential utilisation in malaria control settings. The different characteristics 
of the two portable platforms are summarised in Table 3.1. The lower throughput of the 
Genedrive is a major shortcoming of the device, however this could be compensated for by its 
simplicity, ease of use, kits that are stored at ambient temperatures and rapid run time (Table 
3.1). 
 
Table 3.1. Product specifications of the Genedrive® and MIC™. 
Product specification MIC™   Genedrive® 
Weight  2.1 kg    0.6 kg  
Channels (wavelengths) Green Ex 465nm Em 510nm  Green Ex 465nm Em 510nm 
 Yellow Ex 540nm Em 570nm  - 
 Orange Ex 585nm Em 618nm  - 
 Red Ex 635nm Em 675nm  - 
Reactions per run  48    3  
Instrumentation cost (USD$)  15,000    5,000  
Thermal ramp rate   Heating 5°C/s    Heating 5°C/s  
  Cooling 4°C/s   Cooling 1.2°C/s 
Power requirements Mains or battery  Mains or battery 
Closed system  No    Yes  
Disposal General laboratory waste route   General laboratory waste route 
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3.1.2. Simplification of DNA extraction 
One of the major bottlenecks in molecular testing is the extraction and purification of DNA. This 
process is critical for removing the many inhibitors in whole blood (reviewed in Shrader, 2012) 
and concentrating target DNA, which can be scarce in low-density malaria infections. Although 
the labour of extraction can be reduced by automation (from 24 samples/run to 96), the 
process remains costly and prone to cross-contamination. DNA yields can also vary significantly 
according to the methods used, affecting the sensitivity of downstream diagnostics.  
 
Techniques such as specialised bead extraction (Mens, van Amerongen et al. 2008)  and boil-
and-spin methods (Modak, Barber et al. 2016, Roth, de Bes et al. 2018) have been explored in a 
bid to simplify this step and reduce costs/ labour. Alternatively, different direct-blood 
techniques which eliminate the step altogether have been developed for use in different NAATs 
e.g. NALFIA (Imai, Tarumoto et al. 2017, Choi, Prince et al. 2018). Direct-blood methods are 
becoming more common in isothermal methods (Taylor, Howell et al. 2014, Taylor, Lanke et al. 
2017) which are less prone to inhibition by contaminants. The use of microfluidics has also been 
explored for DNA extraction to aid simple molecular test e.g. to accompany LAMP (Taylor, 
Lanke et al. 2017). Building on microfluidics, lab-on-chip devices (Unwin, Ainsworth et al. 2018) 
are also available for malaria. These integrate the extraction and analysis steps requiring only 
whole blood input; however they still require unique instrumentation for reading and are low-
throughput (Scherf and Wahlgren 2008).  
 Currently, expensive but reliable silicon spin-column methods (e.g. Qiagen) are most widely 
used. In collaboration with genedrive® plc, we investigated the use of RapiPREP-TB beads 
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(MicroSens Biotech, UK) to concentrate P. falciparum DNA in whole blood. Genedrive plc are 
currently optimising a workflow for their use in concentrating MTb DNA, eliminating the need 
for centrifugation in their commercially available MTb tests. Here we use qPCR to analyse DNA 




The work in this Chapter aims to 1) transfer the 4-plex qPCR (optimised in Ch2) to the lower-
cost, more portable Magnetic, 2) investigate simplified DNA extraction techniques including 
RapiPREP TB-beads to facilitate the development of a field-ready, molecular malaria assay and 









The malaria 4-plex assay was tested on the MIC™ using control DNA for P. falciparum, P. ovale 
and P. vivax species (provided by Public Health England/LSHTM, courtesy of Dr Debbie Nolder). 
P. malariae was not included in this study as the MIC™ lacks the appropriate filter for the 
assay’s crimson fluorophore tested in Chapter 2. A ten-fold dilution series: neat, 1:10, 1:102 and 
1:103 (parasitaemia not quantified due to lack of standards at this time in the study), was 
prepared for DNA of each species and analysed using qPCR primers and probes identical to 
those outlined in the Chapter 2 methods (section 2.3.3).  Samples were run in parallel on the 
RotorGene-Q (Qiagen, Germany) and the MIC™ (Biomolecular Systems, UK) in single technical 
replicates. The resultant qPCR cycle threshold (Ct) values were pooled (n=12) for each platform 
and compared using a paired t-test. 
 
3.3.2. Genedrive® assay development  
The development and validation process for a Genedrive® assay is outlined below. The resulting 
assay is described in greater detail in the publication by Unwin et al. (DiNardo, Hahn et al. 2015) 
(appendix 3.1). 
The Genedrive® cartridge consists of three wells (20 µl capacity) enabling either technical 
triplicates or multiplexing of different assays. During the development phase, assays are optimised 
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using wet reagents, however as with other Genedrive® tests these could be lyophilised and stored 
at room temperature. 
Primer design for the Genedrive® assays is identical to that of a typical PCR reaction: a 
conserved sequence around 20 bp in length with a 55-60 °C Tm (melting temperature). 
For probe design, Genedrive plc utilise double-fluorophore conjugated HyBeacon™ probes. 
The target sequence (17-25 bp) should contain two thymidine bases approximately 7 bases apart 
(one helical rotation), to which the fluorophore is conjugated. This ensures both fluorophores are 
orientated in the same direction to enhance the signal. Ideally both thymidines are also adjacent to 
a guanidine, for stable conjugation to the fluorophore. 
Probes that exactly match the target sequence result in a higher melting temperature than that of a 
target with a sequence mismatch.  This enables multiplexing of sequence variants (species ID or 
mutations) using a single primer/probe set, saving time and costs. For multiplex assays, the peak 
Tm of each target must have a minimum separation of 2 °C to generate distinct melting peaks. 
 
As a point-of-care device, the throughput of the Genedrive® is restricted to 1-3 samples per 
run depending on the cartridge design. Optimal assay conditions are thus determined through 
screening on the LightCycler 480 (Roche, Germany), prior to transfer of the assay on to the 
Genedrive® for analytical testing. Initially 6 sets of primers and 4 probes were designed, which were 
screened for highest fluorescence peaks and desired melting temperatures. The reaction mix and 
cycling conditions are described in detail in appendix 3.6 (biotechnologies 2020). Once a 
primer/probe set was selected, the assay was optimised on the Genedrive® platform. Due to its 
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rapid heating and cooling capabilities, the initiation, annealing and extension periods are 
incrementally reduced to minimise total run time whilst still producing good fluorescence peaks. 
The final Genedrive® conditions were: 50 cycles of amplification at 95 °C for ‘0’ sec (allowed to 
reach temperature only), annealing at 62 °C for 10 sec, an extension at 72 °C for ‘0’ sec, followed by 
a melt step increasing the temperature from 42 °C to 80 °C in 0.5 °C increments with continuous 
fluorescence acquisition, and then cooling to 40 °C for 60 sec, resulting in a total run time of 50 
mins.  
An integrated algorithm is used to automate interpretation of the Genedrive® 
results. For this, the minimum peak fluorescence height as well as the melting 
temperature is defined for positive (presence of target detected) and negative 
(undetected) results. These parameters are also defined for an internal control to 
determine test validity. 
 
3.3.3. Simplified DNA extraction 
In line with other Genedrive® products, assays must have minimal sample pre-processing and 
so simplified DNA extraction methods were investigated. 
Asexual P. falciparum 3D7 parasites were cultured in-vitro to a final parasitaemia 
of 5% as per standard protocol (Sidstedt, Hedman et al. 2018) (provided by Wesam 
Bakhsh, LSTM). These cultures were used to spike venous human blood (ETDA 
preserved) directly for “culture-spiked” samples or were used for “DNA-spiked” samples 
following DNA extraction using a DNeasy Blood and Tissue kit (Qiagen, Germany). 
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The use of RapiPREP-TB beads (MicroSens Biotech, UK) in concentrating P. falciparum 
DNA was investigated. These magnetic beads, coated in a proprietary polymer, have been 
previously used for concentrating bacteria such as Chlamydia, Nisseria, MRSA and MTb 
(Sidstedt, Hedman et al. 2018), as well as some viruses (Abu Al-Soud and Rådström 2000). The 
manufacturer’s protocol was adapted as follows: equal volumes of thinning solution (2 % (w/v) 
NaOH was added to 200 µl of culture-spiked whole blood (1% parasitaemia). This was followed 
by the addition of 400 µl of TB-Bead solution, inverting the tube multiple times and then 
incubating at room temperature to capture any DNA present. The tube was transferred to a 
magnetic separation rack (New England Biosystems, UK) and left for 1 min before the flow-
through was removed from the beads. The tube was removed from the rack and 400 µl of wash 
solution (0.04% sodium hydroxide) was added to resuspend the beads. The tube was 
immediately placed back in the magnetic rack and the solution removed and stored at 4 °C for 
later analysis. Finally, 100 µl of elution buffer was added to the beads and incubated for 5 min 
at room temp to elute the DNA. The stored flow-through (wash buffer) was analysed alongside 
the final eluate to assess to proportion of DNA lost before elution.  
Also, thinning and washing steps were experimentally omitted during the optimisation 
process. The resultant DNA yield was assessed by qPCR (as described below (‘Direct-blood 
qPCR) in comparison yields obtained using a DNeasy Blood and Tissue kit (Qiagen, 69504). DNA 
from uninfected blood was also included as a negative control for both methods. (See figure 3.2 
for bead extraction procedure) 
The inhibitory effects of whole blood in the 4-iplex malaria qPCR (outlined in Chapter 2 
methods 2.3.2) were investigated. For this, serial dilutions (in 10-1 to 10-6) of DNA-spiked whole 
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blood and DNA in ddH2O were compared.  
 
Figure 3.2. DNA extraction work flow using RapiPREP beads 
 
3.3.4. Statistics  
The 4-plex malaria qPCR was used to assess both the RapiPREP TB-bead extraction methods 
and the direct-blood methods, using Ct as a proxy of final DNA yield. A cycling threshold (Ct) 
cut-off of 38 was used to determine positivity and the Cts between groups were compared 
using a Mann Whitney test. Correlation coefficients were calculated for the dilution series for 
spiked-blood and DNA qPCRs. 
 
3.3.5. Ethics 
Venous bloods were collected from three healthy, non-endemic volunteers (with no previous 
travel to endemic countries within the last 3 months) in accordance with the HTA and consent 
was obtained through signed LSTM participant consent forms. Blood was stored at -4°C and 
used within 3 hours of collection. 





P. falciparum, P. ovale and P. vivax DNA were all detected on the MIC™, all at lower Ct values 
than those run on the Rotor-Gene Q (Table 3.1). All dilutions of P. falciparum DNA were 
detected by both platforms, the MIC™ limit of detection for P. ovale was 10-2. The RotorGene-Q 
did not detect the P. vivax at 10-3 (Table 3.1) which was detected by the MIC™. 
 
Table 3.1. Comparison of qPCR results run on the MIC™ and Rotor-Gene Q (RG). 
The Table contains Cycling Threshold (Ct) values obtained from serial dilutions of malaria DNA including 




A multiplex melt-curve assay for insecticide resistance in Anopheles gambiae was developed for 
the Genedrive® as a field-friendly diagnostic for use in low-resource settings (publication 
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output 3.9). 
3.4.3. Simplified DNA extraction 
We investigated the effects of adding thinning solution, provided in the RapiPREP TB-bead kit, 
normally used for sputum samples) on DNA yield following the RapiPREP protocol. The loss of 
DNA in the discarded flow-through was also assessed.  
Using qPCR Ct values as a proxy of DNA yield, figure 3.3 shows more DNA (2-6 Cts or 10- 100 
fold) is retained in the eluate compared to the flow-through. The addition of thinning solution 
results in a lower yield of DNA in the eluate compared to when it is omitted. (Figure 3.3) 
Figure 3.4 shows that an additional wash step within the RapiPREP protocol significantly 
reduces (P<0.01) the yield of DNA compared a single wash step. Omission of the beads 
altogether significantly reduced the DNA yield, showing that the beads do play some role in 
concentrating the DNA (fig 3.4). Interestingly, significantly lower Cts were obtained when using 
diluted culture (10-1) directly in the qPCR compared to when neat eluate was added. 
 
Following this observation, DNA-spiked whole blood was directly added to the qPCR to assess 
its inhibitory effects. Figure 3.4 shows that at a dilution of 10-2, Cts were significantly higher in 
the direct- culture (mean= 33.5; 95% CI 32.8-34.3) qPCR compared to the spiked-whole blood 
(mean= 27.8; 95% CI 27.3-28.4) qPCR. Similar Cts were observed for the first dilution of spiked-
whole blood (mean= 28.4; 95% CI 28.0-28.9) and the second dilution (mean= 27.8; 95% CI 27.3-
28.4), indicating inhibition at this dilution. This is reflected in the higher R2 value of the direct-
blood qPCR when the first dilution is excluded (R2= 0.98) compared to when it is included (R2= 
0.91). 
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Figure 3.3. The effect of thinning solution (NaOH) on DNA yields in eluate and flow-through. 
Each dot represents a single technical replicate. Statistical analyses revealed no significant 
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Figure 3.4. Comparison of qPCR results following extraction with different DNA preparatory steps. 
Ct values obtained from qPCR of samples following the RapiPREP TB-bead protocol (grey circles): with one wash+ (serially diluted 
ten-fold) or two washes ++, and omission of the beads (diamonds), or a direct-qPCR of serially diluted (ten-fold) P. falciparum culture 
(black circles), DNA-spiked whole blood (triangles) and DNA extracted by DNeasy kits (squares).  Uninfected red blood cells (uRBC) 








The complexity and associated costs of real-time PCR methods restrict their use to well-
supported laboratories. Simplified methods and more portable platforms increase the 
accessibility of molecular methods for limited-resource settings.  In this study, the use of a 
malaria detection assay on the MIC™ platform was demonstrated, alongside an easy, 
preparatory method for whole blood that could further simplify the above assay. Alongside 
this we developed a new molecular assay for insecticide -resistance on the Genedrive® 
platform, for use in low-resource settings. Having learnt about the process of assay 
development, the Genedrive® offers a promising platform for the development of a malaria 
test in the future, in line with an informed genedrive® plc TPP. 
 
3.5.1. Direct-blood qPCR 
Historically, whole blood is known to contain an array of inhibitors e.g. haem-derivatives 
and immunoglobulins, which inhibit PCR reactions (mechanisms investigated by Sidstedt et 
al. (Tsai, Liu et al. 2019)). Autofluorescence of red blood cells, as well as denatured proteins 
from the high cycling temperatures, can also interfere with fluorescence readings (Silva 
Martins, Silva Pereira et al. 2019). Although cheaper alternatives to the reference standard 
silicone spin-columns are available, they are prone to cross-contamination and still laborious 
for high-throughput screening. Alternatively DNA extraction can be avoided by using 
specialist thermostable DNA polymerases that are more resistant to inhibitors or pre-
treating the sample with amplification facilitators (Lynd, Oruni et al. 2018). 
Our preliminary results show the 4-plex malaria qPCR (optimised in Chapter 2) successfully 
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detects P. falciparum DNA directly from diluted, spiked whole blood without prior DNA 
extraction. Minor inhibition was observed in the least dilute blood samples, but this was 
improved drastically by diluting in water at a 1:10 ratio (for a final 1:40 in qPCR reaction).  
 
Diluting the sample reduces the volume of blood assayed and therefore the amount of 
parasite DNA, which affects the sensitivity of the assay. This could also be overcome by 
amplifying the signal (optimisation of primer/ probe concentrations) or redesigning the 
assay to target higher copy-number genes e.g. TARE1 and VAR2. The total volume of the 
reaction could also be increased to boost the volume of blood assayed. 
 
It appears that the polymerase (proprietary) in the Quantifast Pathogen mastermix used 
here is robust enough to overcome inhibitory factors that might have been historically 
problematic in whole blood. We also suggest that the centrifugation in the RotorGeneQ’s 
platform is key to the success of this assay, spinning solids to the bottom of the tube away 
from the laser course. To properly characterise this assay, it is important elucidate exactly 
which factors are contributing to its success. For this it would be useful to compare other 
mastermixes with different chemistries, test whole blood from different populations and 
determine the LOD of the assay. This understanding could lead to the development of a 
proprietary, potentially lyophilised direct-blood assay, suited to a portable platform. 
 
3.5.2. MIC™ 
Here it is demonstrated that the 4-plex qPCR (Chapter 2) could be transferred to the 
portable MIC™ platform with relative ease. The MIC™ detected all P. falciparum samples, 
using the Rotor-Gene Q as a reference standard. Results showed reduced sensitivity of the 
Page 149 of 266 
 
MIC™ with regards to P. ovale, but potentially increased sensitivity of P. vivax in comparison 
to the Rotor-Gene Q. This suggests the assay needs refining to increase the sensitivity of this 
assay for these particular species. Again, it would be useful to determine the LOD for this 
assay on the MIC™ to explore methods that could improve accuracy, and compare its 
performance to similarly portable open platforms.  
It should be noted that this pilot (assay transfer to the MIC) was run in technical singlets, not 
repeated and the limit of detection (LOD) was not determined. Also, as mentioned above 
P. malariae was not tested in this study. Future work should include more replicates, 
quantified species-specific DNA for LOD determination and more clinical samples for 
diagnostic validation. This is the first use of the MIC™ for the detection of malaria but has 
been utilised other infectious diseases such as dengue, zika and chikungunya (Mulvaney, 
Fitzgerald et al. 2018).  
 
3.5.3. Genedrive®  
In collaboration with genedrive® plc we developed an assay for malaria control to run on 
their mobile platform. Whilst exploring simplification techniques for DNA extraction from 
whole blood (discussed below), we proceeded to develop a test for insecticide resistance 
mechanisms in mosquitoes. The resulting assay detected three mutations in the voltage 
gated sodium channel (VGSC) as well as wild type genotypes. This assay utilised two of the 
three available wells in a Genedrive® cartridge and had an assay runtime of under an hour. 
To achieve the same results using standard real-time PCR three separate assays would be 
required- each with a run time of up to 2 hrs and a total of 6 fluorescent probes rather than 
2. Since publication of our assay (2017), two further publications describe the detection of 
the same tri-allelic gene using 1) Engineered-Tail Allele-Specific-PCR (ETAS-PCR) (Griffin, 
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Hollingsworth et al. 2010) and 2) LNA probes (Slater, Ross et al. 2015). Although highly 
accurate, the first requires visualisation by gel electrophoresis and the second requires 
three fluorescent probes to date, the simplicity and low cost of our Genedrive® tri-allelic 
assay (appendix 3.1) is unrivalled. 
 
Handheld PCR devices are widely available (basic thermocycling heat blocks e.g. Ahram 
Biosystems), however real-time PCR devices that measure fluorescence are less so. One 
such device is the Biofire Film Array system that contains freeze-dried reagents suited to use 
in field-settings (WHO 2014). Instead, innovation in post-amplification detectors, e.g. 
NALFIA are being explored as portable devices that accompany handheld PCR devices.  
In terms of costs, the MIC™ retails at £10,000 whereas the Rotor-Gene Q is around £25,000. 
The cost of the device-specific tubes is comparable, making the main difference the reduced 
capacity (MIC™: 48 samples vs Rotor-Gene Q: 72). The MIC™ is therefore better suited for a 
faster turnaround of fewer samples. Furthermore, it uses a similar centrifugal system to the 
Rotor-Gene Q, so there is also potential to transfer the direct-blood qPCR on the MIC™.   
 
It must be noted that unlike the RotorGene-Q or the MIC™, the Genedrive® is not an open 
platform and so requires the purchase of assay-specific cartridges. Although cost per sample 
is comparable to other molecular tests (using their MTb assay as an example), the main 
limitation of the platform is the low throughput. Designed as a nPOC, the cartridge capacity 
is either one sample (where each well contains a different assay or where technical 
triplicates are desired) or three samples run in single replicates. Thus, a malaria Genedrive® 
assay is better suited for use where a small number of individuals need to be tested quickly 
and easily. One such use scenario is in focal testing and treatment (FTAT) strategies, where 
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transmission is low and these strategies are safer and thought to be more cost-effective 
(Slater, Ross et al. 2015, WHO 2015, Unwin, Ahmed et al. 2020) than mass drug 
administration. In these settings, sensitive tools are especially important to detect the low-
density infections that are most common. Future market analyses need to be conducted to 
inform a detailed target product profile for such an assay. 
 
Finally, the Genedrive® does not operate using centrifugal force, which we hypothesise is 
critical for the success of a direct-blood qPCR. However, its cartridge’s unique capillary wells 
together with the positioning of its laser course could support the use of a direct-blood 
assay i.e. denatured proteins could sediment at the bottom of the well without affecting 
fluorescence measurements. 
3.6. Conclusions 
In conclusion, the findings in this Chapter provide opportunity to further develop a direct-
blood qPCR on a portable rt-PCR machine, offering more cost effective, field-friendly, and 
sensitive testing for malaria.  
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3.8. Publication Output
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4.1.1. Chapter summary 
 
The study resulted in the recent Unwin et al. (Bousema, Okell et al. 2014) publication used 
here as Chapter 4. This Chapter investigates the use of a new commercially available rapid 
diagnostic test (RDT) for P. falciparum malaria. Using the previously obtained molecular 
results (Chapter 2) to formulate a composite reference test, the corresponding stored blood 
samples from Timika, Indonesia were tested for malaria using a new RDT (Alere™), alongside 
a commonly used brand of RDT (CareStart™). The results showed no significant difference in 
the performance of the two RDTs in this moderate transmission setting.  
Subsequent Chapters in this thesis build on the results reported here- Chapter 5: 
further investigating Histidine Rich Protein II (HRP2) mutations that could affect RDT 
outcomes and Chapter 6: expanding evaluations to a prospective study in Kisumu, Kenya, a 
high transmission setting.  
 
In lines with the UoL PGR Code of Practice (Appendix 7, Annexe 2) the publication has been 
formatted for the purpose of this thesis.  
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The sensitivity of rapid diagnostic tests (RDTs) for malaria is inadequate for detecting low-
density, often asymptomatic infections, such as those that can occur when screening 
pregnant women for malaria. We retrospectively assessed the performance of the Alere™ 
Ultra-sensitive Malaria Ag P. falciparum RDT (uRDT) in pregnant women in Indonesia. 
Methods 
The diagnostic performance of the uRDT and the CareStart™ Malaria HRP2/pLDH VOM 
(P. vivax, P. ovale and P. malariae) Combo RDT (csRDT) were assessed using 270 stored red 
blood cell pellets and plasma samples from asymptomatic pregnant women. These included 
112 P. falciparum negative and 158 P. falciparum positive samples detected by a composite 
test (qPCR, LAMP, nPCR) as reference standard. Diagnostic indicators: sensitivity, specificity, 
negative predictive value (NPV), positive predictive value (PPV), diagnostic odds ratio (DOR) 
and the level of agreement (kappa) were calculated for comparison. 
Results 
Compared with the reference test, the uRDT had a sensitivity of 19.6% (95% CI 13.9-26.8) 
and specificity of 98.2% (93.1-99.7%). The csRDT was 22.8% (16.7-30.3) sensitive and 95.5 % 
(89.4-98.3) specific for P. falciparum infections. Performance of the uRDT was non-
significantly different to the csRDT (p=0.169). RDT outcome was stratified by qPCR cycling 
threshold (Ct), and performance of the RDTs was found to be comparable across Cts. 
Conclusion 
The uRDT performed similarly to the currently used csRDTs in detecting P. falciparum 
infections in asymptomatic pregnant women. In these settings, molecular diagnostics are 
currently the most sensitive for malaria.  




Control programs for malaria will need to account for the changing epidemiology of malaria 
as countries progress toward elimination. The current goal to eliminate malaria in 31 
countries by 2030 will require sensitive diagnostic tools  (Okell, Bousema et al. 2012) to 
detect the reservoir of low-density and often sub-patent infections (Okell, Ghani et al. 2009, 
Doritchamou, Bertin et al. 2012, Okell, Bousema et al. 2012, Tadesse, Slater et al. 2018). 
Although the infectivity of these asymptomatic individuals is low, modelling shows that they 
contribute significantly to onward transmission because they make up the majority of the 
population in low-transmission areas (Mayor, Moro et al. 2012, Mohammed, Salih et al. 
2013). 
 
Diagnosis of malaria during pregnancy is complicated by the ability of certain P. falciparum 
parasites to sequester in the placenta, which can result in parasite densities in the 
peripheral blood below the level of detection of existing RDTs and light microscopy 
(Mockenhaupt, Rong et al. 2000, Adegnika, Verweij et al. 2006, Desai, ter Kuile et al. 2007, 
Bousema, Okell et al. 2014, Desai, Hill et al. 2018). Diagnosis and treatment of these 
infections may improve pregnancy outcomes by preventing them from developing into 
patent infections and may control transmission by reducing the parasite reservoir (Mayor, 
Moro et al. 2012, Indonesian Ministry of Health 2013, Ahmed, Poespoprodjo et al. 2019)). 
Lateral-flow rapid diagnostic tests (RDTs) detecting circulating malaria antigen are simple, 
widely used, and the cheapest point-of-care diagnostic tool for malaria. Many countries in 
the Asia-Pacific region use “Test and Treat” strategies at the first antenatal booking visit to 
screen all pregnant women for malaria regardless of symptoms (Slater, Ross et al. 2015, 
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Desai, Hill et al. 2018), or are exploring intermittent screening and treatment (IST) strategies 
to test women at each scheduled antenatal visit (Ahmed, Levy et al. 2015, Slater, Ross et al. 
2015). However, the current generation of standard RDTs for malaria has a limit of detection 
of 100 parasites/µl and is not designed to detect low-density infections in asymptomatic 
pregnant women (Slater, Ross et al. 2015). Low-cost and field-deployable highly sensitive 
rapid diagnostics may improve the detection of malaria in these populations (Das, Peck et al. 
2018). 
 
Currently, only nucleic acid amplification tests (NAATs) are sufficiently sensitive to detect 
these low-density infections (Vasquez, Medina et al. 2018). However, these methods are 
limited to well-equipped laboratory settings due to their inherent complexity and need for 
laboratory equipment.  
Recently, the new Alere™ Ultra-sensitive Malaria Ag P. falciparum RDT (uRDT) was 
developed to bridge the gap between high-sensitivity and field-ready diagnostics (Ahmed, 
Poespoprodjo et al. 2019). To date, studies in Uganda, Ethiopia, Myanmar and Papua New 
Guinea have shown superior sensitivity of the uRDT in comparison to widely used SD Bioline 
RDTs in asymptomatic general population. An additional laboratory study reports a log-fold 
lower limit of detection (LOD) for the HRP2 antigen (80 mg /ml) (Poespoprodjo, Fobia et al. 
2008). It is not disclosed which new components of the tests proffer enhanced sensitivity, 
but the additional 5 minute incubation time may be a contributing factor. However, the only 
study in pregnant women did not observe notable differences in sensitivity between the 
uRDT and existing SD Bioline RDTs. (Poespoprodjo, Fobia et al. 2008)  
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Here we describe the performance of the uRDT and standard RDT CareStart™ Malaria 
HRP2/pLDH Pf/VOM Combo (csRDT) in stored blood specimens of asymptomatic pregnant 
women in Indonesia compared to a composite molecular tests.  
  




4.3.1. Study sites and sample collection 
The study was performed using stored samples of red blood cell pellets (pRBC) reconstituted 
with plasma collected during a recently completed STOPMIP trial (ISRCTN: 34010937) 
comparing intermittent preventive treatment or intermittent screening and treatment 
strategies with single screen and treatment in pregnant women in Indonesia (Ahmed, Levy 
et al. 2015). The trial was conducted between 2013 and 2016 in Timika in Mimika District 
southern Papua-Indonesia, an area with moderate, year-round malaria transmission 
(Ahmed, Poespoprodjo et al. 2019). All four major species of Plasmodium  are endemic in 
the area with P. falciparum accounting for 57.9 % of infections, P. vivax- 33.8 %, 
P. malariae- 4.4 % and P. ovale- 0.5 % amongst pregnant women (Ahmed, Poespoprodjo et 
al. 2019). Co-infections of P. falciparum and P. vivax account for the remaining 3.8 %.  
Whole blood samples were taken from asymptomatic pregnant women (>16 weeks 
gestation) at antenatal visits to screen for malaria infection. During the trial this included 
microscopy, molecular malaria diagnostics (qPCR), nested PCR, and loop-mediated 
isothermal amplification (LAMP). Malaria RDTs (First Response Malaria Ag pLDH–HRP2 
Combo; Premier Medical Corporation, India) were also done at enrolment in the SST and IST 
groups. The FirstResponse RDT data is not included in our analysis as the number of 
matched samples was low. The sample processing and diagnostic tests used in this study are 
described below. 
 
4.3.2. Sample processing 
During STOPMIP trial, venous blood (4 ml) was collected from each participant in EDTA 
tubes at the booking and delivery visits and processed within 24hrs. Samples were 
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centrifuged for 10 min at 15000 rpm and RBCs and plasma separated and stored at -20°C. 
Dried blood spots were also prepared at the field laboratory, where 10 µl blood was 
pipetted on to filter paper (Whatman 3MM) and left to air-dry, stored in zip-lock bags and 
transported to the Eijkman institute of molecular biology for molecular testing. 
 
4.3.3. RDTs 
The RDTs used here recommend using whole blood samples. Due to storage conditions in 
the trial pellets of frozen RBCs were first reconstituted by adding the corresponding plasma 
sample to a final haematocrit (HCT) of 30%.  This reflects the average haemoglobin level 
(~11g/dL) observed previously in this population (Ahmed, Poespoprodjo et al. 2019) and in 
STOPMiP participants (Singh, Bobogare et al. 1999). The Alere™ Ultra-sensitive Malaria Ag P. 
falciparum RDT (uRDT, Alere, South Korea, Catalogue No: 05FK140, Lot No. 05LDC002A) 
detects P. falciparum infections only. The CareStart RDT (csRDT) (CareStart™ Malaria 
HRP2/pLDH Pf/VOM Combo RDT, Catalogue No: G0171, Lot No. RMR17H111, Access Bio, 
USA) detects P. falciparum and non-falciparum parasites (P. vivax, P. ovale and P. malariae). 
With both RDTs, the presence of a line in the ‘C’ window indicated a valid test. Invalid tests 
were repeated. A valid uRDT test was determined positive if a line was observed in the 
P. falciparum-line (Pf-line) window, whilst a valid csRDT was determined positive if the Pf-
line was present regardless of presence or absence of a line in the Pvom window. 
Both RDTs were performed according to the manufacturer’s protocol: briefly, a five µl 
reconstituted blood sample was added to the RDT cassette, followed by three (csRDT) or 
four (uRDT) buffer drops. RDTs were read according to the manufacturer’s guidelines; after 
20mins for uRDTs and 15 mins for csRDTs. RDTs were performed at the Eijkman Institute by 
an operator who was blinded to the reference test results. Presence of a line on an RDT was 
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confirmed by two independent operators. A third operator was consulted in case of 
uncertainty, and the test was declared positive if two operators agreed. 
 
4.3.4. Reference standard: Composite molecular test 
Molecular testing was carried out on DNA extracted (Chelex method) in 2016-2017 from 
DBS samples. Briefly, 6 mm filter paper (Whatman 3MM) punches were incubated on 0.5% 
saponin overnight, before centrifugation and discard of supernatant. Following rigorous PBS 
washing, the DBS was heated in 20% Chelex 100-Ion Exchanger for 10 min (Biorad 
Laboratories, Hercules, CA) at 100 °C, and the remaining supernatant stored at -20 °C 
(Kamau, Alemayehu et al. 2013).  
 
LAMP and qPCR results formed a composite molecular reference. Discordant results 
underwent nested PCR (nPCR) testing as the gold standard, which was run in triplicate and 
results were determined positive if a single replicate was positive by nPCR. These composite 
molecular tests were used as the reference standard (further described by Ahmed et al. 
(Kamau, Alemayehu et al. 2013)). 
 
Nested PCR (nPCR) was performed on LAMP-positive/ qPCR negative samples with primers 
and cycling conditions described in Singh et al. (1999). The nPCR was used as the gold 
standard whereby a single positive result determined the sample as positive for 
P. falciparum. The LOD of this assay is ~6 parasites/ μl (Shokoples, Ndao et al. 2009).  
 
LAMP assays were carried out using the Loopamp™ Malaria Pan Detection Kit (Eiken 
Chemical Company, Japan). Briefly, the LAMP reagents were reconstituted with 15 μl water/ 
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tube and left to stand for 2 mins, before adding 15 μl of extracted DNA. Samples were 
incubated for 40 min at 65 ºC and then 5 min at 80 ºC. Results were interpreted under a UV 
light, where a green colour change indicated a positive result.   
For qPCR, reactions contained, 2 μl DNA, QuantiFast Pathogen PCR Mix (Qiagen™, Hilden, 
Germany) and primers and probes published previously for P. falciparum (Kamau, 
Alemayehu et al. 2013), P. vivax  (Shokoples, Ndao et al. 2009), and P. ovale and P. malariae, 
(Shokoples, Ndao et al. 2009). (Table 4.1) Thermocycling conditions (38 cycles) were as 
follows: 10 min at 95°C, 15 sec for 95°C and 60 sec for 60°C. Fluorescence was acquired 
using the Rotor-Gene Q 5plex HRM Platform (as above) and cycle threshold (Ct) values were 
calculated using the RotorGene Q series software version. The LOD of this LAMP and qPCR 
assays is 2-5 parasite/ μl (Ahmed, Poespoprodjo et al. 2019).  
All molecular testing was carried out by independent operators blinded to clinical 
information. The LAMP, qPCR and nPCR were carried out a year prior to testing with the 
uRDT and csRDT. LAMP, csRDT and uRDT tests were carried out at the Eijkman Institute, 
Jakarta, Indonesia and qPCR testing was subsequently carried out at the Liverpool School of 
Tropical Medicine, UK.  
Positive DNA controls for each species (provided by the Malaria Reference Laboratory, 
Public Health England) and negative controls were included in every molecular assay run. All 
assays were carried out by independent operators blinded to clinical information. Index 
testing was also carried out without knowledge of the reference standard results.  
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Table 4.1. Working concentrations and sources are provided for the qPCR primers and probes.  





Pan reverse (Shokoples, Ndao et al. 2009) AACCCAAAGACTTTGATTTCTCATAA 200 Eurofins 
MAL FP (Shokoples, Ndao et al. 2009) CCGACTAGGTGTTGGATGATAGAGTAAA 50 Eurofins 
MAL probe (Kamau, Alemayehu et al. 
2013) ATTO700-CTATCTAAAAGAAACACTCAT-MGBEDQ 80 Eurogentec 
OVA FP (Kamau, Alemayehu et al. 2013) CCGACTAGGTTTTGGATGAAAGATTTTT 50 Eurofins 
OVA Probe (Kamau, Alemayehu et al. 
2013) Cy5-CGAAAGGAATTTTCTTATT-MGBEDQ 80 Eurogentec 
FAL FP (Kamau, Alemayehu et al. 2013) ATTGCTTTTGAGAGGTTTTGTTACTTT 400 Eurofins 
FAL RP (Kamau, Alemayehu et al. 2013) GCTGTAGTATTCAAACACAATGAACTCAA 400 Eurofins 
FAL probe (Kamau, Alemayehu et al. 2013) FAM-CATAACAGACGGGTAGTCAT-MGBQ 200 Thermo 
VIV FP (Das, Jang et al. 2017) GCAACGCTTCTAGCTTAATCCAC 400 Eurofins 
VIV RP (Das, Peck et al. 2018) CAAGCCGAAGCAAAGAAAGTCC 400 Eurofins 
VIV probe (Das, Jang et al. 2017) VIC-ACTTTGTGCGCATTTTGCTA-MGBQ 200 Thermo 
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4.3.5. Sample size 
The sample size was calculated using G*Power software v3.1.9.2 (University of Dusseldorf, 
Germany). Estimating a proportion of 0.35 discordant results between the two RDTs (based 
on previously published data in similar transmission setting (Ahmed, Levy et al. 2015)), a 
sample size of 120 positive samples was estimated to provide sensitivity with 80% statistical 
power and 99% confidence intervals. Studies have shown both uRDT and csRDT have 
similarly high specificity (>96%) (Calculator-1 , Calculator-2 , Ahmed, Levy et al. 2015). 
Therefore, the sample size was estimated to be able to detect differences only in sensitivity. 
The final sample size (n= 270) used for this analysis were those samples with sufficient 
volumes of both plasma and pRBCs remaining for RDT testing. Of these, 158 were 
P. falciparum positive and 112 negatives by the composite molecular reference test.  
 
4.3.6. Statistics 
Diagnostic accuracy was estimated by calculating the total number of true positives (TP), 
false positives (FP), true negatives (TN), false negatives (FN), sensitivity and specificity (%), 
positive predictive value (PPV) and negative predictive value (NPV). PPV and NPV calculated 
according to prevalence within the sample collection. The reference test method to get the 
TP, FP, TN and FN was the composite molecular test results (LAMP, qPCR and nPCR). 
Agreement between either RDT and the composite reference test was calculated by 
determining the kappa value (k). Kappa values <0.2 were considered a poor agreement, 
0.21-0.40 fair, 0.41-0.6 moderate, 0.61-0.8 very good. (Ahmed, Poespoprodjo et al. 2019) 
The diagnostic odds ratio (DOR) was calculated as the ratio of the odds of positivity in those 
with malaria (defined by molecular composite reference test) relative to the odds of 
positivity in those without malaria). The Ct values were used as a proxy of parasite densities. 
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The significance of the difference observed between the uRDT and csRDT R2 correlation 
coefficients was assessed using a Fisher r-to-z transformation. The analysis was conducted 
using SPSS (version 24.0, Armonk, New York) and an online calculator (Das, Peck et al. 2018) 
which uses the efficient-score method to calculate 95 % confidence intervals.  
 
4.3.7. Ethical approval 
Ethical clearance was obtained from the Liverpool School of Tropical Medicine and the 
Eijkman Institute for Molecular Biology, Jakarta, Indonesia. Written informed consent was 
obtained (Abdallah, Okoth et al. 2015). 
 
  




In total, 270 samples were screened. These included 158 P. falciparum positive samples 
(including non-falciparum Plasmodium co-infections) and 112 negative samples (by 
molecular composite). Only 23 positive samples were detected by either uRDT and csRDT 
(fig 4.1).  
 
4.4.1. Agreement with reference test 
The level of agreement of either RDT with the reference test was poor: uRDT; k=0.15 
(95% CI 0.09-0.21), csRDT; k=0.16 (0.09-0.23), (Table 4.2.1). The uRDT detected 31 (19.6%) 
infections confirmed by the reference test, of which 23 (74.0%) were also detected by the 
csRDT (fig 4.1). The uRDT missed 13 (36%) infections that were detected by the csRDT and 
confirmed by the reference test. The uRDT detected eight infections that were not detected 
by csRDT (fig 4.1). 
 
4.4.2. Diagnostic performance 
The sensitivities compared with the reference test were 19.6%, (95% CI 13.9-26.8) for the 
uRDT and 22.8%, (16.7-30.3) for the csRDT. Both tests showed high specificity (>95%). The 
uRDT DOR was 13.4 (3.1-57.4) and the csRDT 6.3 (2.4-16.7). (Table 4.2.1) When comparing 
the overall performance of the uRDT and csRDT, the difference in proportions detected was 
non-significantly different (p=0.169). 
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4.4.3. Parasite density distribution 
The qPCR Ct value was used as a proxy for parasite density. Overall, 36% of qPCR positives 
fell between Ct 33-35 (reflecting an estimated 1-10 parasites/µl), and nearing the reported 
uRDT LOD of 3.13 p/ μl (WHO 2020), and 25% fell below Ct 30, the estimated LOD of the 
csRDT LOD (~100 parasites/ μl) (Singh and Daneshvar 2013). There was no evidence that the 
relative performance of the RDTs was modified by CT value (p=0.3). (Figure 4.2) 
 
Figure 4.1. Venn diagram of the number of P. falciparum positive samples detected by each 
test.  
Positivity by uRDT, csRDT and the composite molecular reference test (Ref. Std) in 270 
samples from asymptomatic pregnant women. Numbers within the circles (n) indicate the 
number of true positives detected by that test. 
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Table 4.2. Detection of P. falciparum and diagnostic performance of the csRDT and the uRDT. 
4.2.1. Detection of P. falciparum including non-falciparum species. 
  n TP FP TN FN Sensitivity (%) Specificity % PPV (%) NPV (%) DOR Agreement (κ) 
uRDT 270 31 2 110 127 19.6 (13.9-26.8) 98.2 (93.1-99.7) 93.9 (78.4-98.9) 46.4 (40.0-53.0) 13.4 (3.1-57.4) 0.15 (0.09-0.21) 
csRDT Pf-line 270 36 5 107 122 22.8 (16.7-30.3) 95.5 (89.4-98.3) 87.8 (73-95.4) 46.7 (79.8-88.8) 6.3 (2.4-16.7) 0.16 (0.09-0.23) 
 
4.2.2. Detection of P. falciparum excluding non-falciparum species. 
 
Note- n, number of samples; TP, True Positive; FP, False positive; TN, True Negative; FN, False Negative; Sens, sensitivity; Spec, specificity; (Lower 95% CI- 
Upper 95% CI); PPV, Positive Predictive Value; NPV, Negative Predictive Value; DOR, Diagnostics odds ratio; k, Kappa value  
  n TP FP TN FN Sensitivity (%) Specificity % PPV (%) NPV (%) DOR Agreement (κ) 
uRDT 242 31 2 82 127 19.6 (13.9-26.8) 97.6 (90.9-99.6) 93.9 (78.4-98.9) 39.2 (32.6-46.2) 10 (2.3-42.9) 0.13 (0.07-0.13) 
csRDT Pf-line 242 36 2 82 122 22.8 (16.7-30.3) 97.6 (90.9-99.6) 94.7 (80.9-99.1) 40.2 (33.5-47.3) 12.1 (2.8-51.6) 0.15 (0.09-0.15) 
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Figure 4.2. Diagnostic performance stratified by qPCR Ct values. 
The bar chart shows the sensitivity of each test: uRDT (grey) and csRDT (white bar and black 
trendline) stratified by qPCR cycle-threshold (Ct) values. The number of qPCR- positive samples in 
each Ct category is given in brackets (n). Trendlines (dashed) are derived from the rolling mean 
sensitivity calculated for every 10 observations. R squared coefficient values are displayed (uRDT; 
grey text, csRDT; black text) and difference between R2 values is non-significant (n.s, p=0.3 one-
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4.4.4 Exclusion of co-infections 
Considering uRDT only detects P. falciparum infections, we investigated whether the 
presence of P. vivax altered the performance of the RDTs. When P. falciparum-negative/ 
P. vivax-positive samples were excluded from the data set, the number of false positives 
detected only by the csRDT was reduced (from 5 to 3), thus increasing the specificity and 
PPV. This resulted in a near doubling of the csRDT DOR (12.1; 2.8-51.6), while the 
performance of the uRDT remained relatively unchanged. Again, the difference in 








Our study shows that in a moderate transmission setting in Indonesia, amongst 
asymptomatic pregnant women, the uRDT performed similarly to the csRDTs, which is a 
widely used test in the malaria in pregnancy control program in Indonesia.  
 
These results are supported by a study in Colombia, which also used stored samples from 
pregnant women. Although they note a trend of increased sensitivity by the uRDT, it was 
not found to be significantly different from the Standard Bioline RDT (sdRDT) (Vasquez, 
Medina et al. 2018). A Tanzanian study in febrile children and adult outpatients also found 
no difference between uRDT and sdRDT performance, although febrile patients tend to have 
higher parasitaemia (Hofmann, Antunes Moniz et al. 2019). Our results differ from other 
studies conducted in non-pregnant populations that showed a significant increase in 
sensitivity of the uRDT compared to current RDTs (Das, Jang et al. 2017, Das, Peck et al. 
2018, Girma, Cheaveau et al. 2018, Hofmann, Gruenberg et al. 2018). The most apparent 
difference between the conflicting results is the target population (pregnant vs non-
pregnant) and the storage conditions. It would be useful to screen pregnant populations in 
the same settings where differences in RDT performance were observed. One such study 
has commenced in Papua New Guinea (personal communications with Dr Leanne Robinson).  
 
The uRDT is an antigen capture test specific to the P. falciparum HRP2 antigen, whereas the 
csRDT captures pLDH specific to P. vivax, P. ovale and P. malariae (indicated by the VOM 
window), in addition to PfHRP2 (Pf window).  Ahmed et al. (2015) showed that amongst 
pregnant women in Indonesia, when using a different CareStart RDT that captures both pan-
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LDH and PfHRP2, reading the PfHRP2 window alone was less sensitive than using in 
combination with the pLDH results (Ahmed, Levy et al. 2015). These findings and the low 
sensitivity of both RDTs demonstrated here, may point towards low HRP2 concentrations 
that fall below the limit of either RDT (uRDT LOD= 80 pg/ml, csRDT= 200pg/mL). Low 
concentrations of HRP2 could be due to low parasitaemia, degradation of the protein during 
storage or deletions in the gene for this protein.  
 
In our sample set we found a total of 8 samples that were P. falciparum-positive by the 
FirstResponse RDT performed during the trial (2014-2016), 6 of which were also positive by 
microscopy (data not shown). All of these samples were also positive using the uRDT and 
CaraStart in this study. This suggests minimal degradation over the storage period (1-3 yrs). 
The non-linear relationship between HRP2 concentration/persistence and parasite density 
(Das, Jang et al. 2017, Das, Peck et al. 2018), complicates analyses between RDT positivity 
and parasitaemia. Although no trend in sensitivity was observed with increasing Ct values 
(indicative of parasitaemia), however, most samples fell above Ct 30 indicating very low 
parasitaemias.  
Samples were also stored for up to 4 yrs before testing with the uRDT and csRDT, so 
degradation is possible.  Finally, HRP2 polymorphisms have been reported in P. falciparum 
from several countries in South America, Africa and also India (Bharti, Chandel et al. 2016, 
Beshir, Sepulveda et al. 2017, Watson, Slater et al. 2017), but not yet in SE. Asia. As yet, no 
full deletions (only polymorphisms (Baker, Ho et al. 2010)) of HRP2 have been reported in 
Indonesia.  
These mutations have been implicated in the poor sensitivity of RDTs (Watson, Slater 
et al. 2017).  Early laboratory analyses of the uRDT using cultured parasites with HRP 
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mutations demonstrated that the uRDT performance varies considerably depending on 
mutations of the HRP protein (Das, Peck et al. 2018). Consequently, investigations around 
HRP2 polymorphisms in this sample set are underway. 
 
A limitation of this study is the use of different sample types used for the molecular and RDT 
testing. Molecular testing used stored DNA extracted from DBS, whereas RDTs were 
performed using pRBC and plasma samples reconstituted to an artificial HCT of 30%. 
Potential degradation of HRP2 in our stored samples could contribute to poor sensitivity of 
both RDTs since RDT testing was carried out one year after molecular testing. The sensitivity 
of the molecular testing could also be enhanced through targeting higher copy genes 
(Hofmann, Mwingira et al. 2015) or RNA (Murphy, Prentice et al. 2012), or by using 
improved extraction methods (Zainabadi, Adams et al. 2017).  We anticipate that the 
performance of both RDTs could improve using fresh whole blood at point of contact, i.e. for 
the intended user scenario. However, the low sensitivity observed in our analysis is similar 
to reported sensitivities using a range of RDTs in pregnant women in Indonesia. (Ahmed, 








We assessed the diagnostic performance of the uRDT in a diagnostically challenging 
population: asymptomatic, pregnant women in a moderate transmission setting in 
Indonesia. This is the first study testing the uRDT in pregnant women in Asia and will build 
evidence to guide policy around the implementation of this test in these populations. In 
comparison to the composite molecular reference tests, both the uRDT and csRDT showed 
poor sensitivity/ specificity. Given the negative outcomes associated with malaria in 
pregnancy, it is crucial to detect and treat these infections rapidly. Further work is needed 
to assess the diagnostic performance of the uRDT in pregnant women before consideration 
of this test for implementation where csRDT are already being used- particularly in 
asymptomatic pregnant women in moderate transmission settings. 
4.7. Addendum 
 
1. It must be noted that the uRDT only detects P. falciparum, whereas the csRDT has 
the additional benefit of targeting P. vivax/ malariae/ ovale species. Thus, if the 
uRDT is considered for use in co-endemic transmission settings, it important to offer 
additional tests for these other species during pregnancy. Furthermore, as 
mentioned in chapter 1.1.3, the species composition in an area can shift if only one 
species is being targeted (i.e. diagnosed and treated), making surveillance of 
non- falciparum infections equally as important. 
 
2. In addition to the uRDT evaluation studies outlined in the discussion section of this 
chapter, studies, the study published by Mesigwa et al. should also have been 
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included. Their cross-sectional study describes the uRDT sensitivity in The Gambia as 
“modest” and variable depending on the local transmission setting. Their models 
suggest that the uRDT would be best suited for Mass Test and Treat (MTAT) 
programs in settings that have very low transmission intensity, rather than for POC 
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5.0. Declarations  
 
For data collection, DNA extraction, molecular testing and RDT testing see previous 
declarations (in Chapter3). In this study, Dr Grant Kay (GK) provided technical support by 
carrying out the assays for the optimisation and screening (100%) of samples using MSP1, 
HRP and β-tubulin assays. I supported the intelligent and experimental design, interpreted 
and analysed the results of these assays (90%). I carried out 100% of the statistical analyses. 
5.1.1. Chapter summary 
 
In the previous Chapter, the sensitivity of the uRDT (Alere™, Korea) and csRDT (CareStart™, 
USA) was 20% and 23% in a retrospective evaluation of malaria RDTs, among pregnant 
women in Indonesia.  Given the low sensitivity of both RDTs we investigated the target-
antigen that both RDTs, Histidine Rich Protein 2 (HRP2). Deletions of the encoding gene for 
this antigen is known to produce false negative RDT results, however incidence of the 
mutation it is yet to be reported in Indonesia. Using stored samples from Chapter 2, the 
status of this antigen-encoding gene was investigated in pregnant women in Timika, 
Indonesia for the first time. 
  




The deletion of genes encoding antigens targeted by malaria rapid diagnostic tests (RDTs) is 
cause for serious concern. Deletions of the Plasmodium falciparum Histidine Rich Protein II 
(pfhrp2) gene impacts on the performance of widely used RDTs. Following WHO 
recommendations for pfhrp2 reporting, the incidence and impact of these deletions were 
investigated in Timika, Indonesia for the first time. 
Methods 
DNA samples from whole blood collected in a Stop Malaria in Pregnancy (STOP-MiP) trial 
were tested for deletions in the pfhrp2 gene and structural homologue pfhrp3. Samples 
were first screened by multi-copy assay, Loop-mediated isothermal Amplification (LAMP) 
and quantitative polymerase chain reaction (qPCR), for infection with P. falciparum. Stored 
blood samples underwent subsequent testing using two RDTS: uRDT (Alere, Korea) and 
csRDT (Access Bio inc, USA). DNA yields in these samples were confirmed using single-copy 
assays, Merozoite Surface Protein-1 (MSP1) PCR and β-tubulin real-time PCR (rt-PCR). The 
presence of pfhrp2/3 fragments was determined using PCRs for pfhrp2/3 exon 1/ 2. Sanger 
sequencing was used to resolve indeterminate samples. The effect of the different assays on 
RDT outcome was estimated using logistical regression models. 
Results 
Full deletions of pfhrp2 (n=8) and pfhrp3 (n=14) were present in this cohort of pregnant 
women in Timika. Only complete deletion of pfhrp2 was identified as a significant predictor 
for uRDT (β= 2.167, SE± 1.1) and csRDT (β=3.136, SE± 1.3) outcomes. 
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Conclusion 
The evidence for pfhrp2 deletion, alongside the negative association with RDT outcomes 
shown here, suggest dual antigen detecting RDTs are preferable to RDTs that only detect 
PfHRP2. Although further analyses are needed to support these conclusions, the work here 
flags important considerations for current Intermittent Screening and treating during 
pregnancy (ISTp) policies in Indonesia.  
  
  




5.2.1. Diagnosis of malaria 
Accurate diagnosis and prompt treatment are central to the Global Technical Strategy for 
malaria 2016-2030 (WHO 2015). The WHO also advise that antimalarials only be 
administered following confirmation of a malaria diagnosis, mainly by microscopy or a Rapid 
Diagnostic Test (RDT) (WHO 2015).  
Indonesia is co-endemic for Plasmodium  falciparum (63%) and Plasmodium  vivax 
(37%), resulting in an estimated 1.5 million cases of malaria and 2,700 deaths (2017) (WHO 
2018). It accounts for 4% of the global burden of P. vivax malaria cases alone. The negative 
associations of malaria during pregnancy (outlined in Chapter 1, p20) prompted the 
implementation of Intermittent Screening and Treatment during pregnancy (ISTp) policies in 
Indonesia in 2012 (Indonesian Ministry of Health 2012, Indonesian Ministry of Health 2013).  
However, these strategies have not shown additional benefit in comparison to 
Intermittent Preventative Treatment during Pregnancy (IPTp) where all women are treated 
during antenatal visits regardless of symptoms/testing (Desai, Hill et al. 2018, Ahmed, 
Poespoprodjo et al. 2019). Due to the inadequate sensitivity of current RDTs and the good 
safety profile of ACTs during pregnancy (WHO 2015), IPTp methods have proven superior to 
ISTp (Tagbor, Cairns et al. 2015, Awine, Belko et al. 2016, Ahmed, Poespoprodjo et al. 2019).  
Globally, diagnosis is still typically reached through microscopy, although global 
demand for RDTs almost doubled in 2018 compared to 2017 (WHO 2019). Most of this 
demand (412 million RDTs in 2018) is for P. falciparum only RDTs (64%), with just 16 
countries making up the majority of the market (Unitaid 2018, WHO 2019). In Indonesia 
over 360,0000 diagnoses were reached using RDTs in 2018 (WHO 2019).  
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5.2.2. Target-antigen mutation 
Given the global use of RDTs, mutations in the main RDT target-analyte are cause for 
concern (WHO 2019, Poti, Sullivan et al. 2020). Parasites harbouring full deletions of the 
P. falciparum Histidine Rich Protein II (pfhrp2) gene can result in false negative RDTs, whilst 
RDT sensitivity is maintained in the presence of only partial gene deletions. The latter is 
thought to be in part due the capture antibodies embedded in the RDT cross-reacting with a 
structural homologue; pfhrp3, which has similar antigenic epitopes (Bharti, Chandel et al. 
2016, Beshir, Sepulveda et al. 2017). This results in a positive RDT test in the presence of 
P. falciparum with wild type pfhrp3 even when pfhrp2 is deleted. Similarly, wild-type pfhrp2 
strains can mask the presence of pfhrp2 deletions in polyclonal infections. The presence of 
pfhrp2 antigen in these mixed infections will result in a positive and resulting in 
misreporting of pfhrp2 mutations (Beshir, Sepulveda et al. 2017). For these reasons, the 
quantification of the different pfhrp2/3 genotypes should accompany surveillance of these 
mutations in order to further our understanding of their dynamics, selection pressures and 
ultimately- enable rapid programmatic reaction to their emergence (Beshir, Sepulveda et al. 
2017). 
The PfHRP2 antigen is expressed on the surface of infected red blood cells 
throughout the parasite’s life-cycle (within the human host), although at varying levels 
(Howard, Uni et al. 1986, Hayward, Sullivan et al. 2000, Baker, Gatton et al. 2011). The 
pfhrp2 gene spans an intron and two exons, flanked by putative Heat Shock Proteins and 
exported protein pseudogenes (fig 5.1A). Located within the subtelomeric region of 
chromosome 8, pfhrp2 has multiple breakage sites in the flanking genes and within the gene 
itself (Baker, Ho et al. 2010). Re-joining of the gene at breakage sites can result in the 
excision of portions or the entirety of pfhrp2, thus numerous variations of this gene have 
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been reported (Baker, Ho et al. 2010, Dharia, Plouffe et al. 2010) (fig 5.1A). 
Loss of a structural homologue pfhrp3 (located on chromosome 13 occurs through a 
similar mechanism, often accompanied by loss of flanking genes (fig 5.1B) (Dharia, Plouffe et 
al. 2010). The fitness costs associated with deletion of either are not fully understood, they 
are however known to occur independently of each other. Sequence variation in these 
genes is now widespread (Baker, Ho et al. 2010, Gamboa, Ho et al. 2010, Abdallah, Okoth et 
al. 2015, Bharti, Chandel et al. 2016, Beshir, Sepulveda et al. 2017, Kozycki, Umulisa et al. 
2017, Watson, Slater et al. 2017, Gendrot, Fawaz et al. 2019). Mathematical modelling has 
also shown that low malaria prevalence and high frequency of people seeking treatment 
contribute to the selection of pfhrp2 deletion (Watson, Slater et al. 2017).  
5.2.3. Impact of RDT false negatives 
The potential impact of false negative RDTs and missing a malaria diagnosis - particularly 
during pregnancy- has gained due attention. It is however important to recognise that false 
negative RDT results can also arise from analytical insensitivities, misreading/misreporting 
or operational mishaps (WHO 2016). Thus, the WHO has advised caution when reporting 
pfhrp2 deletions, recommending specific testing for confirmation of deletions in order to 
avoid undue panic and costly changes in RDT implementation, as well as mistrust of RDT 
usage amongst health practitioners (Baker, Ho et al. 2010, Cheng, Gatton et al. 2014, Parr, 
Anderson et al. 2018). Once confirmed, they recommend baseline reporting of pfhrp2/3 in 
these 
and neighbouring countries. They suggest that a prevalence of hrp2/3 deletion above 5% 
causing high suspected false positivity should warrant a change in RDT (WHO 2019). They 
have also developed interactive online maps to track pfhrp2/3 reporting (fig 5.2). 





To date, full deletions of pfhrp2 have not yet been reported in Indonesia (fig 5.2). 
Nevertheless, given the particularly low sensitivity of two HRP2-based RDTs in Chapter 4, 
here we investigate the gene structure of pfhrp2 and pfhrp3 in those samples (Unwin, 
Ahmed et al. 2020). Molecular testing is used here to determine the incidence of pfhrp2/3 
partial/full deletions and their impact on the outcomes on RDT outcomes in a cohort of 
pregnant women in Timika, Indonesia. 
Figure 5.1. The gene structure and organisation of pfhrp2 and pfhrp3. 
The pfhrp2 and pfhrp3 genes span an intron across exon 1 and 2 on A) chromosome 8 and B) 
chromosome 13 respectively. Flanking genes are also shown, arrows indicate potential breakage 
points, bp= base pairs. Image source: Abdallah et al.(2015) (Cox 2010) 
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Figure 5.2. Map of pfhrp2 studies and confirmed deletions. 
Dots represent studies that reported presence (red) and absence (grey) of pfhrp2/3 deletions (grey). (Map source: WHO Malaria Threats Map: tracking 
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 5.3. Methods 
 
5.3.1. Study Design and samples 
This retrospective study uses stored DNA samples from asymptomatic pregnant women in 
Timika, Indonesia as part of a Stop Malaria in Pregnancy trial (STOPMiP, ISRCTN: 34010937) 
(Unwin, Ahmed et al. 2020). Venous blood samples were collected, DNA extracted and 
molecular reference testing (LAMP and qPCR) were performed as previously described in 
Chapter 2 (section 2.3.3). In Chapter 4 (section 4.3.3, two RDTs were also performed: the 
uRDT (Ultra-sensitive HRP2-based Alere™ Malaria Ag P.f RDT) and the csRDT (CareStart™ 
Malaria HRP2/PLDH (PF/PAN) Combo RDT) (Unwin, Ahmed et al. 2020). Samples testing 
positive for P. falciparum using the composite molecular reference test were investigated 
here.  
Extracted DNA for positive controls from the following cultured strains of 
P. falciparum were provided by the London School of Hygiene and Tropical Medicine: 3D7 
(positive for both pfhrp2/pfhrp3 (Walker-Jonah, Dolan et al. 1992)), DD2 (pfhrp2-deleted 
(Wellems, Walliker et al. 1987)), HB3 (pfhrp3-deleted (Su, Ferdig et al. 1999)) and 3BD5 
(both pfhrp2 and pfhrp3 deleted (Walker-Jonah, Dolan et al. 1992)). 
5.3.2. Sample flow 
To determine the status of pfhrp2 and pfhrp3, a diagnostic algorithm (fig 5.3) was 
formulated according to WHO recommendations for accurate reporting (Cheng, Gatton et 
al. 2014). First, infection with P. falciparum was confirmed using two single-copy assays, 
followed by examination of exons 1 and 2 using four PCR assays. For each pfhrp2 and pfhrp3 
an ‘exon 1_2’ assay was used for the detection of the region spanning the intron, and 
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another assay ‘exon 2’ for the detection of the portion only on exon 2 (fig 5.1). Investigation 
of flanking genes is recommended for characterisation but optional for reporting, 
unfortunately this was not feasible in this study given the low remaining sample volumes 





5.3.3. Detection of P. falciparum species 
Two single gene copy assays for P. falciparum, Merozoite surface protein-1 (MSP1) 
(Mayengue, Ndounga et al. 2011) and β-tubulin (Fennell, Al-shatr et al. 2008), were used to 
confirm sufficient DNA yield for accurate reporting of pfhrp2/3 deletions. Primers and 
cycling conditions are outlined in Table 5.1 and for all assays 3 µl of DNA was used.  PCR 
Figure 5.3. Decision tree for confirmation of pfhrp2 and pfhrp3 deletions 
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products were visualised by gel electrophoresis (2% agarose/ Trisacetate-EDTA)) and images 
analysed using the ImageLab (v6.01, Bio-rad, UK) software. Bands were interpreted by two 
independent readers blinded to the RDT results, with discordant calls confirmed by a third 
reader. Expected band sizes for each product are outlined in Table 5.1.  
Real-time fluorescence of the β-tubulin qPCR assay was measured using the Qiagen 
RotorGene-Q (Qiagen, Germany) and analysed using RotorGene-Q Software (Source, 




Table 5.1. PCR assays for confirmation of pfhrp2 and pfhrp3 deletions. 
Table source: Grant Kay (LSTM, UK) 
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5.3.4. Detection of pfhrp2 and pfhpr3 
Exons 1 and 2, as well as exon 2 alone were analysed for each pfhrp2 and pfhrp3 using the 
assays outlined in Table 5.1. The concentration of primers (Eurofins Genomics, Germany) 
and cycling conditions were identical to those published previously, except for the addition 
of a final extension step for 10 min at 72 °C. Pfhrp2/3 and MSP1 reactions contained 
DreamTaq Green Master Mix (ThermoFisher Scientific, UK), whilst the β-tubulin qPCR 
contained FastStart SYBR™ mastermix (ThermoFisher Scientific, UK). (Figure 5.3) 
5.3.5. Investigating limits of Detection 
The reported limits of detection (LOD) for the pfHRP2 and pfhrp3 assays are 1 parasite/ µl, 
whilst single-copy target assays for MSP1 and β-tubulin are 10 parasites/ µl (Parr, Anderson 
et al. 2018). This difference ensures that a lack of amplification in the HRP assays following 
confirmation by the single-copy assays is due to mutation of the gene rather than lack of 
DNA. To support our results, we assessed the relative LOD of each assay empirically. For 
this, serial dilutions (100-10-3) of a positive control (provided by Dr Debbie Nolder, 
PHE/LSHTM) were tested by each assay. 
5.3.6. Sequencing 
Samples that produced only very faint bands in any pfhrp2/3 assay underwent Sanger 
sequencing to determine the presence or absence of amplicon. QIAquick PCR Purification Kit 
(Qiagen, Germany) was used prior to sequencing by Source BioScience™ (Nottingham, UK). 
Sequence traces were compared to positive and negative controls using CodonCode Aligner 
software (version 9.0, USA).  
5.3.7. Statistical analyses 
The effects of: 18S rRNA qPCR, β-tubulin rt-PCR, presence/absence of each pfhrp fragment 
and complete absence of both exon1_2 and exon 2 on RDT outcome were estimated using 
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binary and multinomial logistical regression analyses. β- values where P value< 0.05 were 
used to indicate significant predictors of RDT outcome. 
  




5.4.1. Confirmation of infection and DNA content 
Samples that were positive for P. falciparum (LAMP/qPCR) were subsequently tested for 
DNA content using two single-gene copy assays: MSP1 PCR and β- tubulin qPCR (n=149). A 
total of 20 samples were detected by both MSP1 and β-tubulin tests, with sufficient volume 
for further testing. (Appendix figure 5.7.1)  
5.4.2. Presence of pfhrp2 and pfhrp3 
Analysis of the pfhrp2 exon 1_2 region showed amplification in 10 out of the 20 samples and 
10 samples amplified the pfhrp2 exon 2. Only 4 samples out of 20 were positive for pfhrp3 
exon 1_2, and 4 for pfhrp3 exon 2. Overall, 6 samples failed to amplify any region of either 
pfhrp2 or pfhrp3. Eleven out of 20 had at least one suspected deletion in the pfhrp2 region, 
15 in the pfhrp3 region and 18 with at least one deletion in either region. (Figure 5.4.1)  
5.4.3. Impact on RDT outcomes 
Of the 6 samples that did not amplify any of the hrp gene fragments, five were negative by 
both csRDT and uRDT and one was negative by csRDT/ positive by uRDT (fig 5.4.3, appendix 
Table 5.2). Figure 5.4.2 shows the mean and range of the Ct (Cycling Threshold) values 
observed in the β-tubulin rt-PCR, stratified by presence of pfhrp fragments and RDT 
outcome. Notably there were more suspected pfhrp2 deletions in samples negative by both 
RDTs, compared to those positive by both RDTs. (Figure 5.4.2) Additionally, the mean Ct 
observed for samples positive by both RDTs was 30.4 (95% CI 29,4- 31.4), whilst for RDT 
(both) negative samples the mean Ct was 34.3 (95% CI 33.0- 35.7). 










Figure 5.4.1. Combinatorial frequencies of pfhrp2 and pfhrp3 genotypes. 
Top bar chart represents the frequency of combinations of deletions and side chart 
represents the total number of samples with that genotype. 
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The effects of the 18S rRNA qPCR, the β-tubulin rt-PCR and presence/absence of each of 
pfhrp fragment on RDT outcome was estimated using multinomial logistical regression 
analyses. Only β- tubulin rt-PCR was found to be a significant predictor (β= -0.452, p<.05, SE 
0.23) for csRDT outcomes. The 18s rRNA qPCR, pfhrp2 exon 1_2/exon2 and pfhrp3 exon 
1_2/exon2, were non-significant predictors of positivity of any RDT (p> 0.05). Binomial 
logistical regression identified complete absence of pfhrp2 (negative for exon1_2 and exon 
2) as being a significant predictor for both uRDT (β= 2.167, SE 1.1, p= 0.05) and csRDT (β= 
3.136, SE 1.3, p=0.02) outcomes. 
5.4.4 LOD 
The LODs of all assays were estimated using serial dilutions of the same positive control. 
Unexpectedly, both pfhrp2 and pfhrp3 exon 2 assays failed to detect the most dilute sample, 
suggesting a higher LOD (lower sensitivity) for these assays in comparison to MSP1, exon 
1_2 and β-tubulin assays. (Appendix figure 5.7.2) 
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Figure 5.4.2. Distribution of β-tubulin qPCR Ct values and pfhrp2/3 deletion by RDT 
outcome. 
Bar chart shows the number (n) of samples that were negative (white bar) and positive (grey bar) for 
exon 1_2 and exon 2 for each pfhrp2 and pfhrp3. The mean β-tubulin Ct and range of (error bars) are 
also shown. Data are stratified by RDT outcome: A) Negative by both uRDT and csRDT, B) positive 
only by uRDT and C) positive by both RDTs.  
 
 





The efficacy of pfhrp2 RDTs is threatened by deletions in the genes that encode these 
proteins. In this study amongst asymptomatic pregnant women, the deletion of pfhrp2 and 
pfhrp3 regions was most common amongst RDT negative samples, with 60% showing full 
deletions (both exon 1_2 and exon 2 regions) of both pfhrp2 and pfhrp3 genes. Conversely, 
70% of RDT positive samples had both pfhrp2 and pfhrp3 (both exon 1_2 and exon 2) intact.  
Furthermore, full deletion of pfhrp2 was found to be a significant predictor of two 
RDT outcomes (uRDT and csRDT). Partial deletions (absence of either exon 1_2 or exon 2) 
and absence of pfhrp3 were not significant predictors of RDT outcome. These results mirror 
those in a large meta-analytical study by Baker et al.(2011) that looked at 16 RDTs and WHO 
pre-qualification testing (Baker, Gatton et al. 2011). This is the first study that provides 
evidence of complete deletions of pfhrp2 and pfhrp3 in malaria infections in Indonesia, and 
in the southern Asia (Li, Xing et al. 2015, Bharti, Chandel et al. 2016) (fig 5.5). To date, 
deletions have only been reported as near as Myanmar, however this is most likely due to 
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lack of pfhrp2/3 surveillance rather than lack of prevalence. As shown in figure 5.2 these 
mutations are found in bordering countries, so it is very likely that they are also prevalent in 
neighbouring countries such as Papua New Guinea. This has serious implications for 




5.5.1. Context  
To date, deletions of these genes in Asia have only been reported in India (Bharti, Chandel 
et al. 2016) and the borders of China and Myanmar. Only sequence variation- not deletion- 
has been reported in SE. Asia (Baker, Ho et al. 2010). The high frequency of pfhrp2 and 






Figure 5.5 Updated WHO pfhrp2/3 threat map to include this study. 
Image modified from https://apps.who.int/malaria/maps/threats. 
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Chandel et al. 2016, Beshir, Sepulveda et al. 2017), as are the proportions, with a higher 
frequency of deletions observed in the pfhrp3 gene than in pfhrp2 (Dharia, Plouffe et al. 
2010, Gamboa, Ho et al. 2010, Solano, Okoth et al. 2015, Viana, Okoth et al. 2017). 
Additionally, this study echoes findings that pfhrp3 arises independently of pfhrp2 deletions 
(Gamboa, Ho et al. 2010, Abdallah, Okoth et al. 2015, Viana, Okoth et al. 2017, Fontecha, 
Mejia et al. 2018). Rachid Viana et al. report pfhrp3 mutation incidence of 68 % in parts of 
Brazil and Bolivia (Viana, Okoth et al. 2017), where pfhrp2 mutations were rare.  
 
It is well demonstrated that pfhrp3 antigens cross-react with pfhrp2-RDTs, producing 
positive RDT results in the absence of pfhrp2 genes (Baker, McCarthy et al. 2005, Baker, 
Gatton et al. 2011, Das, Peck et al. 2018). This is also shown here, where one sample that 
was pfhrp2-negative/pfhrp3-positive tested positive by both RDTs, whilst another was 
positive by only the uRDT. This could suggest that pfhrp3 contribution to RDT-positivity 
could occur at lower parasitaemia than previously thought (Das, Peck et al. 2018).  
 
Curiously, one sample which completely lacked all regions of pfhrp2 and pfhrp3 was positive 
by uRDT (csRDT negative). This could represent a false uRDT result produced by an infection 
of parasites lacking pfhrp2, whereby a line is produced by cross reactivity as has been 
demonstrated in patients with particularly high levels of Human Anti-Mouse Antibodies 
(HAMA) and Rheumatoid Factor (RF) (Lee, Jang et al. 2014, Gatton, Ciketic et al. 2018).  
Alternatively, the sample could represent a true positive where infections comprise 
1) pfhrp2-intact parasites, but at a parasitaemia above the LOD of the hrp assays or 2) a 
mixed infection where the load of pfhrp2-deleted parasites exceeds pfhrp2-intact parasites 
(see details on clonal infection below). As infection was confirmed by 18S rRNA, β-tubulin rt-
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PCR and MSP1 PCR, a truly positive uRDT result is more likely In this study, although not 
quantified, the relative LODs of the pfhrp2 and pfhrp3 assays were higher than that of the 
MSP1 and β -tubulin assays, whereas the opposite was previously reported: 10 parasites/ µl 
for MSP1 and β-tubulin, and 1 parasite/ µl for both pfhrp2/pfhrp3 assays. This is reflected in 
the Ct values for the 18S rRNA and β-tubulin assays, which fell above the highest Ct 
observed for any pfhrp2 (and pfhrp3 exon2) positive sample. However, it was lower than 
that observed for pfhrp3 exon1_2.  
Further analyses of the flanking genes could help to conclude that the absence of 
gene amplification here is due to gene deletion rather than a low concentration of DNA. 
 
5.5.2. Limitations 
The main limitation of this study is common across studies of asymptomatic malaria- low 
parasite DNA yields. Whilst it is likely that a number of the false negative RDT results are 
attributable to pfhrp2 and pfhrp3 deletions, it is also possible that many arise due to the 
poor sensitivity of RDTs at low parasitaemia.  
 
The dynamics of pfhrp2 and pfhrp3 remain unclear and the precise drivers of selection for 
these mutations are not well understood (Akinyi, Hayden et al. 2013, Watson, Slater et al. 
2017). This is especially so in low transmission settings where low parasite DNA yield 
muddies interpretation of gene absence. This complicates determination of the true 
prevalence of these deletions, especially in areas where low density infections predominate. 
Use of more sensitive qPCR methods for infection confirmation as well as detection of gene 
deletions will improve studies in this field.  
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It is also important to note that infections can comprise more than one clone and therefore 
multiple hrp2/3 genotypes (Kun, Missinou et al. 2002, Naidoo and Roper 2013, Childs and 
Buckee 2015, Ayanful-Torgby, Oppong et al. 2016). It is plausible that molecular methods 
selectively amplify an abundance of hrp2-lacking DNA over trace amounts of hrp2-intact 
DNA, whilst the sensitive RDTs may still detect antigen in these samples. Additionally, the 
clearance rate of different clones will differ depending on priming of the host immune 
response (previous exposure, length of infection etc), and since the uRDT detects antigen 
rather than DNA, it could be truly positive. There is a real need to develop more sensitive 
assays for accurate HRP2 reporting to further our understanding of the impact of these gene 
mutations.  
The recently developed ‘qHRP2/3-del’ multiplex qPCR which integrates pfrnr2e2 
(single-copy gene) as an internal control is an example of this (Schindler, Deal et al. 2019). 
The qHRP2/3 is quantitative, allowing differentiation of infection with multiple strains of 
P. falciparum and the unmasking of trace genotypes. However, as with all molecular 
methods, nucleotide variation in primer binding sites may result in failure to amplify targets 
even in the presence of the gene. Ultimately, sequencing may offer more in-depth insights 




Overall, this study presents evidence of hrp2 deletions that affect RDT outcomes, although 
supporting studies are needed to solidify these findings. This is deeply concerning given the 
setting of Indonesia- a country that is heavily reliant on the use of RDTs to prevent malaria 
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in pregnancy. Here, the introduction of the uRDT in place of currently used RDTs is not 
advisable. Instead, it remains that RDTs that detect alternative antigens in addition to 




Figure 5.7.1. Flow diagram summary of diagnostic tests. 
The total number of samples run in each test and the number of positive (+) and negative (-) results 
obtained are shown (n). 
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Table 5.2. Full data set of pfhrp2 and pfhrp3 presence, RDT outcomes and rt-PCR Cycling 
threshold values. 
  Infection confirmation RDTs HRP2 HRP3 
Sample 18S rRNA β-tub MSP uRDT csRDT Exon1/2 Exon2 Exon1/2 Exon2 
1 31.72 23.48 + + + + + - - 
2 26.02 25.36 + + - + + - - 
3 25.68 27.37 + - - - + - - 
4 29.19 27.43 + + + + + + + 
5 31.52 28.08 + + + + - - - 
6 33.71 30 + + + + - - - 
7 33.79 30.42 + + + + + - + 
8 33.93 31.34 + + + + + - - 
9 32.98 31.64 + + + + + - + 
10 33.29 32.74 + - - - + + - 
11 28.1 33.13 + + + + + - - 
12 32.74 33.35 + + + - - + + 
13 33.20 33.51 + - - - - - - 
14 32.85 34.81 + + + + + - - 
15 31.57 34.84 + - - - - - - 
16 30.74 35.67 + + - - - - - 
17 34.25 36.32 + - - - - - - 
18 37.08 36.57 + + - - - + - 
19 35.66 36.77 + - - - - - - 
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Figure 5.7.2. Observed limit of detection. 
Serial dilutions (100-10-3) of 3D7 DNA were tested in each of the assays and compared to positive 
controls DD2, HB3 and 3BD5. Expected band size for A) MSP1 is 555 bp, B) pfhrp2 exon 2 is 814 bp, 



















D.          E. 
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6.1.1. Chapter summary 
 
In this Chapter the Alere Ultra-sensitive Pf Ag RDT (uRDT) is evaluated prospectively in 
pregnant women in  in W Kenya.  The 4-plex qPCR assay developed in Chapter 2 was used as 
a reference test to compare the performance of the uRDT with the CareStart Pf/Povm combo 
RDT (csRDT). This study, conducted in a high transmission setting, is a large prospective study 




More sensitive rapid diagnostic tests (RDTs) are needed for diagnosis of low density 
infections. Malaria during pregnancy is associated with adverse outcomes and therefore, 
more sensitive RDTs are especially important to rapidly diagnose and treat.  Here we 
compare the performance of the Alere ultra-sensitive RDT to the CareStart™ Malaria 
HRP2/pLDH Pf/VOM Combo (csRDT) amongst pregnant women in Western Kenya.  
Methods  
Samples (n= 493) were collected from pregnant women enrolled in the IMPROVE clinical 
trial from three sites in Kisumu, Kenya. The two RDTs were performed on whole blood 
samples, whilst dried blood spots were stored for DNA extraction and qPCR reference 
testing. Diagnostic indicators (sensitivity, specificity, positive predictive value, negative 
predictive value, diagnostic odds ratios and kappa values) were calculated to assess the 
performance of both RDTs. 
Results 
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The uRDT sensitivity (79.9%; 95% CI 72.5- 85.7%) was higher than that of the csRDT (74%; 
66.2- 80.6%) in comparison to a qPCR reference test. The proportion of positive infections 
detected by the two tests was significantly different (p value=0.000), as was the proportion 
of negatives detected by the two tests (p = 0.000) as the specificity was uRDT; 90.4% (95% CI 
86.6- 93.2%) and csRDT 93.0% (95% CI 86.6-95.4). However, the overall performance of the 
two tests (as indicated by the Diagnostics Odds Ratios, Kappa values and AUROC values) 
were non-significantly different to each other.  
Conclusions 
This is the first study to assess the diagnostic accuracy of the uRDT in pregnant women in a 
high transmission setting. The findings here support the use of the uRDT for treating 








The importance of robust and sustainable surveillance systems for malaria in elimination 
settings is outlined in Chapter 1, and specifically for malaria pregnancy in Chapter 4. Briefly, 
current point of care tests (POCTs), specifically RDTs, are insufficiently sensitive for the 
detection of low density infections.  
6.2.1. The uRDT 
In a bid to improve RDT sensitivity, the Alere™ Ultra-sensitive Malaria Ag P. falciparum RDT 
(uRDT) was developed. As described in Chapter 4, the uRDT has been evaluated across a 
range of transmission settings (Das, Jang et al. 2017, Das, Peck et al. 2018, Girma, Cheaveau 
et al. 2018, Hofmann, Antunes Moniz et al. 2018, Landier, Haohankhunnatham et al. 2018, 
Hofmann, Antunes Moniz et al. 2019), but only twice in pregnant women (Vasquez, Medina 
et al. 2018, Unwin, Ahmed et al. 2020). The two studies in pregnant women, Vasquez et 
al.(2018) and the study performed in Chapter 4 in this thesis (Table 6.1) show that the uRDT 
performs similarly to existing RDTs (CareStart RDT or SD Bioline RDT) (Vasquez, Medina et al. 
2018). The limitations of these studies call for larger prospective evaluation studies of the 
uRDT, to inform decisions around implementation. Table 6.1 summarises the literature 
comparing the performance of the uRDT to existing RDTs. The value added to diagnostic 
performance by the uRDT varies considerably. 
6.2.2. MiP prevention 
The distribution of insecticide treated nets (ITNs) to pregnant women is at the core of 
control strategies to prevent MiP, having been proven to cost-effectively reduce many of its 
adverse outcomes (Cotter, Sturrock et al. 2013, Desai, Hill et al. 2018).  Alongside bednet 
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use, Intermittent Preventative Therapy during Pregnancy (IPTp) is recommended by the 
WHO (WHO 2015). For this, a course of 3 doses of Sulfadoxine-Pyrimethamine (SP), spaced 
at least one month apart, should be given starting in the second trimester. Although 
prophylaxis is administered during antenatal visits, coverage of IPTp amongst eligible 
women in 23 African countries is as low as 19% (2016) (WHO 2015, WHO 2015, WHO 2019). 
MiP in Africa is therefore still one of the major contributors to still-births (WHO 2019).  
These strategies are however compromised by the widespread emergence of SP resistance 
(Chico, Cano et al. 2015, Okell, Griffin et al. 2017). Alternate drugs for IPTp e.g 
Dihydroartemesinin- Piperiquine (DP) have also been evaluated for use in areas with high SP 
resistance. To minimise unnecessary treatment of non-infected women and limit the risk of 
resistance, alternate strategies such as Intermittent Screen and Treat during Pregnancy 
(ISTp) are being explored (Tagbor, Cairns et al. 2015, Awine, Belko et al. 2016, Ahmed, 
Poespoprodjo et al. 2019). This requires diagnostic confirmation prior to treatment, unlike 
ITPp where all pregnant women are treated without testing and regardless of presence of 
symptoms. Consequently, the choice of diagnostics used in ISTp strategies is critical to their 
efficacy (Slater, Ross et al. 2015, Slater, Ross et al. 2019). 
 
Chapter 4 highlights the need for larger scale and more in-depth investigations into the 
effects of pfhrp2 and pfhrp3 deletions and their impact RDT outcomes. This needs 
investigation in different transmission settings, where the selection pressures may vary. The 
development and use of more sensitive and less-subjective diagnostic tools for surveillance 
of these deletions would also aid our understanding of their impact. 
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Deletions of pfhrp2 were previously observed in 19% of PCR-confirmed P. falciparum 
positive samples in Western Kenya (Beshir, Sepulveda et al. 2017). Of the hrp2-deleted 
infections, 10% were both microscopy and RDT positive, with intact pfhrp3 loci. This 
suggests that mutated parasites are still detectable by RDT at higher (microscopy-
detectable) parasitaemias (Sawa, Shekalaghe et al. 2013). It follows that these mutations 
may have a more detrimental impact among populations harbouring low density infections. 
Since MiP in Africa rarely results in fever (Desai, ter Kuile et al. 2007) it is important to 
actively identify and treat these more cryptic infections. 
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Table 6.1. Summary of published uRDT evaluation studies. 
Transmission settings are categorised by prevalence: Low (<5%), Moderate (5-20%) and High (≥20%). 
Author (ref) Country 
(transmission) 





Unwin et al. (Unwin, 








Vasquez et al. 






LM, sdRDT (nPCR) No 
Mesigwa et al. 
(Mwesigwa, Slater 





Cross-section (rtPCR) No 
Hoffman et al.  
(Hofmann, 




Adults b, c Cross-section sdRDT (qPCR) Yes 
uRDT>sdRDT 
Hoffman et al. 
(Hofmann, Antunes 







HRP2 ELISA No 
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Das et al. (Das, Jang 











Landier et al. 
(Landier, 
Haohankhunnatham 
et al. 2018) 
Myanmar 
(low) 




Girma et al. (Girma, 














LM; Light Microscopy, usQPCR; Ultra-sensitive qPCR, ELISA; Enzyme Linked Immunosorbent Assay, sdRDT; SD Bioline RDT, NS; Not Significantly different, a asymptomatic 
individuals only, b excludes pregnant women, c excludes <5 yrs of age  
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6.2.3. Aims 
This study aims to evaluate the performance of the Alere uRDT and CareStart™ Malaria 
HRP2/pLDH Pf/VOM Combo (csRDT) using a qPCR reference test. For this, venous blood was 
sampled from pregnant women enrolled in the Improving PRegnancy Outcomes With 
Intermittent preVEntive Treatment in Africa (IMPROVE) clinical trial in Kisumu, Kenya.  
  
  




6.3.1. Study design and participants 
This prospective study formed a sub-study under the larger clinical trial IMPROVE 
(NCT03208179). The IMPROVE trial aims to assess the effectivity of co-administration of an 
antibiotic alongside antimalarials as intermittent preventive therapy for malaria and STDs in 
pregnant women. Venous blood samples were collected from pregnant women enrolling in 
the IMPROVE trial (viable singleton pregnancy, >16 weeks’ gestation and willing to deliver in 
a hospital) in the Kisumu district, Western Kenya. The trial excluded multiple pregnancies 
(i.e. twin/triplets), HIV-positive status, known heart ailments, severe malformations or 
nonviable pregnancies observed by ultrasound, histories of receiving SP during this 
pregnancy, those unable to give consent, known allergies and any other contraindication to 
any of the study drugs. All enrolled women were tested for malaria using the csRDT for 
IMPROVE and immediately treated if positive.  
Study sites included three of the ten IMPROVE trial sites: Ahero and Rabuor sub-
county hospitals, and Akala health Centre (fig 6.1). Venous bloods were collected during 
October 2018- May 2019 in Rabuor and Ahero, and May 2019 for in Akala (n=493). The two 
initial sites were chosen for their high initial recruitment rates during the IMPROVE study, 
whilst Akala was added to improve recruitment rates. Within the IMPROVE trial, these sites 
were selected for their capacity to process RDTs in addition to those for the IMPROVE study. 
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Malaria transmission is year-round in this area, with two seasonal peaks between June–July 
and December–January. A recent study reported prevalence of P. falciparum malaria in this 
area to be 33% and 51% by microscopy and PCR respectively (Wanja, Kuya et al. 2016).  
 
6.3.2. Detection of malaria 
Blood samples were collected by venepuncture (up to 10 mL in EDTA tubes) unless the 
participant was unwilling, in which case a finger prick (~250 µl) was drawn instead. These 
were used within 1 hr for RDT testing, whilst dried blood spots (DBS; 50 µl) were also 
prepared. DBS were stored with silica at room temp for molecular analysis. 
Two lateral flow diagnostic tests: the uRDT (Alere™) and the currently used csRDT RDT 
(CareStart Combo Pf/Povm RDT) were performed according to manufacturer guidelines. 
Both RDTs were performed by the same operator. For visual reading, independent CRFs 
Figure 6.1. Map of Kisumu county in Western Kenya and the location of the study sites. 
The health care facilities are displayed on the map: 1) Rabuor sub-county hospital, Vihiga 
county 2) Ahero county hospital, Kisumu county and Akala health centre on the border of Siaya 
and Kisumu county. Map modified from Google Maps. 
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were completed for either RDT. Only CareStart RDT results influenced treatment at 
enrolment as the uRDT has not yet been approved for clinical use by the Ministry of Health 
in Kenya. 
Reference testing was carried out at the end of the 8-month study. Briefly, DNA was 
extracted from approximately 25 µl of one DBS using the Qiasymphony Blood and tissue 
DNeasy kit as per manufacturer’s guidelines (Qiagen, cat#). One negative and one positive 
(3D7 culture) extraction control was included per every 72 extractions.  
A multiplex qPCR containing 18S rRNA probes for all 4 major species of malaria, 
P. falciparum, P. vivax, P. malaria and P. ovale, was used a reference standard for these 
asymptomatic infections. (STOPMiP, Unwin Refs) For this, qPCR reactions (10 µl total 
volume) contained: 2 μl DNA, QuantiFast Pathogen PCR Mix (Qiagen™, Hilden, Germany) 
and primers and probes as outlined in Chapter 2 (section 2.3.3) (Shokoples, Ndao et al. 
2009). Thermocycling conditions (38 cycles) were as follows: 10 min at 95 °C, 15 sec for 95 
°C and 60 sec for 60 °C. Fluorescence was acquired using the Rotor-Gene Q 5plex HRM 
Platform (Qiagen™, Hilden, Germany) and cycle threshold (Ct) values were calculated using 
the Rotor-Gene Q series software version 1.7 (Qiagen Inc, Valencia, CA, USA). Negative and 
positive controls (P. falciparum, P. ovale, P. malariae and P. vivax provided by Public Health 
England) were included in every run. 
 
6.3.3. Statistical analyses 
To observe a difference between the sensitivity of the uRDT and csRDT with a power of 0.8 
with 95% confidence, a sample size of 233 qPCR-confirmed positive samples was calculated. 
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Estimating the RDT prevalence to be 25% (Wanja, Kuya et al. 2016) and therefore qPCR 
prevalence ~40%, the sample size was determined to be 580. 
The difference in observed proportions of positive tests by uRDT and csRDT were compared 
using the McNemars proportions test. The Area Under the Receiver Operator Curves 
(AUROC) was calculated. All statistical analyses were performed in SPPS v26. 
6.3.4. Ethics 
Under the IMPROVE study protocol and approved ethics, diagnostic testing was done on 
samples from women enrolling in the IMPROVE study. Informed consent was be obtained 
before women enrolled in the study. The IMPROVE protocol, the informed consent 
document and patient information sheets were reviewed and approved by the Research and 
Ethics Committee of Liverpool School of Tropical Medicine, Liverpool (LSTM), the Research 
Ethics Committees at KEMRI, Nairobi, Kenya (SERU), the College of Medicine in Malawi 
(COMREC) or if so requested at national level, by the Malawian National Health Science 




6.4.1. Incidence of malaria 
In this study (n= 493), overall incidence of P. falciparum infections was 31.0% by qPCR, 
31.5% by uRDT and 28.8% by csRDT. QPCR identified an additional 7 P. vivax infections, 2 
P. ovale and 7 P. malariae infections (3% non-falciparum infections), whilst the csRDT 
estimated prevalence of non- falciparum infections to be 9.1% (Table 6.2).  Table 6.2 shows 
the proportion of each species detected by each test, at each sampling site. The number of 
Page 233 of 266 
 
RDT-positive and qPCR-negative (false positives) was highest in Akala; 4/23 were positive by 
both RDTs, with 2 additional positive only detected by uRDT. Only one of these samples had 
any amplification (Ct 39.2) above the cut-off. The csRDT detected more non-falciparum 
infections than the qPCR reference test, across all sites, potentially due to antigen 
persistence. (Table 6.2) 
 
6.4.2. Diagnostic performance 
The performance of the uRDT was compared to that of the csRDT using qPCR as a reference 
test. Resultant diagnostic indicators are outlined in Table 6.3. The uRDT sensitivity was 
79.9% (95% CI; 72.5-85.7) whilst the csRDT was 74.0% (66.2- 80.6) with overlapping 
confidence intervals. The proportion of infections detected (sensitivity) by the uRDT was 
significantly higher than that of the csRDT (McNemars p= 0.02, 1-β= 0.8, α= 0.05). The 
specificities of the two tests were uRDT; 90.4% (95% CI 86.6- 93.2%) and csRDT 93.0% (95% 
CI 86.6-95.4), however the csRDT specificity was significantly higher (p= 0.01, 1-β= 0.8, α= 
0.05). Overall, this is reflected by the similar DOR and Kappa values (Table 6.3) and is echoed 
in the AUROC values; uRDT 0.87 (95% CI 0.83- 0.91%) and csRDT 0.89 (95% CI 0.85-0.93%). 
(Table 6.3)  
The Venn diagram in figure 6.2 shows that the majority (n= 112) of infections were detected 
by all three tests (uRDT, csRDT and qPCR). 23 infections were positive by both RDTs and 
negative by qPCR. The uRDT also detected 11 qPCR-confirmed infections that were missed 
by the csRDT. The csRDT detected 2 qPCR-confirmed that the uRDT missed. (Figure 6.2) 
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Table 6.2. The incidence of malaria by index tests (uRDT and csRDT) and reference test 
(qPCR). 
Site Test Pf Po Pv Pm Pan 
    n (%) n (%) n (%) n (%) n (%) 
Ahero uRDT 68 30.8% 
        
(n= 221) csRDT Pf-line 63 28.5% 
        
 
csRDT Pan-line 
        
21 9.5% 
 
qPCR 63 28.5% 2 0.9% 3 1.4% 3 1.4% 8 3.6% 
Rabuor uRDT 75 29.8%                 
(n= 252) csRDT Pf-line 64 25.4%                 
  csRDT Pan-line                 24 9.5% 
  qPCR 83 32.9% 0 0.0% 4 1.6% 3 1.2% 7 2.8% 
Akala uRDT 13 56.5% 
        
(n= 23) csRDT Pf-line 11 47.8% 
        
 
csRDT Pan-line 
        
4 17.4% 
  qPCR 7 30.4% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Pf; P. falciparum, Pv; P. vivax, Po; P. ovale and Pm; P. malariae 
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Table 6.3. Diagnostic performance of csRDT and uRDT using qPCR reference test for P. falciparum. 
 TP FP TN FN Sensitivity % (95% CI) Specificity %  (95% CI) 
uRDT 122 33 308 31 79.7 (72.3- 85.6) 90.3  (86.5- 93.1) 
csRDT 113 23 318 40 73.9 (66.0- 80.4) 93.2  (89.9- 95.6) 
 
 PPV % (95% CI) NPV % (95% CI) DOR % (95% CI) Agreement (κ)  (95% CI) AUROC (95% CI) 
uRDT 78.7 (71.3- 84.7) 90.8 (87.1- 93.5) 36.6 (21.5- 62.4) 0.7 (0.6- 0.8) 0.87 (0.8- 0.9) 
csRDT 83.0 (75.5- 88.8) 88.8 (84.9- 91.8) 38.9 (22.3- 67.9) 0.7 (0.6- 0.8) 0.89 (0.8- 0.9) 
TP; True Positive, FP; False Positive, TN; True Negative, FN; False Negative; CI; Confidence Intervals, PPV; Positive Predictive Value, NPV; Negative Predictive Value, DOR; 
Diagnostic Odds Ratio, Kappa; agreement with qPCR, AUROC; Area Under the Receiver Operator Curve, and n; total number of samples.   






Figure 6.2. Venn diagram showing number of positive samples detected by uRDT, csRDT and 
qPCR. 
The number of mutually detected positives is shown within the respective Venn circles. (n)= total 
number of positives detected by a test. 
 
 
6.4.3. Parasite density, distribution and sensitivity 
Using qPCR Ct value as a proxy of parasite load, Cts were categorised into low (qPCR Ct >32), 
medium (Ct 26-32) and high (Ct <26) parasitaemia. The distribution of parasite load was 
skewed toward moderate-low densities (Table 6.4), with only 15 high-density infections 
(<Ct26). The sensitivity of the uRDT and csRDT was highest, but non-significantly different to 
each other amongst moderate infections (csRDT 93%, uRDT 96%). In low density samples, 
the uRDT sensitivity (60%) was significantly higher (p= 0.02) than that of the csRDT (31%). 
(Table 6.4) 






Table 6.4. Diagnostic test positivity stratified by qPCR Ct value as a proxy of parasite load. 
    Parasite density   
  High Moderate Low   
Test < Ct26 Ct26- 32 Ct32 > Total 
qPCR 
n 15 75 63 153 
Mean (± 95% 
CI) 
24.9 (0.6) 28.8 (0.4) 34.8 (0.4) 30.9 (0.6) 
LQ-UQ 24.4- 25.6 27.1- 30.3 33.2- 35.9 27.4- 34.3 
uRDT 
n 12 72 38* 122* 
% 80% 96% 60% 80% 
csRDT 
n 12 70 31* 113* 
% 80% 93% 49% 74% 
Ct; Cycling threshold, LQ; lower quartile and UQ; upper quartile, *p=0.02 (McNemars) 








There is still a need for highly sensitive malaria POCTs. Previously (Chapter 3), the uRDT 
performed similarly to the csRDT amongst pregnant women in a moderate transmission 
setting. However, the study was retrospective, using frozen red blood cell pellets 
resuspended in the patient’s plasma. Since the manufacturer’s guidelines for these tests 
require whole blood, this prospective study follows the recommended guidelines. 
 
This study investigates the diagnostic accuracy of the uRDT in a high transmission in order to 
better address limitations outlined previously. First, it was suggested (in Chapter 4) that the 
similar performance of the uRDT and csRDT could be due to samples falling below the LOD 
of both RDTs. Second, it was difficult to ascertain whether pfhrp2 genotypes play a role in 
RDT outcome due to low parasite DNA yields. Finally, it is important to assess the diagnostic 
accuracy of new tests in different settings as changing prevalence will affect the PPV and 
NPV. 
 
The uRDT sensitivity (79.9%) determined here was higher than the csRDT (74%), akin to 
previous results in high transmission settings in Uganda amongst children and adults (Das, 
Jang et al. 2017). Unlike in Uganda, the uRDT specificity in this study was lower than that of 
the csRDT. In this study these differences were found to be significant, however the same 
analyses were not reported in the Ugandan study (Das, Jang et al. 2017).  







The number of false positives called by only one RDT is in line with the expected specificity 
of either test. However, the 23 false positive infections detected by both RDTs is more 
suggestive of antigen persistence following clearance of an infection and therefore no (or 
low concentrations of parasite DNA. This could be due to recent anti-malarial use or 
immunity-regulated clearance of parasites. It is well established that due to the more rapid 
clearance of DNA compared to parasite proteins e.g. HRP2 antigen, PCR methods are more 
indicative of an active infection, whilst antigen detection can also detect a recently cleared 
infection (Dalrymple, Arambepola et al. 2018). RDT positivity is thus prolonged beyond PCR 
positivity following clearance (Martin, Rajasekariah et al. 2009, Dalrymple, Arambepola et 
al. 2018).  
   
The high proportion of false positives (by both RDTs) observed at the Akala site is interesting 
and most likely reflects the recent clearance of an infection (Dalrymple, Arambepola et al. 
2018) or potentially intrinsic immunological factors (Gatton, Ciketic et al. 2018) in the local 
population. A recent review of factors that could impact RDT outcome showed the false 
positivity rate of RDTs was elevated in the presence of samples containing Rheumatoid 
factor (RF) and Human Anti-Mouse Antibody (HAMA) (Lee, Jang et al. 2014, Gatton, Ciketic 
et al. 2018).  It would be interesting to measure these factors in samples from this site in 
comparison to the other sites.  







Taking sensitivity and specificity into account, the overall diagnostic accuracy of the two 
tests was similar as indicated by the DOR and AUROC values. This supports findings from the 
two other publications assessing the accuracy of the uRDT amongst pregnant women. The 
first, in Colombia (low transmission setting), showed the uRDT offered a slight increase in 
sensitivity compared to the SD Bioline malaria RDT among febrile pregnant women, 
however the study was too underpowered to draw concrete conclusions. (Vasquez, 2018).  
 
The second study (Chapter 4) utilised stored samples that had been reconstituted to a 
uniform haematocrit, which is not recommended by the manufacturer’s guidelines. In that 
moderate transmission context, both the csRDT and uRDT performed similarly poorly 
(sensitivity ~20%), but still in line with previously estimated prevalence using RDTs in the 
same area (Ahmed, Levy et al. 2015). 
 
6.5.1. Parasite density 
When stratified by parasite load, the sensitivity of both RDTs was unexpectedly highest 
amongst moderate infections (93-96%), with high density infections offering only 80% 
sensitivity for both RDTs. Previously, impaired sensitivity of malaria RDTs caused by the 
“prozone” or “Hook” effect has been reported (Gillet, Mori et al. 2009, Luchavez, Baker et 
al. 2011). This effect occurs in the presence of samples highly concentrated in the target 
antigen, which affects the binding capability of the capture antibodies on the RDT. This has 






been documented in HRP2-based malaria RDTs previously, and to a lesser extent in pLDH 
based malaria RDTs (Gillet, Mori et al. 2009). It was shown that a prozone-like effect was 
observed above HRP2 concentrations of 15000 ng/ml (312,000 parasites/ ml) in the 
laboratory and above 4% (microscopy) in clinical settings (Luchavez, Baker et al. 2011). It 
would be interesting to serially dilute the stored blood samples in our high parasitaemia 
category (Ct<26) to investigate this effect on these RDTs.  
Finally, the methods in section 6.3.2 outline the use of capillary blood where venous blood 
was not drawn. Although many diagnostic evaluations and clinical trials use these sample 
types interchangeably, it has been shown that in some settings the use of capillary blood 
can result in higher diagnostic sensitivity due to sequestration of parasites to these 
compartments (Mischlinger, Pitzinger et al. 2018), whereas in asymptomatic populations 
there is little difference (Sandeu, Bayibéki et al. 2017). Stratifying the data here by blood 
source would clarify if RDT performance is affected by sample type, this would be influential 
in developing standard operating procedures for diagnostic screening. 
 
6.5.2. Limitations and future work 
The sample size required to power a comparison of the two RDTs was estimated as 580 
samples a priori. Although we did collect this many samples, verification of the clinical 
research forms was not complete at the time of DNA extraction, and unmatched/ missing 
data reduced the total number of samples analysed to 493. However post-hoc analyses 






reveal this study is sufficiently powered given the larger than expected differences in the 
proportions detected. 
One limitation of this study is that the same operator carried out both RDTs. Independent 
uRDT operators were employed for this study, however due to understaffing at the sites 
operators performed some of the csRDT testing in addition to the uRDTs, which could have 
introduced some operator bias. The pairing of microscopy data, once available, will help to 
scrutinise samples that were positive by both RDTs and negative by qPCR. As mentioned 
previously, additional antigen-based testing (ELISAs) could shed light on prozone effects, 
antigen persistence and the impact of pfhrp2 mutations.  
It must also be noted that this study occurred over a 9 month period, inclusive of local wet 
and dry seasons and therefore of different transmissivity periods. Although this will have 
affected infection density in the study, since the main objective here was to assess the 
performance of the uRDT in comparison to the csRDT, the inclusion of different transmission 
seasons better reflects how both RDTs perform overall. 
 
6.5.3. Impact 
This study adds to the building evidence guiding implementation of the uRDT. Given the 
potential severity of MiP, the uRDT’s significant improvement in sensitivity could plausibly 
translate to genuine impact for case management in asymptomatic pregnant women. 
Although the uRDT specificity was significantly lower than the csRDT, the good safety profile 






of ACTs in pregnant women suggests that in asymptomatic infections- it is more important 
to treat than to risk missing an infection.  
For screening strategies as opposed to case management however, more evidence is 
needed to support implementation. Previously, ISTp strategies have proven inferior to IPTp 
using current RDTs. (Tagbor, Cairns et al. 2015, Awine, Belko et al. 2016, Williams, Cairns et 
al. 2016)  Evaluation studies (diagnostic accuracy/ cost-effectiveness/ feasibility) of ISTp 




In this prospective study, the sensitivity of the uRDT was significantly higher than that of the 
csRDT, in a high transmission setting, amongst pregnant women. However, the overall 
performance was comparable to that of the csRDT due to the lower specificity of the uRDT. 
This is the first study to assess the diagnostic accuracy of the uRDT in pregnant women in a 
high transmission setting.  
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7.1. Overarching research challenge 
 
Asymptomatic, low density malaria infections are prevalent across all epidemiological 
settings, but more so in low to near-elimination settings. Since asymptomatic individuals do 
not seek treatment, they act as a silent reservoir of infection and transmission. During 
pregnancy, malaria infection is especially dangerous, and can be low in density due to 
parasites sequestering to the placenta, making them difficult to detect. These infections 
must be actively identified to treat individuals and so prevent clinical episodes, as well as 
prevent continued transmission at a population level. Current diagnostics are central to the 
case management of malaria, but are inadequately sensitive for low density infections that 
occur across transmission settings. More sensitive and field-ready diagnostics are urgently 
required to suit the settings in which malaria is most commonly prevalent. 
7.2. Principal findings and impact 
 
This thesis describes the development, validation and evaluation of different diagnostic 
tests and assesses their suitability for different use-scenarios. It also highlights the various 
challenges faced when trialling new diagnostics in the field and the complexity of 
interpreting evidence to guide implementation policy. The research presented here falls 
broadly into two categories:  
1) Development and validation of molecular surveillance tools  
2) Assessment of a new commercially available rapid diagnostic test for point of care (POC) 






The first includes the development of a multiplex qPCR for the four main species of malaria 
(Chapter 2), its transfer to the portable rt-PCR MIC™ (Magnetic Induction Cycler) and 
utilisation of whole-blood directly in the assay (Chapter 3). With further development and 
characterisation, these additional adaptations (lack of DNA extraction step and performance 
on a portable platform) could facilitate its use in limited-resource settings. 
 
Alongside this work, a new assay was developed on the handheld rt-PCR Genedrive® 
platform in collaboration with genedrive plc. Mosquitoes were targeted for this assay due to 
the simple DNA extraction procedure. The resultant assay accurately detects multiple 
mutations associated with insecticide resistance simultaneously in the main malarial vector 
Anopheles gambiae. The assay offers a more field-friendly and low-cost alternative to 
current rt-PCR methods. 
Despite simplification, miniaturisation and reduced costs of molecular diagnostics, 
implementation still requires suitable infrastructure to support their use i.e. skilled 
personnel, access to instrumentation maintenance, even electricity to charge battery-
operated devices.  
Thus, RDTs still play a critical role in diagnosing malaria in resource-limited settings. 
Consequently, the second field of research contributes to the body of evidence around the 
performance of a commercially available RDT (Alere, uRDT). Already commercialised and 
meeting the majority of the ASSURED criteria, the uRDT performance was investigated in 
different transmission settings (Chapters 4-6).  






Utilising the 4-plex qPCR (Chapter 2) as a reference test, the diagnostic performance was 
assessed in a difficult-to-diagnose, yet critical population- pregnant women. For this, the 
uRDT was tested in 1) a retrospective study in a moderate transmission setting in Indonesia 
and 2) a prospective trial in a high transmission in Kenya. 
The first uRDT study (Chapter 3) utilised stored samples collected in a Stop Malaria in 
Pregnancy (STOP-MiP) trial in Timika, Indonesia. The sensitivity (20%) and specificity (90%) 
of the uRDT was non-significantly different to those of the CareStart RDTs (csRDT; 22% 
sensitivity, 95% specificity). These findings do not support implementation of the uRDT over 
current RDTs in these settings for use in pregnant women.  
The low sensitivity of both RDTs instigated examination of the pfhrp2 and pfhrp3 
gene structure in these samples (Chapter 4), since mutations have been shown to affect 
HRP2-RDT performance. Although inconclusive, there was some evidence of double 
deletions of pfhrp2 and pfhrp3 in this cohort. Further work to strengthen this evidence 
would confirm- for the first time- that these deletions are present in South East Asia and 
that they impact RDT outcomes. 
In the following prospective uRDT trial in Kenya, the uRDT was significantly more 
sensitive (79 %) than the csRDT (70 %), although less specific (90 % uRDT; 93% csRDT). 
Combining these findings showed the two tests performed similarly overall. However, 
considering the detrimental outcomes associated with MiP together with the good safety 
profile of ACT treatment during pregnancy, the potential clinical impact (Ferrante di 
Ruffano, Hyde et al. 2012) may warrant use of the uRDT over current RDTs for screening 






pregnant women.  
The work here is especially valuable given its focus on pregnant women- an often 
excluded or under-represented demographic- who are vulnerable to additional detrimental 
outcomes associated with malaria. This research builds critical evidence required to guide 
policy decisions around the implementation of this new test, and ultimately strategies for 
the prevention of malaria during pregnancy. 
 
7.3. Context within existing literature, limitations, and future work 
 
7.3.1. Molecular assays and portable platforms (Ch2-3) 
Molecular assays for the detection of multiple species of malaria have been published 
previously (reviewed most recently by Tedla et al.(Tedla 2019)). However, few qPCR assays 
have been adapted for use in resource limited settings, given the requirements of complex 
and costly instrumentation, and a DNA extraction step (de Monbrison, Angei et al. 2003, 
Rougemont, Van Saanen et al. 2004, Shokoples, Ndao et al. 2009, Oddoux, Debourgogne et 
al. 2011, Kamau, Alemayehu et al. 2013, Imwong, Hanchana et al. 2014). Melt curve analysis 
(MCA) is well suited for these settings, offering a cheap alternative to qPCR, requiring only 
one set of primers and an intercalating dye, albeit still requiring DNA extraction.  
We consequently explored Chua et al’s (2015) (Chua, Lim et al. 2015) 5-plex MCA in 
Chapter 2. Encouragingly we observed a similar limit of detection for P. falciparum, however 
we did frequently observe amplification of P. falciparum peaks in our non-template controls 






and non-falciparum samples. Despite using new stocks, intensive decontamination and even 
performing the assay in an additional non-malaria laboratory, this could not be remedied 
and so qPCR methods were explored.  
Joste et al. (2018) have since developed an MCA assay to distinguish between P. ovale 
wallikeri and P. ovale curtisi (Joste, Kamaliddin et al. 2018), which has proven useful in the 
monitoring of treatment efficacy (Kamaliddin, Joste et al. 2019). More recently, Murillo et 
al. (2019) developed an MCA assay targeting the 18S rRNA gene (only for P. falciparum, 
P. vivax and P. malariae) for use in humans and mosquitoes (Murillo, Muskus et al. 2019). 
These tests could offer more robust MCA methods for malaria detection. 
 
The 4-plex qPCR reassuringly achieved similar LODs to the publications in which its probes 
and primers were first developed, although its agreement with LAMP reference (Chapter 2) 
was poor. Validation of this qPCR highlighted common challenges in evaluating new 
diagnostics. First, potential cross-contamination issues during DNA extraction were outlined, 
emphasising the need to minimise sample handling prior to NAAT, preferably in a direct-
blood format. Second, the necessity to use a second reference test (nPCR), to confirm 
discordance between the 4plex and the LAMP reference test, underlines how important 
choosing the right reference test is. Many studies utilise RDTs and microscopy as gold 
standards for evaluating new malaria diagnostics, despite their poor sensitivity. Where 
sensitivity/specificity of the index test may be superior to the reference test, it is useful to 






include a comparator for relative performance (e.g. Chapter 5) and/or refer to a composite 
molecular test (e.g. Chapter 3). 
As mentioned previously, it would be useful to fully characterise the 4-plex assay and 
further validate its performance using 1) lyophilised reagents, 2) whole-blood directly and 3) 
a portable qPCR platform. Our results show that the MIC™is one possible platform that 
would suit a use-scenario with high-throughput requirements (48 samples/ run) e.g. in 
surveillance or for research purposes. Potentially, the unique Genedrive® cartridge shape 
could also support the transfer of the 4-plex qPCR to this platform, which would be better 
suited for rapid (< 1 hr) POC diagnosis (1-3 samples/ run) e.g. at antenatal visits (Desai, Hill 
et al.) or for reactive case detection  in the community (Hsiang, Ntshalintshali et al. 2019).  
 
The additional Genedrive® assay developed here is a proof of principle that a new assay for 
use in low-resource settings could be developed. To date, it is the only assay that includes a 
single primer-probe set to distinguish between wild type and 2 SNPs associated with 
insecticide resistance in mosquitoes. Given its excellent accuracy, the assay developed here 
could easily be expanded to include 1) other insects that have similar mechanisms of 
insecticide resistance e.g. sand flies or triatomine bugs, or 2) a wider repertoire of resistance 
genes. Currently the major limitation of the assay is the low-throughput format of the 
Genedrive® given its intended use as POC. The pooling studies should be expanded to 
further assess the feasibility of pooling higher numbers of mosquitoes for cost- and labour-
effective screening mosquito populations.  In the future, research into the potential market 






size, needs and wants for such products would be useful to guide commercialisation and 
inform target product profiles (TPPs).  
 
7.3.2. A new RDT (Ch4-6) 
Previous reports of the uRDT performance have been conflicting (Table 6.1, page 225). 
Across low, moderate and high transmission settings, in most studies the uRDT 
demonstrated superior sensitivity in comparison to current RDTs across a range of 
demographics. On the other hand, as we observed in our study in Indonesia, the only other 
study carried out in pregnant women also found no significant difference in performance of 
the uRDT and current RDTs. These findings are supported by the most recent uRDT study, in 
a cross-sectional screening in low transmission settings in The Gambia (Mwesigwa, Slater et 
al. 2019). Here, the prospective uRDT study in a higher transmission setting also supports 
this- with regards to overall uRDT performance- the uRDT was demonstrably more sensitive 
than the current RDT. It must be noted that the uRDT only detects P. falciparum malaria, 
and therefore an alternative test may be needed alongside the uRDT where other species 
are co-endemic. 
It would be useful to further investigate the uRDT “false-positives” in Kenya to 
determine if they are indeed indicative of recent infection and therefore truly RDT positive, 
or if cross-contamination, cross-reaction with other blood borne pathogens or mis-
interpretation of the RDT by the operator had led to uRDT false positives. The former would 
mean specificity of the uRDT is actually higher than we report here and therefore would 






bolster evidence for implementation of the uRDT. The effects of the latter would call for 
more cautious interpretation of uRDT positives. 
Since pfhrp2 and pfhrp3 deletions have previously been reported in this area of 
Kenya (Beshir, Sepulveda et al. 2017), it would also be useful to investigate the RDT false 
negatives. After this study, a new qPCR was developed by Schindler et al.(2019) (Schindler, 
Deal et al. 2019) for the detection of pfhrp2 and pfhrp3. This assay could overcome the 
insensitivity issues encountered in Chapter 4.  
The inverse relationship between RDT positivity and Ct value (a proxy of 
parasitaemia) in Chapter 5 also needs to be investigated, with particular focus on the 
Prozone effect. Jang et al. have since developed a new immunoassay specifically to aid the 
evaluation of new malaria RDTs (Jang, Tyler et al. 2019). Their assay quantifies pfhrp2 and 
pLDH, the most commonly RDT- targeted antigens (Jang, Tyler et al. 2019). Quantification of 
these antigens would help to shed light on the phenomenon of unexpected RDT false 
negatives in the presence of highly parasitaemic infections (Gillet, Mori et al. 2009, Gillet, 
Scheirlinck et al. 2011, Luchavez, Baker et al. 2011, Lurdes, Nuno Rocha et al. 2015). 
 
7.4. Unanswered questions and future work 
 
The aims in Chapter 1 (page 63) have been met as described below in the thesis summary, 
however the work also highlights unanswered questions and gaps that still need addressing. 
Table 1.2 in Chapter 1 briefly summarises key characteristics of a molecular diagnostic for 






malaria surveillance; the following section discusses if these have been addressed by the 
work in this thesis and what further work is needed. 
 
The first set of characteristics define the use scenario of the proposed diagnostic. 
Although it is widely accepted that molecular surveillance requires trained personnel, the 
accessibility of the Genedrive® (explored in Ch3) challenges this dogma. Simplified 
technologies such as LAMP, NALFIA and closed cartridge systems also work towards this 
accessibility. Increasing accessibility will better support testing at lower level healthcare 
settings and will enable MTAT/FTAT screening nearer the patient. 
 
 The second category describes the optimal design of the assay. Due to the high 
sensitivity of NAATs the target analyte is suggested to be nucleic acid. In this thesis 
diagnostics were developed for the detection of DNA rather than RNA. However, it is well 
established that RNA targets provide far more sensitive detection of malaria, with the bonus 
of identifying the stage of parasite and even the sex of parasite gametocytes. Historically, 
DNA analysis has been favoured over RNA due to the added complexity of storing and 
preserving fragile RNA strands. Advances in chemistry have resulted in RNA preservatives 
such as Zymo (ZymoResearch 2020) and PrimeStore (Longhorn 2020), which could help 
mitigate these barriers, improving the accessibility of RNA targeting assays.   
The other assay characteristics such as limit of detection and diagnostic performance are 
discussed extensively in each chapter. However, test result delivery and optimal time to 






result (as outlined in Table 1.2) is not really addressed. The 4-plex qPCR developed in 
chapter 2 has an assay run time of nearly 2 hours, whereas the Genedrive® assay ran in 
under 1 hr. The optimal time outlined in Table 1.2 assumes a high throughput use-scenario 
for surveillance. Since the Genedrive® only runs 3 samples, the time per sample is ~ 20 mins, 
whereas on the RotorGeneQ (72 samples/ run) this equates to less than 2 mins per sample. 
The usefulness of these measures depends on the use scenario, but it is likely that for 
surveillance the high throughput format will be more relevant. 
 
Finally, the most influential factor regarding implementation of new tests in limited-
resource settings needs to be assessed- the cost. For nucleic acid testing, considerable 
expense is associated with the isolation and purification steps. 
Due to time constraints- and with the goal of global harmonisation between global uRDT 
evaluation studies- in this thesis we used the most widely used nucleic extraction method 
(e.g. Qiagen kits) for reference standard testing. Cheaper, simpler and faster alternatives do 
exist e.g MagMax™ (ThermoFisher Scientific, UK) and Genesig™ Easy extraction 
(PrimerDesign, UK), however thorough validation studies would be necessary prior to 
replacement of the standard spin column methods. In chapter 3, we explored the potential 
of magnetic bead extraction and concluded that using diluted blood directly in the qPCR was 
as effective as the extraction process. Circumvention of nucleic acid isolation costs ($3-10/ 
sample) will significantly reduce the cost of molecular screening, again improving 
accessibility. Aside from the initial cost of instrumentation ($5k+), other expenses associated 






with molecular screening relate to the use of plastics (filtered pipette tips), tubes and the 
associated waste disposal routes. 
 
Sample type also influences the cost and ease of use of the test e.g if additional 
reagents are needed to stabilise nucleic acids/ degrade nucleases in the sample, or if the 
sample requires a cold chain or specialised personnel. For both molecular surveillance and 
RDTs, whole blood is the gold standard for diagnosis of malaria. The use of non-invasive 
samples (outlined in 1.4.6) could be more cost-effective (by circumventing specialised staff 
for sample collection) and a more patient-friendly method of diagnosis. It would be useful to 
validate the use of urine, saliva or faeces in the 4-plex qPCR developed here, as outlined in 
the TPP described in 1.2.2 (Table 1.2). 
 
The simple RDT format and requirement for only a finger-prick of blood means that 
there are very minimal associated costs for these tests. Additional costs may instead be 
incurred when switching RDTs, potentially necessitating staff re-training and changes in 
procurement logistics. Thus, thorough cost analyses are needed to determine the level of 
improvement in sensitivity that would warrant switching to a new RDT in different settings 
with different transmission reduction goals. More insight into the cost-benefits of 
diagnostics in various use-scenarios will better inform control and elimination strategies, as 
well as guide TPPs for new diagnostics. 
 






Excitingly, the findings in this thesis also highlight several additional research themes that 
could be explored/ expanded, contributing to essential translational malaria research.  
First, for molecular surveillance it would be useful to genotype locally circulating 
parasites in addition to monitoring “diagnostic resistance” genes such as pfhrp2/3, with 
particular reference to asymptomatic infection. We need to better understand how low-
level transmission is maintained, whether through re-infection of the same strain, 
recrudescence of dormant parasites or new strains. Some studies have shown that in areas 
of low-transmission, clinical malaria most often arises from newly imported parasite strains 
(Kun, Missinou et al. 2002, Hofmann, Karl et al. 2017, Searle, Katowa et al. 2017). Expanding 
this using more sensitive molecular diagnostics for asymptomatic malaria would be 
particularly useful for understanding the dynamics of infection, the pathogenesis and 
general malaria transmission in near-elimination settings.  Subsequently, whole genome 
sequencing may be more cost-effective than detecting multiple genes individually. 
Promising technological advances in sequencing, mainly the portable Nanopore MinION™ 
Sequencer (Imai, Tarumoto et al. 2017, Imai, Tarumoto et al. 2018) may allow this in the 
near future. 
Addressing a major limitation of this thesis- the lack of absolute quantification using 
synthetic DNA- it would be useful to use standard curves for each species to obtain the limit 
of detection and identify parasitaemia precisely. Following this, further stratification of 
parasite load could enable comparison with other studies, helping to further characterise 
and compare the performance of the uRDT in different settings. 






In addition to quantification, as mention in chapter 5 it would be useful to include 
genotyping of circulating strains in order to gain further  understanding of infection 
dynamics, particularly with regard to emerging mutations that may affect diagnosis or 
treatment. 
It would also be useful to extend the analyses of the uRDT studies to include 
stratification of parasite density by gravidity or other clinical variables of the participants. 
Although it is known that immunity to malaria increases with gravidity, there is little work 
investigating sub-microscopic parasite densities and gravidity (Bouyou-Akotet, Ionete-
Collard et al. 2003, Ouédraogo, Tiono et al. 2012, Haggaz, Elbashir et al. 2014, Mayor, 
Bardají et al. 2015). The overall dynamics of low density infection have only recently been 
investigated (Slater, Ross et al. 2019, Whittaker, Slater et al. 2019), and not with special 
consideration for pregnant women.  
 
Okell et al.(2012) (Okell, Bousema et al. 2012) and Slater et al. (2015) (Slater, Ross et al. 
2015) modelled the effects of using next generation RDTs with a ten-fold lower limit of 
detection in malaria control programs. Broadly, they estimate that an RDT with an LOD of 10 
parasites/ul would detect 80% of the overall infectious reservoir. Given the availability of 
new data from the uRDT and recent meta-analyses of the dynamics of malaria in low 
transmission settings, it would be useful to validate and further refine these models- 
particularly in pregnant women- to help guide the development and implementation of new 
diagnostics.  






7.5. Thesis Summary 
This thesis demonstrates: 
1) The development of a new molecular test for 4 species of malaria, in which whole 
blood can be used directly and which has demonstrated transferability to a portable 
qPCR platform.  
2) In a well-designed prospective trial, that the new uRDT is more sensitive than 
existing RDTs when used in a high transmission setting for screening pregnant 
women, whereas as in a low transmission it setting it offers no additional sensitivity. 
3) The Genedrive® offers a simple, portable platform for molecular detection of 
insecticide resistance, suitable for use in malaria control settings. 
 
In addition to these, several important considerations for diagnostic development, 
validation and evaluation are highlighted. The research presented here is useful for product 
developers, researchers and health policy advisors; it encompasses nuances of designing, 
validating and evaluating malaria diagnostics, contributing to critical evidence needed to 
guide malaria control strategies. 
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